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Abstract 
 
An active particle tracking microrheology technique has been developed to 
study the viscoelastic properties of human fibrin and plasma clots. In order to 
perform microrheology measurements, a magnetic microrheometer device 
has been adapted and a technique developed, following the procedure of 
Evans et al., to measure the frequency dependent viscoelastic moduli (G ( ) 
and G ( )). This technique has been supported by complementary 
investigation methodologies, such as protein analysis, turbidity, and multiple 
microscopy techniques.  
 
As a result of this study new insights into the viscoelastic dynamics of fibrin 
have been revealed. Three stress relaxation mechanisms, as predicted by 
Morse et al. for networks of semi-flexible fibres, were observed and occur on 
distinctly different timescales. The scaling of the tension dominated 
contribution was measured to scale as G  ~ c2.7  0.2 in agreement with the 
prediction of Mackintosh. The presence of FXIII resulted in stiffer less 
deformable clots but was found to have no effect on the viscoelastic 
dynamics of clots. Frequency measurements of the loss tangent revealed 
that on timescales intermediate between stress relaxation modes clots were 
much more susceptible to permanent deformation. The effect of fibrinogen, 
thrombin and calcium on the viscoelastic behaviour of clots was also 
investigated. Increased fibrinogen levels produced clots which displayed 
predominantly elastic behaviour on shorter time-scales . 
 
The molecular mechanism underpinning the role of fibrinogen  in fibrin clot 
polymerisation, structure and viscoelasticity was also investigated. We report 
new data which show that fibrinogen  is associated with the formation of 
mechanically weaker, non-uniform clots composed of thinner fibres. This is 
caused by direct disruption of protofibril formation by  and not through 
thrombin inhibition or binding to FXIII. In addition, the effects of the plasma 
proteins FVIIa, FIXa, FXIIa and FXIII on clot properties are also reported.  
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Chapter 1 
1 Introduction 
 
1.1 Haemostasis 
 
Haemostasis is the physiological process which protects the integrity of the 
vascular system (1).  An extremely important function of the haemostatic 
process is the ability to minimise blood loss in the event of vessel trauma.  
The body's ability to stem the flow of blood is commonly referred to as 
coagulation; this process is of central importance to life as it prevents an 
organism from bleeding to death.  In the event of damage to a blood vessel 
several steps occur to arrest the flow of blood: 
 
 Vasoconstriction: blood vessels constrict minimising their diameter 
and reducing the flow of blood. 
2 
 
 Primary haemostasis: exposed collagen in the damaged cells of the 
blood vessel lining activate platelets leading to their attachment to the 
damaged cells and to themselves (2).  These platelets aggregate into 
a ‗haemostatic plug‘, forming within seconds after vessel trauma. 
 Secondary haemostasis (coagulation): Tissue factor exposed by 
damage of the vascular wall binds factor VII and initiates coagulation. 
In addition, platelet activation leads to the exposure of negatively 
charged phospholipids on the platelet membrane and to the release of 
procoagulant factors from the platelet granules, further activating the 
common and contact pathways of coagulation.  The final result is the 
formation of a blood clot. 
 Finally, Plasmin begins to dissolve the clot; a process termed 
fibrinolysis, in order to restore normal blood flow after tissue repair. 
 
Two pathways exist to initiate coagulation; termed contact activation pathway 
(intrinsic) and tissue factor pathway (extrinsic) (Figure 1-1).  Both coagulation 
pathways rely on inactive enzyme precursors (zymogens) becoming 
activated through limited proteolysis by an upstream coagulation factor and 
initiating the next stage of coagulation.  The enzymes involved in coagulation 
are serine proteases (the active site of the enzyme possesses a serine 
residue), all of which cleave peptide bonds of proteins.  Only factor XIII 
(FXIII) is a different zymogen, being a protransglutaminase, which on 
activation by thrombin cross-links proteins such as fibrin and collagen by 
forming covalent bonds between the -chains and between - and A -chains 
(3).  
 
The intrinsic pathway, activated when zymogen FXII comes into contact with 
a negative surface, is believed to play a relatively minor role in the 
haemostatic response. The role of FXII has been contested as people with 
FXII deficiency, unlike other coagulation factor deficiencies, do not suffer 
from major bleeding (4). Recent in vivo data show that FXII inhibition or 
deficiency in rodent models reduces blood clot formation whilst maintaining 
3 
 
normal bleeding times (5-8), suggesting a role for FXII in pathological 
thrombus formation but not normal haemostasis. 
 
 
 
Figure 1-1: The intrinsic and extrinsic coagulation cascade (adapted from (5)). The 
intrinsic pathway is activated via FXII through several mechanisms while the extrinsic 
pathway is activated by blood vessel trauma. Both responses culminate in the formation of a 
fibrin clot.  
 
The extrinsic pathway plays a much more vital role and is activated upon 
damage to blood vessels which exposes tissue factor (TF), a transmembrane 
protein expressed on perivascular cells. FVII is activated by TF, and has 
been shown to demonstrate auto-catalytic activity, and by thrombin (once 
initial minute amounts have been generated). FVIIa then reacts with TF to 
from TF-VIIa, which in turn activates factors IX and X. FXa and its cofactor 
Va and several other molecules form a complex called prothrombinase. This 
complex (on the surface of activated platelets) converts prothrombin (FII) into 
thrombin (FIIa). Thrombin then initiates a number of reactions (including 
activation of factors V and VIII) that result in further activation of FX; this 
produces a self-enhancing cycle which rapidly increases the amount of 
thrombin and consolidates the haemostatic response. 
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The main role of thrombin is to convert the precursor fibrinogen (FI) into its 
active form fibrin (FIa) which then self-assembles to form a fibrin clot, termed 
the common pathway. Thrombin also activates FXIII which forms covalent 
bonds between fibrin molecules; this is termed cross-linking (or ligation) and 
results in a more stable clot. The terms cross-linking and ligation are used 
interchangeable throughout the literature. The term cross-link is commonly 
used in haemostasis and thrombosis to indicate the product of FXIII activity, 
therefore throughout this work the term cross-link will be used to identify 
these types of covalent bonds produced by FXIIIa. 
 
1.2 Fibrin Clot Formation 
 
Fibrinogen, the primary structural protein of a blood clot, has a molecular 
weight of 340 KDa, is ~45 nm in length, ~4 nm in diameter, and consists of 
two identical halves each containing an outer D-region connected by a 
coiled-coil segment to a central E-region (Figure 1-2 A) (6, 7). These 
connecting coiled-coil segments consist of three polypeptide chains termed 
A , B  and  and all have their amino termini joined together in the central E-
region via five symmetrical disulfide bridges (8-12). Anti-parallel disulfide 
bridges form a ‗disulfide ring‘ within this region (8, 9). Disulphide bonds also 
hold the chains in place at various other locations across the structure. 
 
The A -chain consists of 610, the B -chain 461, and the major -chain form, 
A, 411 amino acid residues respectively (10). A minor -chain variant 
termed  accounts for between 8 to 15% of the total fibrinogen -chain 
population and is composed of 427 residues (7). The B  and   chains 
carboxyl-termini reside in the D-region, while that of the A  chain loops back 
towards the central region of the fibrinogen molecule (Figure 1-2 A) (7).  
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Figure 1-2: Fibrinogen structure and fibrin polymerisation (adapted from (11)). (A) 
Polypeptide chain structure of fibrinogen (12). The A , B  and  polypeptide chains are blue, 
green and red respectively. The numerous disulfide bonds are represented by black bars. 
Fibrinopeptides A and B (FpA and FpB) are magenta. (B) Schematic representing the ―knob-
to-hole‖ interaction of fibrin showing A:a bonding. The C-domains, which interact 
intramolecularly, are shown only in the upper molecule for clarity. (C) Schematic 
representing protofibrils and intermolecular interaction between the C-domains upon lateral 
aggregation of protofibrils. The -  cross-links between D regions are represented by small 
open rectangles. They are shown only between the D-D ends for simplicity, however they 
may also occur in a transverse manner (Figure 1-5) (11). (D) Scanning electron micrographs 
of fibrin clots (images taken from (13)). Left: clot with thick, long fibres and few branch 
points formed with a low thrombin concentration (Coarse). Right: clot with thin, short fibres 
and many branch points formed with a high thrombin concentration (Fine). Scale bar = 5μm. 
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Two fibrinopeptides termed A (FpA) and B (FpB) reside at the N-termini of 
the A  and B  chains respectively (Figure 1-2 A). FpA and FpB are 
negatively charged and prevent fibrinogen molecules from aggregating in the 
absence of blood vessel damage (14). During clotting thrombin converts 
fibrinogen into fibrin by cleaving FpA and FpB from the central E-region of 
the molecule. This exposes knobs (A and B) which can then interact with 
complementary holes (a and b) that are always exposed in the D-regions of 
the fibrinogen molecule (Figure 1-2 B) (15). 
 
 
 
Figure 1-3: Scanning electron micrograph of fibres in a fibrin clot. The surface 
appearance of the fibres indicates that fibrin fibres can produce rope-like twisted structures. 
Image kindly provided by Sumitra Mohan. Scale bar = 500 nm.   
 
Cleavage of FpA exposes a Gly-Pro-Arg (GPR) sequence while cleavage of 
FpB exposes a Gly-His-Arg-Pro (GHRP) sequence. Specific A:a interactions 
(16) are responsible for the longitudinal growth of fibrin monomers into a half 
staggered structure called the proto-fibril (Figure 1-2 B and C), which has a 
periodicity of 22.5 nm. This periodicity of the protofibril is responsible for the 
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banding pattern of fibrin fibres observed by scanningelectron microscopy 
(Figure 1-3). 
 
Thrombin cleaves FpA more rapidly than FpB and this is sufficient to initiate 
fibrin polymerisation (16). The snake venom batroxobin cleaves FpA without 
cleaving FpB to produce the desA-fibrin monomer. Polymerisation of desA-
fibrin results in a network similar to normal fibrin except for some differences 
in ultra structure (17). The stiffness of clots formed from thrombin is 2- to 4-
times greater than clots formed only by cleavage of FpA (18), indicating a 
role for B-b bonding in enhancing the molecular interactions involved in 
protofibril assembly. The majority of FpBs are cleaved after the process of 
fibrin assembly has been initiated and fibrin polymers have formed (19, 20). 
The role of B:b interactions has been studied in one of two ways; either using 
fibrinogen with impaired FpA release, or enzymes which specifically remove 
FpB to produce desB-fibrin. These variants were all able to form a -fibrin 
clot (14, 21, 22). It has been suggested however that polymerisation in the 
latter case arises through B:a instead of B:b interactions (23). 
 
FpB release has been reported to result in the formation of thicker fibres by 
enhancing lateral aggregation of growing protofibrils (14, 24). The release of 
the C-domains after FpB has been removed is thought to aid lateral 
aggregation by molecular interactions of the C-domains in the intra-
protofibril space (Figure 1-2 C) (25). The work of Litvinov et al. used optical 
tweezers to measure the forces of individual knob-hole interactions 
underlying fibrin polymerisation (16). They found polymerisation was mainly 
driven by strong, stable and highly specific A:a bonding, where the strength 
of binding is of the order of 250 pN. 
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Figure 1-4: Confocal microscopy image of a fibrin clot. The image is of a single optical 
plane within a fibrin clot which contains fluorescently labelled fibrinogen. Note the vast 
majority of fibres are extremely straight in this type of imaging. Image obtained by the author 
of this work, further details provided in chapter 2. Scale bar = 20 μm. 
 
Once proto-fibrils have grown sufficiently, up to around 15 monomers in 
length (26), they begin to aggregate laterally and form fibres (Figure 1-2 C). 
Fibres display a twisted, rope-like structures on their exterior (Figure 1-3). 
When protofibrils aggregate to form fibres this seems to suggest that they 
twist around one another (27). This twisting limits the radial growth of fibres if 
we assume that the protofibril periodicity of 22.5 nm needs to be maintained. 
Increasing the diameter of a fibre requires stretching a protofibril in order to 
increase its path length; this sets an upper limit on the radial size of fibrin 
fibres to 50 nm (28). This increases up to 100 nm when accounting for the 
flexibility of fibrinogen molecules. Fibres may also aggregate to form even 
thicker fibres. Fibre growth halts when the energy required to stretch an 
added protofibril exceeds the energy of bonding. Thus, protofibrils on the 
exterior are under tension and this accounts for the observation that fibres 
making up a clot are extremely straight when observed under fully hydrated 
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conditions such as with the laser scanning confocal microscope (Figure 1-4). 
The fact that fibres are under tension will have important implications for the 
viscoelastic properties of a clot.  
 
 
 
Figure 1-5: Schematic diagram of fibrin assembly, branching, lateral fibril association, 
and -chain cross-linking (adapted from (7)). Cross-linked -chains are positioned 
‗transversely‘ between fibril strands are represented by small open rectangles.  
 
Fibrin fibres form branches with one another resulting in a 3-dimensional 
fibrous network (Figure 1-2 D). This forms the structural basis, or scaffold, of 
a blood clot. It was initially proposed by Ferry et al. that a fine clot consisted 
of a random assembly of long stiff fibres which did not branch (29). However, 
it has since been shown that fibrin fibres do branch, forming an intricate 
interlinked network. Free fibre ends are rarely observed in an undamaged 
normal clot (30). They may occur when the fibrin clot is lysed by plasmin, 
which cuts perpendicularly through a fibrin fibre. Two types of branching exist 
in fibrin networks (Figure 1-5), termed bilateral and equilateral branch points 
(31, 32). Bilateral branching occurs when a double-stranded protofibril 
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converges laterally with another fibril to form a four-stranded fibril junction. 
Equilateral branching forms by convergent interactions between three fibrin 
molecules giving rise to three fibres at a junction. It has been suggested that 
equilateral junctions are the dominant branch point type and form with far 
greater frequency than bilateral branches (22, 33). However, recent evidence 
suggests that branch points may be more complex in structure and form 
triangular structures, with struts crossing from one leg to the other, 
particularly when placed under mechanical stress (34). 
 
 
 
Figure 1-6: Transmission electron micrographs of negatively contrasted fibrin fibres 
that show the substructure of branch point (figure from (35)). The majority of branch 
points consist of three fibre segments of approximately equal diameters which join together 
at small acute angles with their band patterns aligned. The 22.5 nm band pattern 
characteristic of fibrin can be easily observed. Scale bar = 0.2 μm. 
 
The structure of branch points in coarse clots has been studied using the 
electron microscope (35) and stained human fibrin (Figure 1-6). Stain 
distribution is directly related to protein density; stain is excluded from 
regions of high protein density, appearing bright, while stain penetrates 
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regions of lower protein density, appearing darker. These results suggest 
that branch points arise due to the divergence of fibrils that were associated 
with one another as a fibre and these formed early in polymerisation with 
additional protofibrils added to all parts of the network (13). Fibres form by 
the lateral aggregation of protofibrils while branch points form by the 
divergence of protofibrils from one another. So, a high degree of lateral 
aggregation during polymerisation will result in a network of thick fibres with 
low branching (Figure 1-2 D Left), while more protofibril divergence will result 
in a clot consisting of thin fibres and many branches (Figure 1-2 D Right). 
 
Once a fibrin clot has formed it must remain at the site of a wound to stem 
the flow of blood while any vessel damage is repaired, after this, the clot 
must be broken down and removed so as not to cause any serious 
pathological complications e.g. heart attack or stroke. The viscoelastic 
properties of a clot are crucial to its function; a clot must display both the 
elastic properties of a solid and the viscous properties of a fluid. Blood clots 
must be strong enough to stop bleeding and withstand the pressure of blood 
flow while at the same time be easily digestible by enzymes in order to be 
removed. Clot structure plays a simultaneous role in modulating both the 
viscoelastic properties and the mechanism of fibrinolysis. The structure must 
be finely tuned in order to strike the right balance between halting bleeding 
and minimising the effects of cardiovascular disease. 
 
The physiological importance of blood clot viscoelasticity is demonstrated by 
the effect different haemostatic disorders have upon a clot‘s physical 
properties. Patients with myocardial infarction, whereby interruption of the 
blood flow to the heart leads to subsequent heart muscle damage, form clots 
with a much tighter and more rigid fibrin network compared with healthy 
controls (36, 37). Similarly, patients who suffered from heart attacks at an 
early age posses clots with an increased stiffness of around 50%, compared 
with control clots (38). On the other hand factor VIII-and factor IX- deficient 
patients (haemophiliacs) form clots with a reduced stiffness that is 3- to 5-
times lower than clots formed by healthy subjects (39). Other studies of 
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patients with an auto-antibody inhibiting cross-linking involving the -chain 
showed clots with a stiffness 4-times lower than that of fully cross-linked clots 
(40). Achieving an optimal viscoelastic balance in a clot‘s mechanical 
properties is therefore critical to prevent disorders of either bleeding or 
thrombosis with their associated high degrees of morbidity and mortality. 
 
1.3 The Mechanical Properties of Fibrin Clots 
 
From a clinical perspective, the study of the mechanical properties of blood 
clots is an extremely important area. Very little is known of the mechanical 
properties of in vivo clots. Better understanding of a clot‘s mechanical 
properties could help to underpin mechanisms involved in vascular disease 
and should ultimately lead to the development of better treatments and 
preventions. Establishing the origin of blood clot viscoelasticity is also an 
active area in the field of biophysics and has been studied extensively for 
over five decades (33, 41-54). 
 
The study of the mechanical properties in blood clots from clinical samples is 
typically carried out using the technique of thromboelastography (TEG), 
which is also used to assess the overall efficiency of blood coagulation (55, 
56). It was first developed by the German Dr. Hellmut Hartert at University of 
Heidelberg School of Medicine in 1948 (57). Thromboelastography works by 
placing a small sample of blood (typically 0.36 ml) into a cup (heated to 
37 C) which is slowly oscillated. Coagulation is induced by the addition of 
activator, typically tissue factor or kaolin. A pin suspended freely from a 
torsion wire is placed into the blood. As the clot forms the fibrin strands 
couple the motion of the cup to the pin; the response of the clot to this 
torsional stress is transmitted through the pin and recorded. By measuring 
the response of a clot in this way many parameters governing blood 
coagulation may be extracted e.g. clot formation time, rate of clotting, and 
Rmax, an indicator of maximal clot firmness. However, the latter mechanical 
property has not been related to the viscoelastic properties commonly used 
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to characterise materials and therefore has no physical meaning other than 
in comparison with other such thromboelastography measurements. 
 
Fibrin networks are viscoelastic polymers which exhibit both viscous and 
elastic characteristics. Elastic materials obey Hooke‘s law which states that 
stress (the force applied per unit area) is directly proportional to strain, but 
independent of the rate of strain. For a purely elastic material the stress,  is 
given by: 
 
 G  1-1 
 
where G is the elastic modulus and  is the strain. Viscous materials obey 
Newton‘s law, which states that stress is directly proportional to the rate of 
strain but independent of the strain itself (58). For a purely viscous material 
the stress is given by: 
 
   1-2 
 
where  is the viscosity and   is the rate of strain (d /dt). Most materials can 
be classified as either solid (elastic) or liquid (viscous) and this is based upon 
the time frame in which we observe and interact with them. However, there is 
also a class of materials which behave viscoelastically. One example is silly 
putty (polydimethylsiloxane (PDMS)), which when thrown against a wall 
(short timescale) will behave elastically and bounce off the wall. When left for 
a long period (long timescale) it will behave viscously and flows like a liquid. 
 
An oscillatory force applied to an elastic material will produce a strain which 
is transmitted almost instantaneously, thus the stress and strain are in phase 
with one another. The same force applied to a viscous material will result in 
the fluid flowing and deforming. As the rate of stress is increased, the time 
available for this flow to occur is reduced and the strain increases. The stress 
and strain are out of phase by /4. Thus, a viscoelastic material will exhibit a 
phase shift which varies between 0 and /4, depending on the frequency of 
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oscillation. The maximum stress, 0 and strain, 0 are constant for any given 
frequency. The ratio of these two quantities: 
 
 
0
0*G  1-3 
 
is known as the complex modulus, where G* is a complex number where G  
represents the real and G  represents the imaginary parts: 
 
 GiGG  1-4 
 
The storage modulus, G  represents the elastic properties and is widely used 
to characterise clot stiffness, while the loss modulus, G  represents the 
inelastic, or viscous properties and is used to characterise the amount of 
energy dissipated by a clot (59). Also used to characterise clot viscoelasticity 
is the loss tangent: 
 
 
G
G
tan  1-5 
 
which gives the ratio of energy lost to energy stored in a cyclic deformation 
(33). For a viscous liquid tan  >> 0 i.e. G  >> G , and the viscous behaviour 
dominates. For an elastic solid tan  << 0 i.e. G  >> G , and the elastic 
behaviour dominates. For a viscoelastic material with tan  = 1 then it 
dissipates and stores equal amounts of energy. 
 
The viscoelastic properties of a clot determine how it responds when 
subjected to a force. Physiological forces arise from either venous or arterial 
blood flow which will apply substantial and varying shear forces upon a clot; 
venous wall shear rates are <300 s-1 (60), arterial ~650 s-1 and in stenosed 
arteries shear rates increase to 2600 s-1 (61). The venous system is 
characterised by low flow and low pressure conditions as opposed to the 
high flow and high pressure in the arterial system. A stiff clot, one possessing 
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a large elastic component and a small viscous component will deform very 
little to a given stress and return to its original shape. A weaker clot; one 
possessing a large viscous component and a small elastic component under 
the influence of the same stress will incur a large and more permanent 
deformation. As indicated above, a clot with very similar elastic and viscous 
components will incur a permanent deformation of similar magnitude to the 
reversible deformation. 
 
 
 
Figure 1-7: Stress vs. strain curves for cross-linked and uncross-linked fibrin clots 
(data from (62), figure from (63)). The elastic modulus is determined from the slope of 
each curve. Strain hardening is apparent in both clots by the non-linear stress-strain 
response. 
 
In order to measure the viscoelastic properties of any material a stress must 
be applied and the resulting strain measured. A stress-strain curve can be 
used to determine the elastic modulus, G  of a material, a quantity which is 
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independent of both the size and shape of the material (58, 62). An example 
of this can be seen between a clot with and without cross-linking (Figure 
1-7), which is known to increase a material‘s stiffness. For the same stress 
you get a much larger strain in uncross-linked clots; indicative of a much 
weaker network. Cross-linking increases a clot‘s stiffness by the formation of 
bonds between individual fibrin monomers (Figure 1-12). The nature of these 
cross-links and their effect on clot stiffness is still currently in debate. 
 
 
 
Figure 1-8: Log-log plot of the storage (G ) and loss (G ) moduli as a function of 
frequency for fine and coarse clots (data from (44), figure from (63)).    
 
Viscoelastic measurements are typically carried out by placing a material 
between two circular plates or a cone and plate (58): the bottom plate is kept 
stationary while the top is rotated in order to produce a shear stress. This 
type of stress is applied parallel to the face of a material and in this way one 
part of the material moves with respect to another. Measurements can be 
applied either dynamically where the top plate is oscillated, or statically 
where the top plate is rotated and held to apply a constant stress and the 
resulting strain is measured (creep experiments). 
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The first major study into the viscoelasticity of clots came from Ferry et al. 
(44) who looked at the dynamic viscoelastic properties of human fibrin clots. 
Two different types of clot structure as determined by the pH and ionic 
strength were investigated: termed ―fine‖ and ―coarse‖ (Figure 1-2 D). Clots 
formed with a low thrombin concentration have a high opacity and consist of 
thick fibres (coarse) while clots formed with a high thrombin concentration 
have a very low opacity and consist of thin fibres (fine). Opacity can be used 
as a measure of the typical diameter of fibres within a clot. It has been shown 
from turbidity measurements that it is possible to estimate the size and 
density of fibrin fibres within a clot (64). 
 
Ferry et al. measured the storage and loss moduli of clots over a frequency 
range of 0.01 to 160 Hz with a Birnboim transducer apparatus; a stainless 
steel cell and rod. This allowed the viscoelastic behaviour of clots to be 
studied over a range of timescales, i.e. slow and fast deformations. For fine 
and coarse clots G  and G  (in dynes cm-2) are plotted as a function of 
frequency (Figure 1-8). For fine clots, G  is independent of frequency, 
suggesting fibrin clots are nearly a perfect elastic system. This consistency in 
a clot‘s elasticity means that the stiffness of a clot is the same irrespective of 
the rate of application of stress. Such behaviour suggests a clot‘s stiffness 
must be important physiologically as the rate of application of stress is likely 
to vary greatly depending upon where a clot is located within the body. 
 
For coarse clots, G  was found to be higher suggesting that clot structure has 
a significant effect upon clot stiffness. The storage modulus of coarse clots 
showed a slight dependence upon frequency suggesting a small inelastic 
component. For both fine and coarse clots their inelastic components show a 
dependency upon frequency. At low frequencies, i.e. slow changes in 
deformation, G  is small and clots behave elastically. While at much higher 
frequencies i.e. fast changes, clots begin to deform irreversibly and are 
beginning to display viscous behaviour. 
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The work of Ferry et al. continued onto studying the linear viscoelastic 
behaviour of fine and coarse clots, on much longer time scales, from 20 up to 
104 s, through the measurement of shear creep and creep recovery in small 
deformations (45). A torsional rheometer was used for this work where clots 
are formed between two circular plates. A large change in the compliance of 
coarse clots between those with and without cross-linking was observed and 
attributed to increased stiffening. The discovery that cross-linking increases 
clot stiffness, contrary to their earlier work (44), was also confirmed by other 
studies at the time (46-48). 
 
The dependency of the initial modulus, corresponding to 20 – 30 s after 
stress has been applied, upon fibrin concentration was also investigated for 
non-cross-linked and cross-linked coarse clots. The dependency for non-
cross-linked clots was G  ~ c1.5 while for cross-linked clots it was G  ~ c2.3. 
The modulus of fine non-cross-linked clots was also found to vary as G  ~ 
c1.5. Different concentration dependences of G  have been reported by many 
other studies: G  ~ c1.67 (fibrin clots formed with 0 - 6mg/ml fibrinogen (33)), 
G  ~ c2 (fibrin clots formed with 0.05 - 0.8mg/ml fibrinogen (48)), G  ~ c2.1 
(fibrin clots formed with 5 - 20 mg/ml fibrinogen (65)), G  ~ c1.7 (plasma clots 
(65)), G  ~ c (platelet free plasma clots (66)) and most recently G  ~ c2.22 
(fibrin clots formed with 0 - 40mg/ml fibrinogen (67)). 
 
Mackintosh et al. developed a model for networks of semi-flexible 
biopolymers in which the elastic properties arise from chains that are very 
straight between entanglements and branches (68). A semi-flexible polymer 
is defined as having a persistence length, ℓp (distance along the polymer 
chain over which vectors drawn tangent to the chain become uncorrelated) 
equal to the contour length, ℓc (distance between branch points or filament 
length). The persistence length increases with increasing filament rigidity and 
decreases with increasing temperature. For a flexible polymer ℓc >> ℓp and for 
a rigid polymer ℓp >> ℓc. Their model predicts the concentration dependence 
of the storage modulus for both entangled and branched networks. An 
entangled network is one which consists of filaments which can cross and 
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loop around one another forming transient branches. For an entangled 
solution the storage modulus scales with monomer concentration, c as:  
 
 2.2~ cG  1-6 
 
For densely cross-linked gels, i.e. a branched network, the storage modulus 
displays a stronger dependence upon the concentration: 
 
 5.2~ cG  1-7 
 
The majority of studies find concentration dependencies which fall below that 
predicted by this model. Discrepancies may arise due to the different 
systems and concentration ranges used. In addition, features and 
fundamental assumptions of the model may also account for any differences 
observed. 
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Figure 1-9: (A) Schematic representation of G  versus  for the three sample 
concentrations depicted in (B) (adapted from (69)). The three concentrations are dilute, 
semi-dilute and concentrated. Their generic behaviour as a function of chain density is 
shown in (B) where density increases from left to right. Note physical systems range 
between the examples shown here. 
 
Figure 1-9 depicts the frequency behaviour of G  for three different polymeric 
samples. For dilute solutions displaying fluid-like behaviour then G  should 
fall with decreasing frequency. These materials display some of the smallest 
storage moduli, while concentrated polymer solutions have some of the 
highest storage moduli. Semi-dilute solutions range between these two 
examples. For long times (small frequencies) they display little resistance 
and behave like fluids. At short times (high frequencies) they begin to display 
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high resistance. In between these timescales, G  displays varying behaviour 
associated with polymer entanglements (plateau region in Figure 1-9).  
 
Boal et al. provides a qualitative explanation for the different shear relaxation 
modes which can occur on each distinct timescale (69). At short times only 
molecular rearrangements and transitions can occur. While at long times 
large scale motion of the polymer chains can occur. On intermediate 
timescales the polymer chains move on length scales characterised by 
distances between entanglement points. These are loops and knots which 
form between polymer chains as they move around one another. Here the 
polymer chains are behaving like a network of branched chains resulting in a 
frequency-independent shear resistance. This model describes the 
viscoelastic behaviour of flexible polymer solutions where chains cross and 
loop around one another but do not form a permanent branched network like 
fibrin. 
 
 
Figure 1-10: (A) Schematic representation of the different stress contributions (figure 
from (70)). (B) Schematic of G ( ) (solid line) and G ( ) (dashed line) for a solution of 
coil-like chains (figure from (71)). Each plateau in G  indicates frequency regimes where 
G*( ) is dominated by either curvature or tension contributions. A low frequency orientation 
plateau is assumed to make a negligible contribution on all times for coil-like polymer 
solutions and is thus ignored.   
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A more complete mathematical treatment is provided by Morse‘s model (71-
73) which describes the viscoelastic properties of semi-flexible polymer 
solutions between the rod-like (ℓp >> ℓc) and coil-like (ℓc >> ℓp) limits. Morse 
derives a general expression for the stress tensor for a solution of worm-like 
chains and identifies three stress contributions: 
 
 tens: a tension contribution arising from tangential forces that resist 
stretching or compression of the chain 
 curve: a curvature contribution arising from forces that oppose 
transverse deformation or rotation of chain segments 
 orient: an orientational contribution arising from forces that resist 
movement of the entire chain 
 
These different stress contributions are depicted in Figure 1-10 A. The 
general expression of the stress tensor may be applied to any concentration 
regime and from this a prediction of the behaviour of G ( ) can be calculated 
(Figure 1-10B) for a whole host of parameters e.g. ℓp, ℓc and ℓe, the 
entanglement length (defined as the distance between polymer 
entanglements) (71). One such example, for a solution of coil-like chains in 
the tightly-entangled regime (ℓp >> ℓe), is given in Figure 1-10 B. This predicts 
the existence of a low-frequency, curvature dominated plateau and a higher-
frequency, tension-dominated plateau. This behaviour corresponds with the 
qualitative description of Boal et al. (69) presented above and in addition, the 
high-frequency tension dominated plateau predicted by Morse‘s model is the 
same one as that predicted by Mackintosh et al. (68) (Equation 1-6). 
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Figure 1-11: Values of G ( ) (solid line) and G ( ) (dashed line) which is an 
approximation to the behaviour of a lightly branched gel (figure from (71)). The model 
parameters were chosen to be representative of a 1 mg/ml solution of F-actin. Note the 
plateau in G which extends to lower frequencies while G  diverges to lower and lower 
values. 
 
Morse also looked at the effect of branching on the viscoelastic behaviour of 
a solution of worm-like chains. This model assumed relatively few free 
filament ends and that each filament was relatively straight between 
branches; a scenario not to dissimilar to the physical architecture of fibrin 
networks. The calculated behaviour of G ( ) is presented in Figure 1-11. The 
storage modulus is predicted to plateau  while the loss modulus diverges 
becoming smaller and smaller. Thus, it appears that the effect of branching is 
to dramatically alter the stress relaxation behaviour at lower frequencies. 
 
Ferry et al. went onto measure the effects of strain and clot age on creep and 
creep recovery (45). For old (6 hours+) coarse cross-linked clots it was found 
that compliance during creep is independent of strain magnitude indicating 
linear viscoelastic behaviour; after 103 seconds, recovery is more than 98% 
complete. Such recovery is attributed to the fact that the clot is fully formed 
before creep experiments begin; none of the network is formed under strain. 
For young (<4 hours) coarse cross-linked clots the compliance is smaller 
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indicating a stiffer clot and recovery is very different; differences are 
explained by the fact that the clot is formed under strain. This suggests clots 
subjected to stresses before they are fully formed can result in a much stiffer 
clot with altered elastic properties. This will have interesting implications for 
the interpretation of in vitro data where experiments are typically carried out 
under static flow conditions. 
 
Next, Ferry et al. studied the behaviour of fine cross-linked and coarse non-
cross-linked clots (41). It was found that fine clots subjected to small strains 
obey Hooke‘s law and display no inelastic behaviour. The dependence of the 
storage modulus on fibrin concentration for fine cross-linked and coarse non-
cross-linked clots was G  ~ c1.5. The dependence of G  for fine cross-linked 
clots is very close to that reported previously for fine non-cross-linked clots 
(45). This is attributed to the fact that cross-linking may not have been 
completely absent from their earlier work. It was found in both fine and 
coarse clots that creep is largely suppressed by cross-linking and this 
involves only the -chains as indicated by gel electrophoresis. 
 
The work of Mockros et al. looked at the viscoelastic properties of cross-link 
inhibited clots using a cone-plate rheometer (46). It was found that cross-
linking increased clot stiffness in both plasma and purified clots. The 
introduction of inhibitors produced a substantial reduction in clot stiffness; at 
high enough inhibitor concentration clot stiffness approached that of non-
cross-linked clots. A dependence of the storage modulus and loss tangent 
upon total ionic strength, μ was found, with a peak stiffness and minimum 
dissipation at μ = 0.17.. 
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Figure 1-12: Schematic model of the possible orientations of cross-links in fibrin 
protofibrils (figure from (54)). A: longitudinal orientation of -chain cross-links. B: 
Transverse cross-links of -dimers. In this diagram, transverse crosslinks occur only 
between molecules within the same double-stranded protofibril. C: transverse dimeric cross-
links of -chains between adjacent protofibrils. D: longitudinal and transverse cross-links of 
-chains between adjacent protofibrils. The patterns of cross-links shown in C and D are only 
two of many that may potentially be formed between protofibrils arranged within a three-
dimensional fibre. E: possible orientation of -tetramers, -polymers and -hybrid polymers 
between two adjacent protofibrils. 
 
Other related work at the time of that being carried out by Ferry et al. were 
studies into the effects of calcium ion and cross-linking upon fibrin structure 
and elasticity by Shen et al. (47). It was found that the presence of calcium 
results in the development of a clot with a much higher elastic modulus. By 
measuring the development of cross-linking activated by FXIIIa, it was found 
that cross-linking of the -chains results in an increase in the elastic modulus 
while cross-linking of the -chains does not, contrary to previous work by 
Ferry et al. (41). 
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More recently Ryan et al. studied the effects of natural and synthetic 
inhibitors of FXIIIa in order to determine which cross-linking species are 
responsible for augmenting clot stiffness (54). Cross-linking was controlled 
using two inhibitors, cross-linked chains were identified by SDS-PAGE 
analysis and clot stiffness was measured using a cone-plate rheometer. The 
formation of -dimers, -multimers, -polymers and -hybrids (Figure 1-12) 
were all detected. It was found that FXIIIa-induced dimeric cross-linking of 
the -chains alone is not sufficient to stiffen the fibrin network but that clot 
stiffness was more strongly correlated with the formation of -multimers, -
polymers, and -hybrids. 
 
Collet et al. used a fibrinogen with a truncated -chain in order to study 
cross-linking (74). They also report a lower effect of -chain cross-linking on 
clot stiffness. A study by Standeven et al. (75) investigated FXIIIa cross-
linking using recombinant fibrinogens with modified FXIII cross-linking sites 
on the -chain. In this study, -chain cross-linking contributed significantly to 
clot stiffness through the formation of -dimers while -hybrids had the 
smallest effect on clot stiffness. In addition, no differences in clot 
morphology, polymerisation and fibrinolysis rate were reported for the 
recombinant cross-linking variant. The apparent discrepancy between these 
observations and that of previous authors may be attributed to the 
interference of antibodies and inhibitors along with the removal of substantial 
parts of the fibrinogen molecule as in the studies of Ryan et al. (54) whilst in 
the study of Standeven et al. (75) cross-linking was controlled by specific, 
small mutations in the cross-linking sites. 
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Figure 1-13: Quantitative data of fibrin network architecture as a function of 
fibrinogen, thrombin and CaCl2 concentration (figure from (33)). A: effects of fibrinogen 
concentration on non-cross-linked fibrin networks. B: effects of thrombin concentration on 
non-cross-linked fibrin networks. C: Effects of calcium concentration on fibrin networks. 
Clots were formed with either 0 mM (solid symbols) or 1 mM (open symbols) FXIIIa inhibitor. 
 
In order to understand the role of clot structure in modulating clot 
viscoelasticity Ryan et al. carried out detailed structural analysis upon a 
variety of clot architectures and correlated this with viscoelastic 
measurements (33). Network architecture was manipulated by varying 
fibrinogen, thrombin and CaCl2 concentrations. Quantitative measurements 
of clot architecture (Figure 1-13) were made by analysing computerised 
three-dimensional models which were constructed from stereo pairs of 
scanning electron micrographs (76). 
 
Large fibre diameters and lengths were established only when branching 
was minimal. Increases in fibre length were generally associated with 
increases in fibre diameter. Viscoelastic properties of clots were measured 
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with a cone-plate rheometer and correlated with structural features of the 
networks. Clot stiffness increased with increasing fibrinogen concentration. 
This was attributed to increased fibre and branch point density as fibre length 
and diameters were relatively insensitive to fibrinogen concentration. At 
constant fibrinogen but varying thrombin and calcium concentrations, 
maximal rigidities were established in samples (both cross-linked and non-
cross-linked) which displayed a balance between large fibre sizes and a high 
degree of branching. Clot stiffness decreases with increasing thrombin (after 
0.5U/ml concentration) and calcium concentration (after 1.5 mM). The effect 
of FXIIIa upon network structure was minimal, with a slight increase in fibre 
length and decrease in fibre diameter being observed. This suggests 
increased clot rigidity most likely arises from the stiffening of the individual 
fibres as opposed to structural alterations at the network level. 
 
Another aspect of fibrin clot viscoelasticity is the phenomenon of strain-
hardening. At low strains stress is directly proportional to strain (Hooke‘s law) 
and the elastic modulus is constant (41). At larger strains the elastic modulus 
begins to increase and a clot becomes stiffer, increasing by up to a factor of 
20 (51). Strain-hardening is also apparent in clots with and without cross-
linking. Roberts et al. (62) observed a non-linear stress-strain response in 
cross-linked and non-cross-linked fibrin clots at strains above 10% (Figure 
1-7). The work of Shah et al. (77) showed that the addition of platelets to 
both human plasma and fibrin clots increases clot stiffness and eliminates 
strain-hardening. 
 
The molecular origin of strain-hardening in fibrin clots is currently unknown. 
The theory of Doi et al. proposes that the elasticity of gels consisting of stiff 
rod-like polymer chains arises from the elastic deformation of the chains 
which are forced to bend under strain (78). Janmey et al. used this theory to 
interpret strain-hardening as arising from the increased number of contacts 
between fibres at large deformations (79). Within this framework an increase 
in elastic modulus is due to an increase in the number of elastically active 
network junctions. This interpretation accounts for the increase in stiffness at 
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moderate strains, however fails at larger strains. The effect of platelets which 
eliminates strain-hardening as observed by Shah et al. is explained by the 
platelets applying tension to the fibres and pulling out the slack which 
increases fibre stiffness as opposed to increasing the number of elastically 
active junctions (77).  
 
Storm et al. report a theory that accounts for strain-hardening in a range of 
semi-flexible polymer networks at low to intermediate strain (80). The model 
links the theoretical force-extension behaviour of single fibres, based upon a 
worm-like chain (WLC) model, to the bulk modulus of the network. They 
predict that strain-hardening is intrinsic to all similar filamentous networks 
and they stiffen at low strains without requiring multiple elements of different 
intrinsic stiffness. That is, strain-hardening arises due to the entropic 
response of the individual fibres which then contributes to the overall 
macroscopic response. 
 
A review by Weisel proposed that if the bending of fibres gives rise to clot 
elasticity then the stretching of fibres could play an important role at larger 
strains and account for strain-hardening behaviour (13). Very recently work 
into the multiscale mechanics of fibrin clots has begun to shed light on the 
mechanisms responsible for strain hardening. Brown et al. (81) report that 
fibrin fibres orient themselves and stretch along the direction of the applied 
strain. At low strains fibres can stretch as the constituent protofibrils 
straighten and untwist within the fibre. Next, they propose molecular 
unfolding occurs and this could be responsible for the linear strain response 
up to higher strains. However, once the coiled coils, or some other compact 
structures in fibrin such as the D-region, have completely unfolded this leads 
to strain-hardening. To test this mechanism they modelled the stress-strain 
behaviour using the model of Storm et al. (80) and find that protein unfolding 
is required to fit the model to the experimental data. 
 
Hudson et al. report an interesting consequence of strain-hardening on the 
mechanical behaviour of fibrin clots (82). Using a combined 
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fluorescence/AFM nanomanipulation system they stretched 2D fibrin 
networks suspended over channels. They find that fibre strain-hardening 
distributes strain more evenly throughout the network i.e. once a fibre begins 
strain-hardening it pulls on any adjoining fibres transferring strain to them. 
This reduces the strain maxima and increases network strength. They find 
the behaviour observed in their experiments doesn‘t fit easily with the model 
of Storm et al. (80) but suggest that accounting for protein unfolding could 
resolve inconsistencies. 
 
 
Figure 1-14: (a): an individual fibrin fibre with a polystyrene bead attached (figure 
from (83)). A force is exerted on a bead using optical tweezers in order to either stretch or 
bend a fibre (scale bar = 1μm). (b): schematic diagram of a fibre bending showing the 
measured parameters used for the calculation of the elastic modulus. 
 
Work by Collet et al. measured the properties of individual fibres in clots with 
and without cross-linking (83). They used optical tweezers to either bend or 
stretch individual fibres (Figure 1-14). The elastic moduli measured for 
individual fibres in plasma clots was 1.7 and 14.5 MPa for non-cross-linked 
and cross-linked fibres respectively. This agrees with the earlier work of 
Ryan et al. (84) who suggested that FXIIIa cross-linking increases clot 
stiffness via the stiffening of individual fibres. It is also reported that fibres 
were much stiffer for stretching than for bending, as expected from their 
diameter to length ratio. The elastic moduli of non-cross-linked fibres was 1.7 
MPa for bending and 1.9 MPa for stretching and for cross-linked clots was 
14.5 MPa for bending and 11.5 MPa for stretching. This suggests cross-
linking makes a fibre more flexible for stretching. In addition, this work 
31 
 
supports Weisel‘s theory that fibre stretching plays a role in the strain-
hardening response of fibrin clots. 
 
Measurements on single fibres have also been carried out by Guthold et al. 
using the Atomic Force Microscope (AFM) (26, 85, 86). They have 
developed a technique to image and mechanically manipulate individual 
fibrin fibres. The first of these studies (26) used the AFM to image then 
stretch individual fibrin fibres upon mica surfaces. Fibres were stretched until 
they snapped and the rupture force was determined as a function of fibre 
diameter. 
 
Rupture force increased with increasing diameter as FR ~ d
1.30±0.06. It was 
also observed that the light intensity (number of molecules per cross-section) 
of single fibres as a function of their diameter increased as I ~ d1.25±0.11. This 
suggests that fibrin fibres are fractals where the number of molecules per 
cross-section increases as d1.3, which implies that the molecular density 
varies as (d) ~ d-0.7. That is, thinner fibres are denser than thicker fibres; this 
points towards the idea that fibrin fibres are extremely porous. Considering 
the average concentration of fibrinogen in the blood is around 2.5 mg/ml, a 
clot made from fibrinogen at this concentration is only 0.25 g out of 100 ml of 
volume, meaning fibrin constitutes ~0.25% of the total clot volume (63). The 
remaining 99.75% of the clot consists of liquid which occupies the space 
between protofibrils in the fibres and the much larger spaces between the 
fibres (pores). 
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Figure 1-15: Model for fibre extension (figure from (86)). A: crystal structure of 
fibrinogen. A cartoon depiction of the C domain is added to the crystal structure as a blue 
line with a blue square; C domains can interact with one another within a protofibril and 
between protofibrils. B: schematic model of half-staggered assembly of three fibrin 
monomers into a protofibril. C: -helix to -strand conversion of the coiled coil and a 
straightening and alignment of the molecules could account for ~100% strain. D: strains up 
to 320% could be accommodated by a partial unfolding of the globular -nodule; 230% strain 
is depicted. Further extension of the C domains could occur E: C domains promote lateral 
aggregation of protofibrils; they can be elastically extended.  
 
Later studies (85, 86) built on the previous work by using the AFM to 
manipulate single fibres suspended over 12 μm wide channels. They report 
that cross-linking renders fibres less extensible, stiffer and less elastic than 
non-cross-linked fibres. In order to explain their findings they propose a 
molecular model for the stretching of fibrin fibres (Figure 1-15). They also 
propose a longitudinal, as opposed to transverse, orientation for -  cross-
links (Figure 1-12).   
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In addition, Guthold et al. used the AFM to investigate the mechanical 
properties of branch points (34). In this instance they suspended branched 
fibres over channels and stretched them until they ruptured. They find that 
non-cross-linked and cross-linked branches show different rupture 
behaviour. Non-cross-linked branches ruptured 68.5% of the time at the 
branch and 31.5% of the time along the fibre. In contrast, cross-linked 
branches ruptured 39.5% of the time at the branch and 60.5% along the 
fibre. This suggests cross-linked branches are stronger than cross-linked 
fibres, while the opposite is true for non-cross-linked fibres. This could be 
explained by the lower extensibility of cross-linked fibres.  
  
There has been much debate over the longitudinal versus transverse 
orientation of -  cross-links within the literature (87, 88). Mosesson (7) 
proposes that -chain cross-links are orientated transversally between 
molecules of different fibrin strands (Figure 1-16). Cross-linking is 
represented in this way in order to explain the important viscoelastic 
response of fibrin, that after a maximum stretch of 1.8-times, cross-linked 
fibrin is able to recover its original form (89), while non-cross-linked fibrin 
cannot (90). The precise location of cross-linked -chains has been debated 
for many years but as yet has not been agreed upon. 
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Figure 1-16: Schematic diagram of a transversely cross-linked fibrin fibril being 
stretched and relaxed (figure from (7)). When a double-stranded fibril is maximally 
stretched 1.8 times it becomes single-stranded, and the individual fibrin molecules remain 
connected to one another through covalently cross-linked -chains. Upon relaxation, the fibril 
recovers its original form. It is suggested by Mosesson that only cross-linked -chains 
positioned transversely between fibril strands can account for this behaviour. 
 
The work of Collet et al. (83) suggested the origin of clot elasticity arises from 
the bending of fibres; however no indication as to the underlying molecular 
basis of clot elasticity was presented. Recently, two independent studies (91, 
92) have attempted to elucidate the molecular origin of clot elasticity by 
suggesting that the coiled-coils of fibrinogen are responsible. Both studies 
used the AFM to mechanically unfold fibrinogen molecules (Figure 1-17). In 
the first of these studies by Brown et al. (91), forced unfolding was performed 
upon engineered linear oligomers of fibrinogen; multiple fibrinogen molecules 
joined end-to-end. It was found that the force extension curves of these 
oligomers produced saw tooth patterns with a peak-to-peak length consistent 
with the independent unfolding of the coiled-coils. This work suggests that 
the coiled-coil of fibrinogen is more than just a passive structural element 
and that their unfolding could account for the large extensibilities recently 
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observed in fibrin fibres (86). This also demonstrates the biological function 
of protein unfolding (94).     
 
The second of these studies by Lim et al. (92) used the AFM to probe the 
mechanical properties of single fibrinogen molecules and fibrin protofibrils. 
They found that the mechanical unfolding of fibrinogen‘s coiled-coil domains 
is characterised by a distinctive intermediate force plateau in the systems‘ 
force-extension curve. This force plateau is related not only to the unfolding 
of fibrinogen‘s coiled coils but also of its central E domain. This highlights the 
complex nature of the unfolding events within fibrinogen. 
 
 
 
Figure 1-17: Schematic of the experimental pulling geometry of fibrinogen molecules 
using the AFM (figure from (91)). Fibrinogen oligomers adsorbed on mica were extended 
by the AFM tip shown in yellow. When a single coiled-coil is unfolded the oligomer contour 
length increases by 23 nm. 
 
The C-terminal region of the A -chain forms the fourth strand of the 
quadruple-helical portion of the coiled-coil (Figure 1-2 A) and is known to 
interact with the central region through the C-domain (93). It has been 
suggested by Brown et al. (91) that this structural feature may reduce 
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refolding and contribute to the mechanical stability of fibrinogen. Lim et al. 
(92) observed sequential unfolding of coiled coils in a protofibril as opposed 
to simultaneous unfolding of all coiled coils and attributed this behaviour to 
the fourth helical strand located at the C terminus of each set of coiled-coils. 
Again, it is suggested that interactions occurring here may restrict the 
unfolding of fibrinogen and help to buffer forces between connected 
fibrinogen molecules. However, it is difficult to speculate exactly what is 
occurring due to the unique architecture of this region. Improved simulations 
on more appropriate timescales to identify which domains of fibrinogen are 
stable along with the use of recombinant fibrinogens lacking the C-domain 
will help to underpin these questions. 
 
1.4 Thesis Aims 
 
The main aim of this project was to develop an experimental method to study 
the viscoelastic behaviour of fibrin clots. This thesis will seek to describe the 
viscoelastic properties of fibrin clots studied using this technique. Throughout 
this work the effects of fibrinogen, along with many other blood proteins 
involved in coagulation, will be studied in order to better understand their role 
within fibrin clot viscoelasticity. In addition, studying clot polymerisation and 
structure through various complimentary techniques will provide a better 
understanding of the role of viscoelasticity in clot structure and function. The 
specific aims of this work are listed in detail here:   
 
 Develop an experimental technique to measure the frequency 
dependent viscoelastic moduli of fibrin clots using a magnetic 
microrheometer. 
 Using this technique, study the viscoelastic properties of fibrin clots 
and compare these measurements with current theories on the 
behaviour of viscoelastic networks. In particular, determine the effects 
of FXIII on clot viscoelasticity which has been widely reported upon in 
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the literature. Such measurements will serve as a good validation to 
the experimental technique developed in this work.  
 Study the effects of fibrinogen, thrombin and CaCl2 concentration on 
fibrin clot viscoelasticity, all of which are known to modulate fibrin clot 
structure. In this way it will be possible to correlate variations in clot 
structure with changes in clot viscoelasticity. The role of these 
reactants in modulating clot viscoelasticity is still not fully understood.  
 In addition, study the effects of the fibrinogen  chain splice variant  
on fibrin clot physical properties and determine the molecular 
mechanism underpinning the variations observed. Currently, there is 
much debate on the effects of fibrinogen  in clot structure and 
function along with its role in cardiovascular disease. 
 Finally, study the effects of the plasma proteins FVII, FIX, FXII and 
FXIII on polymerisation, structure and viscoelasticity of plasma clots. 
This will lead to a better understanding of how the coagulation 
cascade modulates the viscoelastic properties of clots. 
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Chapter 2 
2 Materials and Methods 
 
This chapter outlines all the biological materials and reagents used throughout 
this work. An introduction to standard experimental techniques and sample 
preparation are also provided. The techniques and preparations described here 
will be utilised throughout the remainder of this work, when procedures and 
preparations differ, changes will be explicitly stated.   
 
2.1 Materials 
 
The main constituents used to assemble fibrin clots are thrombin and 
fibrinogen. Thrombin (human alpha-thrombin, American Diagnostica, CT, US) 
was diluted in distilled water (dH2O) to a final concentration of 250 NIHU/ml 
(NIHU is a National Institiue of Health standard Unit). The concentration of 
thrombin is measured in active units where 1 NIHU/ml = 9.16 nM (94). Thrombin 
loses activity rapidly at room temperature so after dilution it was immediately 
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aliquoted (on ice) and stored at -80ºC. Before use, thrombin was defrosted, 
diluted in TBS buffer (50 mM Tris, 150 mM NaCl, pH 7.4) to the required 
concentration and then used immediately. Clotting was also performed using 
Reptilase (Diagnostica Stago, Asnières sur Seine, France), a snake venom 
which cleaves FpA only. This was diluted in dH2O to 20 BU/ml and stored at -
80ºC. 
 
For the majority of experiments standard commercially available human 
fibrinogen (Plasminogen, von Willebrand Factor and Fibronectin depleted, 
Enzyme Research Laboratories (ERL), Swansea, UK) was used. This 
fibrinogen is purified from frozen plasma and received in lyophilised form. It was 
prepared by reconstituting in TBS buffer heated to 37ºC; upon reconstitution the 
solution was diluted in TBS buffer to a stock concentration of 2 mg/ml and then 
aliquoted and stored at -80ºC. Fibrinogen concentration is determined by 
absorbance at 280 nm using an extinction coefficient of 1.51 (95) with a 
Nanodrop Spectrophotometer (Labtech International, UK). 
 
A/ A and A/  fibrinogens were purified from human plasminogen-depleted 
fibrinogen (ERL) as described previously (96) using anion exchange 
chromatography. This work was carried out by Dr Shirley Uitte de Willige 
(Division of Cardiovascular and Diabetes research, Section on Mechanisms of 
Thrombosis, Faculty of Medicine and Health, University of Leeds, Leeds, UK).  
 
Fluorescently labelled fibrinogen (fibrinogen from human plasma, Alexa Fluor® 
488, Paisley, UK) was used for confocal microscopy imaging. It was prepared 
by dissolution in dH2O to a concentration of 2.0 mg/ml and then aliquoted and 
stored at -80ºC until use. 
 
All deficient human plasmas (FVII-DP, FIX-DP, FXII-DP and FXIII-DP) were 
obtained from ERL. The plasma was thawed by heating to 37ºC in a waterbath 
for 5 minutes, aliquoted and then flash-frozen in liquid nitrogen and stored at -
80ºC until use. Human plasma proteins (FVIIa, FIXa, FXIIa and FXIII) were also 
obtained from ERL. The lyophilised proteins were dissolved in dH2O to a 
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concentration of 50 μg/ml (FVIIa), 1.29 mg/ml (FIXa), 400 μg/ml (FXIIa) and 110 
g/ml (FXIII); they were then aliquoted and stored at -80ºC until use. 
 
Cross-linking of fibrin by FXIIIa was controlled with the synthetic inhibitor 1, 3, 4, 
5-tetramethyl-2[(2-oxopropy-1)thio]imidazolium chloride (L682777, ZEDIRA 
GmbH, Darmstadt, Germany), which was dissolved in DMSO and further diluted 
in dH2O to a concentration of 40 mM and stored at -20ºC until use. This inhibitor 
is highly specific for the active site of the FXIII A-subunit (97). 
 
2.2 Methods 
 
2.2.1 SDS-Polyacrylamide Gel Electrophoresis 
 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) is a 
technique which separates proteins according to their molecular weight. 
Proteins are mixed with an SDS detergent which denatures secondary and 
tertiary structure and applies a negative charge to the protein in proportion to its 
mass, i.e. the larger the protein the greater the charge. Next, the protein is 
heated to near boiling point in reducing sample buffer which further denatures 
the protein‘s structure; breaking up tertiary protein folding and quaternary 
structure. These denatured proteins are then applied to one end of a 
polyacrylamide gel which is submerged in buffer and an electric field is applied 
across the gel for a set amount of time. The negatively charged proteins migrate 
through the gel, each protein migrates at a different rate depending upon its 
size (charge), resulting in a separation of protein by molecular weight. After this, 
a gel is stained in order to image the separated proteins. A molecular marker of 
known molecular weight is run in a separate lane on the gel to identify different 
proteins chains.  
 
SDS-PAGE was used to separate fibrinogen polypeptide chains and FXIII 
cross-linked chains according to their molecular weight. Fibrinogen samples 
were prepared in 5 μl of blue NuPAGE loading dye (Invitrogen, Paisley, UK) and 
2.5 μl of reducing sample buffer and then heated to 95ºC for 10mins with a hot 
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plate. For cross-linking reactions, fibrinogen (final concentration 0.5 mg/ml), 
CaCl2 (2.5 mM) and either inhibitor (1 mM) for no cross-linking or FXIII (3.7 
μg/ml) for cross-linking were diluted in TBS buffer, and pre-mixed in 0.5-ml 
Eppendorf tubes. Thrombin (1.0 U/ml) was then added to initiate clotting, which 
was allowed to proceed for 0, 1, 2, 5, 15, 30, 60, 120 and 360 minutes at room 
temperature. The clotting reaction was stopped by the addition of loading dye 
and reducing sample buffer and then heating. For the 0 minute time point 
reactions loading dye and reducing sample buffer were added prior to thrombin 
injection and heating proceeded immediately after. 
 
 
 
Figure 2-1: SDS-PAGE gel analysis. Left: ImageJ screenshot of a cross-linking gel showing 
the software selection of 2 lanes. Right: software plots of the two lanes; each peak corresponds 
to a polypeptide chain band on the gel. The background level of a lane is set by the red line. 
Here the contrast intensity of a band relating to the  dimer cross-linking product has been 
measured. 
 
Samples were then either frozen at -80ºC or immediately loaded onto a gel. 20 
μl of sample were loaded into each well of a 4 - 12% Bis-Tris gradient gel 
(Invitrogen, Paisley, UK) and electrophoresis was carried out using a NuPAGE 
unit (Invitrogen, Paisley, UK). 200V was applied across the gel for 90 mins in 
MOPS running buffer (Invitrogen, Paisley, UK). After this time, the gel was 
removed and washed in dH2O (3 times for 5 minutes each on a shaker at room 
temperature) and then stained with Gelcode blue protein stain (Pierce, 
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Rockford, IL, USA) for 1 hour. Gels were then de-stained with dH2O on a shaker 
at room temperature overnight. Finally, the gel was photographed digitally using 
an Alpha Innotech (San Leandro, CA, USA) gel-documentation system.  
 
All digital images of gels were analysed using the software ImageJ (National 
Institute of Health, Bethesda, MD, USA). This program has a feature which 
enables the bands of a gel to be quantified. In brief, each lane was selected 
with a rectangular region which encapsulates the polypeptide chain bands; from 
this a plot is produced (see Figure 2-1). This plot is a 2D representation of the 
3D rectangular region where the x axis represents the molecular weight and the 
y axis is the contrast intensity of the gel. The background intensity was then set 
by drawing a line along the plot which defines the background level. Finally, the 
area under a peak can be measured giving the intensity of that polypeptide 
band. Each band is normalised to the B  chain band (which is not subject to 
cross-linking by FXIIIa) of that same lane. This allows quantitative information to 
be extracted from a gel, e.g. the relative amount of cross-linking and kinetics. 
 
2.2.2 Turbidity 
 
Turbidity is a technique which measures the level of cloudiness of a fluid i.e. 
measures the amount of suspended matter. Light is passed through a solution 
and scattered by any intervening matter, a detector measures the amount of 
transmitted light and therefore the relative amount of matter present. 
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Figure 2-2: Schematic diagram representing an experimental turbidity setup (adapted 
from (98)). The intensities of the incident light (I0) and transmitted light (I) are used to determine 
the absorbance (A ) of the intervening solution via Equation 2-1.  
 
Turbidity can be expressed as the absorbance A  (also termed the optical 
density) by measuring the intensity of the incident light (I0) and the intensity of 
the transmitted light (I) through a solution (see Figure 2-2) and using the 
following equation:  
 
 
I
I
A 0log  2-1 
 
Turbidity is a common technique used to measure the time development of 
fibrin polymerisation. The absorbance typically displays an initial lag phase 
followed by a rapid increase which then reachs a plateau (see Figure 2-3). The 
lag phase corresponds to the formation of protofibrils from fibrin monomer after 
fibrinopeptide cleavage. The rapid rise in optical density results from lateral 
aggregation of protofibrils that have reached a minimum length. The final value 
of turbidity, at the plateau, is directly related to the average size of the fibres or 
fibre bundles (30). It has been shown that turbidity is directly proportional to the 
average cross-sectional area of fibres (64), with a high level of absorbance 
indicating larger fibre diameters.  
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Figure 2-3: Turbidity curve of a fibrin clot during the first 30mins of polymerisation. 
Insert: the first derivative of the absorbance (dA/dt) as a function of time. 
 
In addition to fibrin polymerisation, turbidity can also be used to monitor fibrin 
clot lysis (fibrinolysis). Again, the absorbance displays a rapid increase as the 
network forms and fibres grow. However, instead of a plateau in the absorbance 
there is a peak after which the absorbance begins to decrease as the network is 
broken down by plasmin generated from plasminogen by tissue plasminogen 
activator (tPA), added to the activation mixture at the start of the experiment.  
 
All turbidity experiments were performed in 96-well plates using a BioTek 
ELX808 micro plate reader supplied by Labtech International (Ringmer, UK). 
Typically, in a single well 90 μl of fibrinogen (final concentration 0.5 mg/ml), 
CaCl2 (2.5 – 7.5 mM), TBS buffer and any other reagents (e.g. FXIII (3.7 μg/ml)) 
were premixed, after which 10 μl of thrombin (0.5 – 1.0 U/ml) was added to 
initiate coagulation. For lysis experiments the fibrinogen was incubated with 
plasminogen (0.3 μM) and the thrombin (1.0 U/ml) with tPA (1 nM). Upon the 
addition of the thrombin-tPA mixture clotting and lysis proceed simultaneously. 
Immediately after the addition of thrombin the plate was transferred to the 
reader and measurements were taken at regular intervals e.g. every 12s for 1 
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hour (unless otherwise stated), at a wavelength of 340 nm at room temperature 
(unless otherwise stated). Generally, each clot was prepared in triplicate. 
 
Data analysis was performed using the software OriginPro 8 (OriginLab, MA, 
USA). In order to compare the kinetics and structure of different fibrin clots 4 
parameters were extracted: the lag time, maximum rate, final absorbance and 
plateau time. The lag time is measured as the time elapsed until an increase in 
absorbance is observed (99). The maximum rate is defined as the maximum 
rate of change in the absorbance. The final absorbance is taken once the curve 
has reached a plateau and no further increases in absorbance are observed. 
And the plateau time is the time taken to reach the final absorbance. For lysis 
experiments, the lysis time is also determined and defined as the time taken for 
the maximum absorbance to reduce by half.   
 
The first time derivative of the absorbance (dA/dt) was calculated and plotted to 
assist in determining these quantities (see Figure 2-3 insert). This plot shows 
the rate of change of absorbance with time. Over the first minute of clotting 
dA/dt = 0 indicating no change in the absorbance; this defines the lag time. The 
curve rapidly increases, then peaks and begins to decrease; the peak in dA/dt is 
the maximum rate. The lag time and maximum rate give kinetic information on 
the rate of protofibril and fibre formation respectively. The final absorbance 
gives information on the average fibre diameter while the plateau time gives a 
measure of time taken for the entire network to form. 
 
2.2.3 Measurement of Clotting Time 
 
The clotting time, or gel point as it is referred to in polymer chemistry, is the 
point at which a substance turns from liquid to solid. Within a clot this is the time 
at which a minimum number of fibrils interconnect and span a length scale of 
the clot such that the clot becomes a gel (100). The gel point can be detected 
manually or automatically. Manual inspection typically involves forming a clot in 
a tube which is then tilted periodically until clot formation is detected by eye 
(33).  
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For manual inspection in this thesis, clots were formed in Eppendorf tubes in 20 
μl final volumes and the timer was started. At set times (30, 35, 40, 45, 50, 55 s) 
a pipette was used to draw up some of the clot mixture. Prior to the gel point the 
clot can easily be drawn up into the pipette. After the gel point, once it has 
clotted, the mixture cannot be drawn up and a piece of clot is attached to the 
end of the pipette.  
 
Automatic determination of the gel point was carried out using an Amelung 
coagulometer. Samples were pre-mixed in plastic cuvettes; a small ball bearing 
(~2 mm in diameter) was placed inside the mixture. The setup and the 
geometry of the cuvette are such that the ball bearing stays stationary while the 
cuvette rotates. The cuvette was placed within the coagulometer where it was 
heated to 37ºC and slowly rotated. Next thrombin was added to initiate 
coagulation and timing commenced automatically. Once the clot gels, the ball 
bearing is captured within the network and begins to rotate, this motion is 
detected electromagnetically and the time at which this occurs is recorded. 
Each sample was repeated 5 times. 
 
2.2.4 Confocal Microscopy 
 
Confocal Microscopy is an optical imaging technique which allows visualisation 
deep into samples, the creation of 3D images and the observation of biological 
processes. Confocal microscopy, unlike conventional microscopy, uses point 
illumination and a confocal pinhole positioned in front of a detector to remove 
out-of-focus light, only allowing light from the focal plane to reach the detector 
(see Figure 2-4). This dramatically improves image quality and allows the 
collection of optical slices to construct a 3D representation of a sample. 
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Figure 2-4: Schematic diagram of laser scanning confocal microscopy (LSCM) setup 
(figure from (101)). A laser spot produced by a pinhole aperture is scanned over a specimen 
exciting the fluorescent dye present in a focal plane. The light from only this focal plane is 
collected by a detector. 
 
For this work, laser scanning confocal microscopy (LSCM) was utilised (Figure 
2-4 shows a typical LSCM setup) to image fibrin network structures in fully 
hydrated form and in 3D. Coherent laser light (excitation source) is passed 
through a pinhole aperture to produce a point illumination source which is 
focused onto a dichromatic mirror. The reflected light from the mirror is scanned 
across a sample in a defined focal plane exciting the fluorescent emitting dye.  
This produces secondary fluorescence emission which passes back through the 
dichromatic mirror and is focused into a point at the detector pinhole aperture. A 
significant amount of fluorescence emission occurs above and below the focal 
plane. This is termed out-of-focus light and is removed by another pinhole 
aperture positioned at the detector. Light from above or below the focal plane 
focuses either in front or behind the pinhole aperture and is therefore physically 
blocked or misses the detector. Light originating from within the focal plane is 
focused at the pinhole aperture and passes through to the detector. As only a 
small fraction of out-of-focus light passes through the pinhole aperture the 
majority remains undetected and does not contribute to the resulting image. The 
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fluorescent light which passes through the pinhole aperture is collected by a 
photomultiplier tube (PMT) which converts the light into an electrical signal 
which is then sent to a PC where the resulting image is processed and 
constructed.  
 
Scanning a single focal plane pixel by pixel creates an optical slice of a sample. 
Combining multiple scans of different focal planes allows the construction of a 
3D image. By repeating this process over time a series of images can be 
collected and reconstructed in order to observe biological processes.  
 
For a typical experiment fibrinogen (final concentration 0.5 mg/ml), CaCl2 (2.5 
mM), 5% fluorescently labelled fibrinogen (0.5 mg/ml) and any other reagents 
were diluted in TBS buffer and pre-mixed in 0.5 ml Eppendorf tubes. After the 
addition of thrombin (1.0 U/ml) to initiate clotting, the reaction components were 
quickly, but gently, vortexed to ensure they were thoroughly mixed and then 
immediately transferred into square glass capillaries of internal diameter 0.5 
mm. The capillary was placed inside the mixture which was drawn up through 
capillary action. All confocal imaging for this work was carried out using an 
upright Zeiss LSM 510 META Axioplan 2 microscope (Carl Zeiss Ltd., UK) with 
40 x (low magnification) and 63 x (high magnification) oil immersion objectives. 
For each clot type studied, multiple single optical sections (100 x 100 μm and 
200 x 200 μm) were taken at different areas throughout the clot. Also, multiple 
optical sections were taken and combined to form three-dimensional 
reconstructed images of each clot. A measure of fibre density was determined 
by drawing a line through a micrograph and counting the number of fibres which 
cross it. This was repeated 5 times in 5 different 100 x 100 μm micrographs.  
 
2.2.5 Scanning Electron Microscopy 
 
The scanning electron microscope (SEM) was first developed by M. Knoll in 
1935 (102) whereby a focused beam of electrons was scanned across a sample 
surface by magnetic deflection. A typical SEM setup consists of an electron gun 
(cathode and anode), two condenser lenses, two pairs of beam deflection coils, 
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an objective lens and some apertures (see Figure 2-5). Within the sample 
chamber are the sample stage and the detectors for the different signals 
generated by the electron-sample interaction. The SEM is maintained under 
vacuum to ensure the beam electrons have minimal interaction with any 
intervening gas molecules on their way to the sample. 
 
 
 
Figure 2-5: Schematic diagram of an scanning electron microscope (SEM) setup (figure 
from (103)). Electrons are focused by a series of lenses and then scanned over a sample. The 
various signals produced from the electron-sample interaction are collected by detectors which 
surround the sample. 
 
Beam electrons are emitted from the cathode and accelerated by a voltage to 
the anode. The electrons then pass through condenser lenses which focus the 
beam down into a small spot, around 5 – 10 nm in diameter (104). The objective 
lens ensures a large working distance (distance from the objective to the 
sample) which allows the various signals produced from the sample to be 
collected efficiently. The deflection coils deflect the beam in the x and y axes 
allowing the sample to be raster scanned. 
 
As the beam scans a sample the incident electrons interact with the surface and 
produce various signals: cathodoluminescence, X-rays, along with back-
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scattered, transmission and secondary electrons. Imaging throughout this work 
used secondary electron detection. These are the electrons which are excited 
and emitted from the sample surface. These are collected by a detector, the 
signal is then amplified and sent to a PC where the resulting image is 
processed and constructed. 
 
In contrast to confocal microscopy, SEM is a surface imaging technique and 
therefore does not allow visualisation deep inside a sample. It does however 
provide much greater spatial resolution, of the order of nm compared with 
hundreds of nm for confocal microscopy. 
 
Scanning electron microscopy was used to investigate the structure of fibrin 
clots. Typically, fibrinogen (final concentration 0.5 mg/ml), CaCl2 (2.5 – 7.5 mM) 
and any other reagents were diluted in TBS buffer and pre-mixed in 0.5 ml 
Eppendorf tubes in 110 l volumes; thrombin (0.5 – 1.0 U/ml) was then added 
to initiate clotting. The mixtures were immediately transferred in volumes of 50 
l to Eppendorf lids which were pierced multiple times with a sharp syringe in 
order to assist solvent permeation. The lids were wrapped in parafilm in order to 
prevent clot leakage during formation. Clots were allowed to form in a humidity 
chamber at room temperature for the required time. After this period clots were 
washed in sodium cacodylate buffer (67 mM C2H6AsNaO2, pH 7.4) to remove 
excess salt. 
 
In order to image biological samples with the SEM, chemical fixation is required 
to preserve and stabilise the structure. Clots were fixed in 2% glutaraldehyde 
overnight. Clots were again washed in sodium cacodylate buffer and then 
dehydrated in a series of increasing acetone concentrations (30 - 100%) 
overnight. Clots must be dehydrated as imaging is performed under vacuum. 
Clots were further dried using a critical point drier. Here, the acetone present 
within the sample is replaced with liquid CO2. The clots are then heated to 
~31°C where the CO2 evaporates leaving the samples dry. After this, samples 
are mounted onto SEM stubs and then sputter-coated with platinum using a 
Cressington sputter coater 208 HR (Cressington Scientific Instruments Ltd., 
Watford, UK).  
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Each clot type studied was photographed in at least 5 different areas at 5,000, 
20,000 and 100,000 x magnifications using an FEI Quanta 200 FEG SEM (FEI, 
Hillsboro, OR). Average fibre diameters were measured from at least 50 
random fibres in each sample using ImageJ software. A region of a micrograph 
is selected at random and the diameter of every fibre in that area is measured. 
This will ensure no bias towards, for example, thicker or well focused fibres thus 
minimises any sampling effects. A measure of fibre density was obtained in the 
same way as for confocal microscopy. 
 
2.2.6 Atomic Force Microscopy 
 
The atomic force microscope (AFM) was first developed in 1986 by Binnig et al. 
(105) and is part of the scanning probe microscope (SPM) class of instruments. 
SPMs operate by scanning a probe over the surface of a sample whereby 
images are built up a line at a time by recording the physical interaction 
between probe and sample. The AFM probe consists of a very sharp tip (radius 
of curvature of the order of nanometres) mounted onto a flexible cantilever (see 
Figure 2-6 Insert) which is oscillated at or near its natural resonant frequency 
(~kHz). This mode of operation is termed tapping mode (TM) since the probe is 
in intermittent contact with the surface, i.e. it taps over the surface. TM-AFM is 
particularly useful for studying biomolecules as it eliminates the lateral shear 
forces generated when using contact mode. In this mode of operation the tip is 
in continuous contact with the surface as it scans and as such can damage and 
displace weakly bound molecules. As a result TM-AFM has been used 
extensively to study biological systems (106), (107).  
 
The AFM forms an image by detecting very small deflections in the cantilever 
caused by interaction forces which arise between the tip and sample. The 
optical lever method (108), the most common detection technique, uses a laser 
which is reflected off the back of the cantilever onto a split photodiode detector 
to measure this interaction (see Figure 2-6). The laser beam will strike the 
centre of the detector, with equal amounts of light in each quadrant when there 
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is zero deflection. However, when the cantilever is deflected this will change the 
angle of the cantilever and hence the beam spot will move position on the 
detector. By measuring the amount of laser light in each quadrant the deflection 
of the cantilever can be inferred. 
 
 
 
Figure 2-6: Schematic diagram of an atomic force microscope setup. Insert: SEM image of 
the tip-cantilever assembly (adapted from (109) and (110)). 
 
As the tip is in intermittent contact with the surface at the extreme of its 
oscillation, this leads to dissipation of energy from the cantilever and a decrease 
in the amplitude of oscillation. This allows the amplitude to be used as a set-
point parameter, which is defined by the user. Thus, when the tip encounters a 
surface feature and is deflected, the feedback loop maintains the pre-defined 
amplitude by varying the tip-sample separation. In this way, the tip tracks the 
topography of the surface and by repeating this process line-by-line a 
topographical map of the surface is constructed. Precise scanning in the x and y 
axes is achieved with piezoelectric scanners which are capable of nanometre 
positioning resolution. 
 
The AFM was used to image the very early stages (< 1 minute) of 
polymerisation to investigate any differences between A/ A and A/  fibrinogen 
protofibril assembly (see chapter 7). Samples were prepared following the 
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procedure of Abou-Saleh et al. (107). Fibrinogen (final concentration 0.5 
mg/ml), CaCl2 (2.5 mM) and TBS buffer were pre-mixed in 1.5 ml Eppendorf 
tubes to a final volume of 20 l. After the addition of thrombin (1.0 U/ml) to 
initiate clotting, the reaction components were quickly vortexed and then 
allowed to clot for 10, 20, 30, 40 and 50 s. After the required time, the reaction 
was stopped by dilution by adding 1480 l of TBS buffer to the clot. 50 l of this 
mixture was then deposited onto a freshly cleaved mica disc (pre-treated with 2 
mM NiCl2 for 5 mins) and allowed to incubate for 2 minutes. After this time the 
disc was rinsed with dH2O and dried with nitrogen gas. Samples were then 
imaged in air with a Nanoscope IIIa MultiMode AFM (Veeco Instruments, Santa 
Barbara, CA) operated in tapping mode. Image processing and analysis were 
performed with Nanoscope (Veeco Instruments) and ImageJ software. 
 
2.2.7 Magnetic Microrheology  
 
Microrheology is the study of how materials store and dissipate energy on the 
micrometre or sub-micrometre length scale (111). This presents a major 
technical obstacle as optical methods of mechanical spectroscopy are generally 
set at the micrometre length scale. Thanks to multiple technological and 
theoretical advances over the past few decades the study of physical 
phenomenon on the very smallest of length scales has been made possible. 
The review of T. A. Waigh (112) gives a good introduction to these techniques.  
 
A major advantage of microrheology is that only small quantities of material 
(~10 - 20 μl) are required. This has allowed microrheological techniques to be 
readily applied to biological systems such as single molecules and living cells. 
There has been particular success in the field of fibrin research where samples 
purified from a patient‘s blood or those from recombinant fibrinogens are 
particularly time consuming to create and result in limited quantities. 
Microrheological measurements can also be performed in much more 
physiological environments than those achieved via bulk rheology, e.g. inside a 
living cell. Furthermore, many important biological processes occur on the 
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micrometre scale, as it is here where much of the mechanics of cells and 
biopolymers operate. 
 
 
 
Figure 2-7: Schematic diagram of a magnetic microrheometer system for particle 
manipulation (figure from (113)). A close up of the sample region is shown, which is 
surrounded by 2 electromagnets and a microscope. Images from the microscope are captured 
by a CCD camera and fed to a PC for processing and analysis. Amplifies supplying current to 
the electromagnets are interfaced to the PC by a Field Programmable Gate Array (FPGA) card.   
 
Active microrheology is a technique which measures the rheological properties 
of a material by applying forces to probe particles. In this instance, the probe 
particle interacts with the material it‘s embedded within and from the 
displacement response, the viscoelastic moduli may be extracted (114). In the 
field of magnetic microrheology, instruments utilise strong electromagnets 
coupled with imaging microscopy to manipulate particles and measure their 
movement. 
 
The idea of magnetic microrheometers was first conceived in 1949 by Crick and 
Hughes in an experiment in which magnetic particles inside living cells were 
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manipulated using a permanent magnet (115). The idea of manipulating 
magnetic particles using magnetic fields is the basic principle behind magnetic 
microrheology and is still in use today. However, apparatus are much more 
advanced employing sophisticated optics and multiple electromagnets in 
conjunction with computer systems allowing 3D manipulation, oscillation and 
rotation of particles (see Figure 2-7 for a typical schematic of a magnetic 
microrheometer). In the literature 1D, 2D and 3D devices have been reported 
(113, 116-118) with wide ranging applications. 
 
Magnetic microrheometers work by exerting a force upon a magnetic particle 
using an external magnetic field gradient. The magnetic particles can be 
paramagnetic, superparamagnetic or ferromagnetic. Ferromagnetic particles, 
those which posses a permanent magnetic moment, can produce forces of up 
to ~800 pN (118). Paramagnetic particles possess little or no magnetic moment 
in the absence of a magnetic field. Thermal energy is sufficient to randomise the 
magnetic moments of each individual atom so that the net magnetic moment is 
zero. As an external magnetic field is applied the magnetic moments begin to 
align with the field and the particle becomes magnetised, eventually the particle 
will become saturated when all moments are aligned. Superparamagnetic 
particles consist of very small ferromagnetic crystals which possess their own 
magnetic moment. As with paramagnetism, thermal energy will randomise the 
directions of these moments resulting in zero overall magnetisation. Again, in 
the presence of a magnetic field the moments of each crystal domain align. 
Forces of up to ~200 pN are achievable with para- and superparamagnetic 
particles. Throughout this work, 4.5 μm diameter superparamagnetic particles 
(Dynal, Oslo) were used. These particles posses a core of Fe2O3 single domain 
crystals and have no remnant magnetic moment in the absence of a magnetic 
field. 
 
As mentioned, when a paramagnetic particle is situated within an external 
magnetic field it will become magnetised. The particle will then behave like an 
individual bar magnet and move towards the region of higher magnetic flux. The 
force, F on a magnetic particle in an external magnetic field gradient is given by: 
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where m is the magnetic moment of the particle and B is the magnetic field. 
Alternatively, Equation 2-2 can be written as: 
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where: 
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In one dimension, i.e. a magnetic field gradient which exists only in the x axis, 
then Equation 2-3 becomes: 
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It can clearly be seen that the field gradient and not the absolute magnitude of 
the field generates the force. An extremely large magnetic field possessing no 
gradient will not induce any motion in a particle. The properties of the magnetic 
particles themselves also govern the magnitude of the forces generated. The 
magnetic moment of a particle of volume V is given by: 
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where M is the magnetisation, the amount of magnetic moment per unit volume, 
and a is the particle radius. The magnetic moment of a particle varies as: m  
a3, therefore any small increase in particle radius will lead to a substantial 
increase in the force. Similarly, reducing the size of the particle will lead to a 
reduction in the available force. Particle sizes can range from nano- to 
micrometres in diameter. When choosing a particle it is therefore a trade off 
between the forces required and selecting a particle of suitable size. For 
58 
 
instance, extremely small particles may not generate sufficient force to deform 
the medium they‘re embedded within. On the other hand very large particles 
may distort their surrounding environment and alter the properties of the 
medium; interpretation of experimental results will be far from straightforward.  
 
Three modes of operation are available in any active rheological measurement: 
constant force, step-like force and oscillatory force mode. A constant force can 
be used to obtain a viscosity measurement. Here, the equation of motion of a 
particle is given by Stokes‘ law: 
 
 vaF 6  2-7 
 
where F is the constant applied force,  is the fluid viscosity and v is the velocity 
of the particle. By using a fluid of known viscosity it is possible to calibrate the 
force applied to a magnetic particle as a function of the electromagnet voltage 
using this mode of operation (see chapter 3). A step-like force is used to 
measure the creep-response of a material where the time-dependent particle 
displacement x(t) is related to the time-dependent compliance J(t) via: 
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here F is the amplitude of the step force applied to a particle. This mode is used 
extensively throughout this work. Finally, an oscillatory force is typically used to 
measure the frequency dependent viscoelastic moduli (G ( ) and G ( )) of a 
material. Here, particles are driven at a controlled frequency and amplitude by 
an oscillatory force, f(t) given by:  
 
 )sin()( 0 tftf  2-9 
 
where f0 is the amplitude of the sinusoidal force and  is the frequency. The 
time dependent displacement, x(t) of the particle is given by: 
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where x0 is the maximum displacement of the particle and  is the phase shift of 
the particle displacement with respect to the driving force. These two quantities 
can be used to calculate the frequency dependent viscoelastic moduli via: 
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where G  is the storage modulus and G  is the loss modulus. The storage 
modulus is a measure of how much elastic energy is stored during deformation 
and gives a measure of stiffness. The loss modulus is a measure of how much 
energy is dissipated during deformation and gives a measure of viscosity. From 
the storage and loss moduli it is possible to calculate the loss tangent: 
 
 
G
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which is the ratio of energy lost to energy stored during a cyclic deformation.  
 
Oscillatory measurements are trickier to perform than the other two modes of 
operation. Again, using a fluid of known viscosity it is possible to calibrate the 
forces applied to particles. However, in addition to this, any phase shift between 
particle motion and driving force must also be measured. For instance, there will 
be a finite time delay between the signals sent to the amplifiers and the 
resulting magnetic field generated by the electromagnets. Also, there exists a 
finite time for the magnetic field to decay once the electromagnets are switched 
off; this causes problems when oscillating particles at high frequencies as the 
magnetic field does not ―switch off‖. Finally, in order to measure the viscoelastic 
moduli of a material over a range of timescales, multiple particles must be 
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oscillated at many different frequencies. As a result this type of measurement 
can be extremely time consuming to perform. 
 
A more straightforward approach was chosen which does not rely on oscillating 
particles and allows the frequency-dependent viscoelastic moduli to be obtained 
from a step-like force mode of operation. This procedure is described in detail in 
Chapter 4. Details of the magnetic microrheometer used throughout this work 
are detailed in Chapter 3. 
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Chapter 3 
3 Magnetic Microrheometer 
 
The previous chapter gave a description of the experimental equipment, 
techniques and sample preparations used in this work. An introduction to the 
theory and experimental procedures of microrheology were also provided. This 
chapter describes the magnetic microrheometer device used to perform 
microrheological measurements. Experimental set-up and modelling are 
presented along with the force calibration procedure.   
 
3.1 Magnetic Microrheometer Configuration 
 
The magnetic microrheometer (see Figure 3-1) was designed and constructed 
by Dr R. Harrand (119). The present configuration consists of four pole pieces 
(core dimensions: 10 cm in length and 2 cm in diameter), made of soft iron of 
relatively high permeability (~250), each pole is wrapped in ~480 turns of 
copper wire turning it into an electromagnet. Each iron core possesses a 
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pointed end, based on the design of Huang et al (118), in order to maximize the 
force on the magnetic particles. The poles are all held in a soft iron frame which 
increases the field strength by closing the field lines and completing the 
magnetic circuit; increases of up to 300% have been reported (118). Each pole 
piece is connected to its own power supply; amplifiers are Kepco BOP 20-5M 
units (Kepco, Inc., NY, US). The magnets are positioned over an Olympus IX-71 
inverted microscope (Olympus, UK) equipped with a 40x ultra long working 
distance air objective (numerical aperture 0.55).  
  
 
 
Figure 3-1: Magnetic microrheometer device. For further details on the design, construction 
and calibration see (119). The 4 electromagnets are held in an iron frame which sits on top of 
an inverted microscope. The sample holder (indicated by the yellow line) sits on 2 posts 
positioning it between the 4 electromagnet tips and within the optical axis of the microscope. A 
CCD camera attached to the microscope is used to capture images which are fed to a PC 
where particle tracking software analyses the images. A thermocouple is positioned within the 
sample area in order to measure the temperature during experiments, which can also be placed 
inside the sample holder.  
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The microscope is positioned on a vibration isolation table in order to reduce 
mechanical noise. Images are taken with a standard CCD camera, operating at 
25 Hz, which is attached to an optical output on the microscope. The device is 
also covered with a thick curtain which eliminates particle drift which would 
normally render measurements useless. It is believed that this drift occurs due 
to air flow over the sample region. The sample holder for the device was built 
(by Dr R. Harrand) from the stage of the Olympus microscope. The sample 
stage is placed to one side of the microscope and a rigid arm was attached. 
This arm possesses two stands upon which the sample sits, this ensures the 
sample is positioned in the centre of the electromagnets (defined as the x-y 
plane) and within the optical axis (z axis) above the microscope objective. The 
stage can be manually moved in the x and y axes. This allows the user to scan 
a sample and select a suitable particle.  
 
 
 
Figure 3-2: Sample holders for the magnetic microrheometer device. (a) Hildenberg 
capillaries used to hold glycerol and magnetic particles for force calibration experiments. (b) 
VitroCom microcells (50 mm length, external diameter 0.7 mm and internal diameter 0.5 mm) 
used to hold fibrin clots for confocal microscopy and magnetic microrheometer experiments.   
 
Samples are held in thin glass capillaries (see Figure 3-2); either Hildenberg 8 
cm long capillaries (Hildenberg GmbH, Germany) or VitroCom 5 cm long 
rectangular microcells (VitroCom, NJ, US). Both sample holders allow forces on 
the magnetic beads to be maximised by ensuring the distance between pole 
pieces can be minimised. The VitroCom microcells also hold very small 
quantities of material (< 20 μl), particularly useful for biological samples. The 
Hildenberg capillaries are used to hold glycerol for force calibration and have 
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one end which is slightly larger and can accommodate a syringe which is used 
to inject glycerol; owing to its high viscosity. This also allows a thermocouple to 
be inserted directly into the glycerol for real-time temperature measurements. 
The smaller VitroCom microcells are used to hold fibrin clots. After both 
capillaries are filled the ends are sealed with Vaseline. This minimises sample 
evaporation and also reduces the uptake of water by glycerol. The viscosity of 
glycerol will change dramatically due to its hygroscopic nature if left exposed for 
long periods.  
 
In conjunction with the electromagnets and imaging system a data processing 
system is also required. An NI PXI-8186 (National Instruments, TX, US), 
external stand-alone chassis and CPU system, is used to hold the data capture 
and control cards. The PXI unit holds two cards, an NI IMAQ-1409 image 
capture card and an NI FPGA-7831R input/output card. The image card is used 
to capture images from the CCD camera and the FPGA (Field Programmable 
Gate Array) card is used to either read data from an RS-232 port or output data 
such as a signal to a connector block. The last piece of equipment, the NI SCB-
68 signal connector block, allows the FPGA card to interface with the amplifiers; 
this bridges the gap between the control software and the electromagnets.  
 
Custom written software (by Dr R. Harrand) used to control the device was 
written using the graphical programming language LabVIEW 7.1 (National 
Instruments). Several LabVIEW programs have been written in order to 
communicate with the NI instruments; an example of one of these is given in  
Figure 3-3. The particle tracking program is one in particular; this analyses 
images taken from the CCD camera and allows real-time tracking of the 
particles. The software locates a circular feature (e.g. a magnetic particle) within 
an area specified by the user and determines the x, y coordinates. The data is 
saved to an ASCII file, which avoids the need to store large amounts of data in 
the form of video footage. 
 
Software has also been written to control the electromagnets (see Figure 3-3). 
LabVIEW generates signals which allow the voltage sent to the electromagnets 
to be controlled precisely. In detail, the user specifies a direction e.g. up, down, 
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left or right, this convention is chosen as it represents the direction the particle 
moves on the monitor used to output the images from the CCD camera and 
corresponds to movement in the x-y plane. A force is also specified by the user, 
the software then sends a signal to the amplifiers through the signal connector 
block. The software determines the magnitude of the signal and to which 
electromagnets it should be sent. For instance, to exert a 50 pN force on a 
magnetic particle in the right direction the software does the following. Firstly, it 
calculates what size voltage corresponds to 50 pN (see section 3.3) and then 
sends this voltage to electromagnet 2, and sends the opposite voltage to 
electromagnets 1, 3, and 4, thus setting up a magnetic field gradient across the 
sample region. This induces 3 north poles and 1 south pole; a field gradient is 
created in the direction of the south pole (see Figure 3-4). 
 
 
 
Figure 3-3: An example of a LabVIEW block diagram program. This program was written in 
order to apply a calibrated force pulse to a magnetic particle. The user specifies a force and the 
corresponding voltage is calculated. A particle can be moved in 1 of 4 directions i.e. up, down, 
left or right, where the directions correspond to the x and y axes.  
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3.2 Magnetic Modeling 
 
The magnetic microrheometer device described here was, as mentioned, based 
on the design of Huang et al. (118) and therefore mechanisms of how to 
generate forces in 2D was understood. Their device consists of 8 
electromagnets; four magnets in a quadrapole arrangement (as in Figure 3-1) 
sit on top and mirror four magnets placed below. It was shown through 3D 
magnetic modeling that inducing 6 north poles and 2 south poles a magnetic 
field gradient could be created in the direction of the 2 south poles.  A 
reproduction of this design was chosen by (119) and using the 2D magnetic 
modeling program Vizimag (www.vizimag.com) alternative ideas on 
configurations and where to send different voltages were tried and tested. 
 
The program Vizimag allows 2D modeling of magnetic components such as 
solenoids and permanent magnets, giving information on field strength and 
direction. The magnetic field density in any direction may also be plotted (see 
Figure 3-5(b)). Even though the software models in 2D, it gives all objects a 
circular cross-section, so a rectangle is treated as a three dimensional cylinder. 
This allows the electromagnets of the actual device to be modeled particularly 
well. 
 
The main conclusions of the modeling carried out prior to the device being built 
are detailed here, for full details please see (119). Firstly, it was found using a 
model of a single electromagnet that there is a rapid decrease in field strength 
as a function of distance from the electromagnet tip. Having close proximity 
between sample and tip can therefore be as important as having large 
electromagnets and/or high currents (both important for generating high forces).  
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Figure 3-4: (a) Vizimag model of 4 electromagnets (3 north poles and 1 south pole) with iron 
frame. (b) Colour map of the flux density indicating the large amount of magnetic field density in 
the south pole magnet.   
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The entire magnetic microrheometer was modelled using 4 electromagnets held 
in an iron frame (see Figure 3-4). The device actually consisted of 8 
electromagnets but each pair was treated as a single magnet. This represent 
the device particularly well as it was operated by inducing north poles in the tips 
of 6 electromagnets (3 magnet pairs), and 2 south poles in the remaining 2 
electromagnets (1 magnet pair). It was found that this configuration produced 
the largest field gradient within the sample region (located equidistantly 
between all four electromagnets) and this was due to the upper north pole 
redirecting the flux from the 2 side electromagnets into the lower south pole. 
The back iron frame also rapidly increased the central field strength from 
around 500G to 3000G (500% increase) by closing the field lines and 
completing the magnetic circuit. For the modelling outlined here each 
electromagnet was represented as a solenoid possessing an iron core 
(permeability = 250) with a current of 1.8 A and dimensions of 10 cm in length 
and 2 cm in diameter. At either end of the solenoid there are regions of the 
same permeability which better represent the geometry of the electromagnets. 
 
The magnetic microrheometer device consisted of 8 electromagnets and was 
capable of producing forces in the range of 40 to 80 pN in 2D. This somewhat 
restricted the device as a useful fibrin clot microrheometer as the range of 
fibrinogen/thrombin concentrations which could be probed was limited. For 
example, at higher fibrinogen concentrations the network rapidly becomes much 
stiffer and forces of this magnitude produce extremely small particle 
displacements. As such, the signal-to-noise becomes very poor and as the 
device has to be operated at maximum voltage, thermal noise further disrupts 
particle tracking. In order to increase the force range of the device a re-design 
was required; 4 of the electromagnets were removed and the bottom frame 
containing the 4 remaining magnets was raised up (see Figure 3-1 and Figure 
3-5(a)). This allowed the separation of the magnets to be reduced (previously 
the microscope objective prevented this) and also brought the pole piece tips 
into much closer proximity with the sample. Previously, the tips sat above and 
below the sample region, now the tip and sample are located in the same plane. 
This new configuration was modelled and the results are shown in Figure 3-5. 
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Figure 3-5: (a) Vizimag model of 2 electromagnets (1 north pole and 1 south pole). (b) Plot of 
the flux density moving down between the 2 pole pieces (indicated by the white arrow in (a)). It 
can clearly be seen that a peak in the magnetic field strength is situated between the 2 pole 
piece tips. A magnetic particle situated at the tip of this peak will be located in a region free of 
any magnetic field gradient in the z axis. 
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A substantial magnetic field gradient exists in the z axis (see Figure 3-5(b)) and 
this is known to disrupt x and y translation as a particle drifts out of the focal 
plane and can no longer be tracked. Eventually the particle will either be pulled 
or pushed into the capillary walls. However, there is a peak in the magnetic field 
strength which resides between the two pole piece tips, here the magnetic field 
reachs a plateau and there is a region free of any magnetic gradient. The 
sample region was positioned here resulting in x and y translation free of 
movement in the z axis. The device is now capable of producing forces up to 
120 pN. 
 
3.3 Force Calibration 
 
The single most important aspect of calibration for the magnetic 
microrheometer, and one which must be carried out whenever the 
electromagnets are repositioned, is force calibration. All other calibration 
procedures e.g. pixel-to-distance calibration, were carried out by Dr R. Harrand. 
The most common method of force calibration involves Stokes‘ law and a fluid 
of known viscosity. As introduced in section 2.2.6 the force exerted on a 
magnetic particle in a viscous liquid can be calculated by Equation 2-7. In order 
to control the applied force it is necessary to know the exact relationship 
between the voltage of the electromagnets and this force. By analysing the 
motion of magnetic particles it is possible to calculate the applied force.   
 
Calibration was performed in 99% glycerol (Sigma-Aldrich, UK) using 4.5 μm 
diameter particles. This glycerol solution has a viscosity of η99% = (740  20) 
mPa.s at 25°C (measured by Dr D. Auhl using a cone-plate rheometer). At this 
temperature, 99% glycerol should have a viscosity of 745.2 mPa.s (120); indeed 
confirming the glycerol is 99%.  
 
Calibration samples are prepared by mixing magnetic particles with glycerol in 
the ratio 1:300 μl. As mentioned, this mixture is injected into a capillary which is 
then positioned within the microrheometer. A suitable particle is selected, one 
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which is located away from the capillary walls in order to minimize boundary 
effects, and one which is positioned away from any other particles.  
 
Custom written LabVIEW calibration software (Dr R. Harrand) was then used to 
send voltages of between 0.5 and 5.5 V in 0.5 V steps to the electromagnets 
and move the particle in the x and y axes. This allowed the force as a function 
of voltage to be determined in the direction of all 4 electromagnets (see Figure 
3-6). This force-voltage relationship was then programmed back into LabVIEW 
(see Figure 3-3) and allows the user control over the force, rather than the 
voltage. 
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Figure 3-6: Force versus voltage calibration curves for 4.5 μm particles in 99% glycerol. 
The data are fitted with a sigmoidal curve of the form: F = [ ( A1 – A2 ) / (1 + ( V / V0 )
p 
] + A2 
where F is the force, V is the voltage and A1, A2, V0 and p are all fitting parameters. The 
parameter A1 is set to 0 i.e. 0 force at 0 voltage. Errors represent the standard error in the mean 
obtained from multiple data sets. 
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In order to obtain the force calibration curves the data were fitted with a 
sigmoidal function: 
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where F is the force (calculated from Equation 2-7), V is the voltage across 
each electromagnet and A1, A2, V0 and p are all fitting parameters determined 
using the software OriginPro 8. This equation is rearranged, with V as the 
subject, and then programmed into LabVIEW (see Figure 3-3) allowing a user to 
specify a force. The corresponding voltage is then calculated and a signal to 
produce this voltage is sent to each electromagnet‘s amplifier. 
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Figure 3-7: Viscosity versus temperature for different glycerol-water mixtures. 
Experimental data taken from (120). These data were programmed into the LabVIEW 
calibration program to enable real-time force calculation. 
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Multiple repeat measurements were taken using the automated calibration 
program and the results were averaged. Variations in calibration data arise due 
to drift within the samples. This is minimised as much as possible by sealing the 
capillary ends with vaseline. The viscosity of glycerol also varies considerably 
with temperature and water content (see Figure 3-7). Data tables relating the 
percentage of glycerol to temperature and viscosity were programmed into the 
software, and the temperature from a thermocouple was read via an RS-232 
port. This allowed the viscosity of a particular percentage of glycerol/water to be 
calculated as the temperature fluctuated during a calibration experiment. 
 
20 22 24 26
100
1000
 
 
V
is
c
o
s
it
y
 (
m
P
a
.s
)
Temperature (
o
C)
Glycerol/water %
 99
 90
 80
 
Figure 3-8: Viscosity measurements of different percentage glycerol/water mixtures. The 
lines are the bulk rheology measurements taken from the literature (120). Error bars (ranging 
between 5 and 10%) are too small to be distinguished on the logarithmic scale.  
 
Calibration was checked by measuring the viscosity of different glycerol/water 
mixtures (see Figure 3-8). This is essentially an inverse of the calibration 
procedure; a force is applied to a particle and the subsequent motion is tracked. 
From this and using Equation 2-7 the viscosity of the glycerol can be calculated. 
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By applying a range of forces to different beads within different percentage 
glycerol/water samples the viscosity was measured and was in good agreement 
with the data from the literature. This confirms the magnetic microrheometer is a 
suitable device for measuring the bulk properties of materials.  
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Chapter 4  
4 The Mechanical and Viscoelastic Properties of 
Fibrin Clots  
 
4.1 Introduction 
 
This chapter outlines the development and validation of the magnetic 
microrheometer as a suitable device for studying the physical properties of fibrin 
clots. We studied the effect of magnetic particles on clot polymerisation and 
structure and investigated the effects of forming clots inside microcells. We 
present techniques for studying the mechanical and viscoelastic properties of 
fibrin clots. These techniques are used to study the physical properties of fibrin 
clots and assess the effect of the plasma protein FXIII. We present data which 
provides new insight into the behaviour of fibrin clot viscoelasticity. 
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4.2 The Effect of Magnetic Particles on Clot 
Polymerisation and Structure 
 
Turbidity measurements were performed on fibrin clots both with and without 
magnetic particles in order to determine the effect their presence has on clot 
polymerisation and structure. This is crucial to ensure the magnetic 
microrheometer device is a suitable microrheometer for measurements on fibrin 
clots as any structural alterations or effects on polymerisation may have a 
bearing on measurements. Samples were prepared as described in section 2.2.2 
with magnetic particles added at the same concentration as that used for 
microrheology experiments. ERL fibrinogen at a concentration of 0.5 mg/ml was 
incubated with 2.5 mM CaCl2 and magnetic particles. Thrombin was then added 
at 1.0 U/ml concentration, after which, absorbance was measured every 25 s 
over the first 80 mins of clotting (see Figure 4-1). 
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Figure 4-1: Absorbance versus time for clots formed in the presence and absence of 
magnetic particles. Error bars represent the standard error in the mean from 3 repeat 
measurements. For clarity every 4
th
 measurement has been plotted. Insert: Plot shows the 
absorbance over the first 5 mins of clotting (the full data set is plotted).  
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The analysis of the turbidity data in Figure 4-1 is provided Table 4-1. From these 
data it can be concluded there are no significant differences in polymerisation, 
within experimental errors, due to the presence of the magnetic particles. The lag 
phase could not be determined as there was an immediate increase in turbidity 
for both clots. The only significant difference in turbidity occurred at ~17 mins, 
however, since there was no difference in the rate of polymerisation prior to this 
and the final plateau for both clots was identical, this transient difference appears 
inconsequential. 
 
Table 4-1: Polymerisation data of clots formed with and without magnetic particles  
Polymerisation Parameter Particles No Particles 
Lag time (minutes) n/a n/a 
Maximum rate (units min
-1
) 0.012  0.001 0.010  0.001 
Final Absorbance 0.108  0.004 0.106  0.004 
Plateau Time (minutes) 31  2 34  4 
 
The final absorbance is related to the size and/or density of fibres in a clot e.g. a 
clot composed of a low density of thick fibres may have a very similar absorbance 
to a clot consisting of many more thin fibres. As such, turbidity does not reveal 
the true structural picture of what is occurring down to the single fibre level. In 
order to ascertain more completely the effect magnetic particles have on clot 
structure SEM and confocal microscopy were used to image individual particles. 
In this way, it is possible to determine the effect, if any, the particles have on the 
surrounding clot. For instance, will the fibres aggregate around the particles or 
will they be repelled leaving the particle in a region of lower clot density? Such 
minor, local structural rearrangements may have very little or no effect on the 
overall absorbance but will have major implications for microrheology 
experiments. 
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Figure 4-2: Confocal micrograph of 4.5 m magnetic particles trapped within a clot. The 
bright green spots are 4 magnetic particles; they appear distorted due to either lying above or 
below the optical plane. This micrograph is a single optical slice. The scale bar indicates 50 μm. 
 
Clots for SEM and confocal microscopy (see Figure 4-2 and Figure 4-3) were 
prepared as described in sections 2.2.4 and 2.2.5 respectively. All concentrations 
of particles and reactants were the same as that used for turbidity experiments 
described above. For both imaging techniques, samples were scanned for 
regions of clot containing magnetic particles and, once located, images were 
obtained. 
 
From confocal imaging (see Figure 4-2), it can be seen that particles resided in 
regions of both high and low fibre density. In addition, particles did not appear to 
repel or attract the surrounding fibres, as one might expect if they were 
interacting in some way. Closer inspection revealed that some fibres appeared to 
go closely past particles and were not influenced by their presence. This 
indicates the particles have very little or no effect on the surrounding structure. As 
such, it could be assumed that the local fibre architecture around a particle is 
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representative of the architectural arrangements of the fibrin network throughout 
the clot. 
 
 
 
Figure 4-3: SEM micrographs of magnetic particles trapped within a clot. The large panel 
(10 000x) shows a magnetic particle and the surrounding clot structure, scale bar indicates 5 m. 
The two smaller panels (50 000x) show how the particles interact with the individual fibres of the 
clot, scale bar indicates 1 m. 
 
Higher resolution SEM revealed particles and individual fibres in much greater 
detail (see Figure 4-3). Here, the fibres appeared to wrap around the particles 
and hold them in position. This lends support to the idea that the particles 
become trapped within the network by the fibres which grow around them. 
Microrheological measurements performed with these particles should therefore 
reveal the true viscoelastic properties of a clot. Deviations may occur when the 
characteristic length scale of the clot i.e. fibre length or mesh size, approaches 
that of the particle size. In this instance, the viscoelastic properties will be highly 
dependent upon the local fibre structure. However, repeat measurements of 
multiple particles distributed throughout a clot would average out these 
differences.  
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4.3 Microcell Effects on Clot Structure and Mechanical 
Properties 
 
Confocal microscopy was used to image clots formed within microcells to assess 
the effect of the microcell on clot structure. Again, this is an important test as 
alterations to clot structure due to interactions with the capillary walls may affect 
measurements. Samples were prepared as described in section 2.2.4 with final 
clot concentrations the same as that used in section 4.1 for the clot containing no 
magnetic particles. Multiple overlapping confocal micrographs were taken from 
one side of the capillary to another and then stitched together to form a mosaic 
image of the entire capillary diameter (see Figure 4-4(A)). 
 
 
 
Figure 4-4: (A) Confocal microscopy mosaic image of a clot formed within a VitroCom 
microcell. Scale bar represents 50 μm. (B) Zoom of the capillary wall. The red line is used to 
determine fibre density; by counting the number of fibres which cross the line an effective fibre 
density can be measured. (C) Plot of fibre density across the capillary from left to right, 
measurements were taken at 20 μm intervals. Error bars represent the standard error in the mean 
from 3 repeat measurements.  
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Imaging revealed the capillary walls as bright green bands at either extreme of 
the image with a clot enclosed within. The optical plane was positioned in the 
centre of the capillary. A zoom of the capillary wall (see Figure 4-4(B)) revealed a 
dark region where there were little or no fibres. To investigate this further, fibre 
density was measured at regular intervals, every 20 m, across the capillary. The 
fibre density at the walls was zero as no fibres crossed here. Moving from the 
walls of the capillary towards the centre there was an increase in fibre density. 
Fibre density then plateaus at around 100 m and was constant for ~300 m, 
after which it rapidly dropped off as the other wall was approached. At 20 m 
from the walls the fibre density was 0.12  0.02 fibres m-1, this increased to 0.23 
 0.01 fibres m-1 at the centre of the capillary. Fibre density therefore increased 
1.9-times towards the centre of the microcell.  
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Figure 4-5: J
-1
 versus distance from wall of a clot formed inside a microcell. The inverse 
compliance, J
-1
 is measured as described in Figure 4-6 and is used as a measure of clot stiffness. 
Measurements were taken every 25 μm moving away from the microcell wall. The stiffness at 0 
μm could not be determined as it was not possible to displace particles located here; it was 
assumed they were stuck to the wall. Error bars represent the standard error in the mean from 3 
repeat measurements. 
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From the above observation, it was hypothesised that the location of a particle in 
relation to the capillary walls will have an effect on the mechanical properties 
measured. In order to investigate this further the stiffness as a function of 
distance from the capillary wall was measured. Again, samples were prepared as 
described in section 2.2.4 with final clot concentrations the same as that used in 
section 4.1 for the clot containing magnetic particles. Next, the microcell was 
placed inside the magnetic microrheometer and the microscope objective was 
focused onto the inside of the bottom capillary wall. This was defined as the 
starting position i.e. 0 μm. The plane of focus was then moved up through the clot 
at intervals of 25 μm. As the microscope is inverted the observational point is 
from below the clot. At each interval, 5 particles were selected; those which were 
in focus, and then tested. A force pulse of 2 s in duration was applied to each 
particle and from this the stiffness was determined (as described in Figure 4-6). 
In this way, the stiffness as a function of distance from the capillary wall was 
measured (Figure 4-5). 
 
Particles at 0 μm could not be displaced; it is assumed that these particles are 
stuck to the microcell wall. When moving away from the capillary wall there was 
an increase in clot stiffness which reached a plateau at ~100 μm and was 
maintained up to 350 μm. It was not possible to see further into the microcell as 
the maximum working distance of the microscope objective was reached. At 25 
μm from the microcell wall, the stiffness was 2.8  0.2 Pa which increased to 3.6 
 0.1 Pa. at the centre of the microcell. Stiffness increased 1.3-times when 
moving towards the centre of the microcell.  
 
This correlated well with the fibre density measurements (Figure 4-4). The 
increase in stiffness is attributed to an increase in fibre density. Whyfibre density 
is lower at the microcell wall is unknown. It could be postulated that some 
interaction between the microcell material and fibrin inhibits fibre growth or that 
the wall repels the fibres. It‘s important to note that the clot structure observed at 
the centre of the capillary appeared ―normal‖; clots prepared within standard 
confocal microscopy slides showed very similar structures. For all subsequent 
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experiments, only particles located more than 100 μm from the microcell wall will 
be tested. 
 
4.4 Stiffness during Polymerisation 
 
Once FpA and FpB are cleaved from fibrinogen to form fibrin, this rapidly self-
assembles into a 3D fibrous mesh. Depending on thrombin to fibrinogen ratio this 
process can occur in a time-span ranging from seconds up to minutes. Before a 
certain time point, defined as the gel point (see section 2.2.3), the network is a 
viscous liquid, after which it rapidly changes into a solid. After this time, the clot 
becomes viscoelastic and it is possible to measure the compliance of the clot and 
the subsequent rapid increase in stiffness using the magnetic microrheometer. 
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Figure 4-6: Displacement response of a particle trapped within a clot. Both the y (red) and x 
(black) displacement is plotted along with the step-like force pulse (blue). The blue shaded 
regions indicate the positions measured by the auto analysis program. Here the x displacement 
(xs = x2 – x1) has been measured. In this way the analysis program can calculate the compliance 
(J = 6 rs / F where s = (xs
2
 + ys
2
)) for every force pulse applied over the course of an 
experiment. Typically, the inverse compliance, J
-1
 is calculated and used as a measure of clot 
stiffness during polymerisation. 
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Magnetic particles are trapped within a clot by simply mixing the particles with 
fibrinogen and any other reagents and then adding thrombin to initiate clotting. As 
the clot forms the magnetic particles become trapped by the fibres and the 
particle is held inside the network (Figures 4-2 and 4-3). All clots for magnetic 
microrheometry experiments are prepared in this way. In detail: 
 
 Fibrinogen is mixed with magnetic particles in an Eppendorf tube. Typically 
1 μl of particles in dH2O in a final clot volume of 50 μl gives an optimum 
number density of particles within a clot e.g. enough particles to obtain 
multiple repeat measurements but not too many that it is difficult to locate 
a sufficiently isolated particle. 
 Any other reagents are also added at this stage e.g. CaCl2, FXIII, etc. 
 The reactants are thoroughly mixed either using a pipette or by vortexing, 
after which thrombin is added. 
 Immediately after this, the reactants are again mixed and then transferred 
to a VitroCom microcell. The microcell is placed inside the mixture and the 
clot is drawn up by capillary action. 
 The ends of the microcell are sealed with Vaseline. 
 Next the microcell is placed inside the magnetic microrheometer as quickly 
as possible.  
 The microscope objective is focused at the centre of the capillary and the 
clot is scanned for a suitable particle. 
 Finally, using the LabVIEW software a particle is selected and tracked 
while forces are applied. 
 
One approach is to apply force pulses of the same magnitude at regular intervals 
e.g. 10 pN every 10 s for a duration of 2 s, as clotting proceeds. Figure 4-6 shows 
such a force pulse and the subsequent particle displacement measured by the 
tracking software. This displacement response is used to obtain a measure of clot 
stiffness, at that instant of time, as detailed in Figure 4-6. In this way, the time 
development of a clot‘s stiffness can be measured (see Figure 4-7). For an 
experiment of 1 hour, applying force pulses every 10 seconds produces 
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substantial amounts of data to analyse, which typically takes around 2 hours. An 
analysis program was written to automate this procedure, and as a result post 
experimental analysis time was dramatically reduced. 
 
The early work of Roberts et al. (62) revealed clots undergo a rapid increase in 
stiffness which then reaches a plateau once the clot is formed. Following the 
procedures detailed above, very similar behaviour in purified fibrin clots was 
observed (see Figure 4-7). ERL fibrinogen at a final concentration of 0.2 mg/ml 
was incubated with 2.5 mM CaCl2 and magnetic particles. Thrombin was then 
added at a concentration of 0.5 U/ml, after which, force pulses were applied 
every 10 s for 2 s over the first hour of clotting. Note that the magnitude of these 
force pulses is adjusted manually as the experiment proceeds, to ensure that the 
displacement response is essentially elastic (as in Figure 4-6) while maintaining a 
good observable displacement. This ensures minimum sample deformation while 
maintaining good signal-to-noise. 
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Figure 4-7: J
-1
 versus time of a clot over the first 2 hours of clotting. Much like turbidity there 
is an initial rapid rise in J
-1
 followed by a plateau. Insert: J
-1
 vs. time over the first 5 mins of 
clotting. The initial rate of change of J
-1 
has been measured giving information on the kinetics of 
fibre formation.  
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Initially, a rapid increase in clot stiffness was observed up to around 10 minutes, 
after which the stiffness began to reach a plateau. Once this plateau has been 
reached, a clot is assumed to be fully developed both structurally and 
mechanically. The viscoelastic and/or other mechanical properties of a clot can 
be measured once this point has been reached. In Figure 4-7, the insert shows 
how clotting increased over the first 5 minutes; here the rate of change of 
stiffness (dJ-1/dt) is measured from a linear fit to the data. In a model of fibrin 
polymerisation as proposed by Weisel et al. (30) this period corresponds to when 
protofibrils begin to aggregate laterally. Another study by Weisel et al. revealed 
that at the gel point, ~70% of fibres have reached their maximum length and 80% 
of branch points have formed while fibre diameter is less than 25% (121). Our 
data coupled with these observations indicate that the rapid increase in stiffness 
may be primarily due to radial fibre growth. In addition, Ryan et al. reported a 
strong correlation between fibrin diameter and clot stiffness (84).  
 
The earliest time at which clot stiffness can be measured is ~2 minutes. This is 
due to the time taken to seal the microcell, transfer it to the microrheometer and 
locate a suitable particle. This point was defined as the initial stiffness (JI) and 
represents the mechanical properties of the nascent network before it has 
undergone further structural changes. As mentioned, once the curve has reached 
a plateau, it is assumed all structural and mechanical changes have ceased and 
as such this point was defined as the final stiffness (JF). Comparison of 
measurements taken immediately after clot stiffness has reached a plateau with 
those taken many hours later (~24 hours) revealed no difference in clot stiffness. 
These parameters will be subsequently used to quantity the mechanical changes 
in clot polymerisation. 
 
4.5 Clot Stiffness and Network Inhomogeneity 
 
The magnetic microrheometer is capable of producing forces in two dimensions. 
This x-y movement is ascribed the convention up, down, left and right 
corresponding to the direction the particle moves on the optical display. In order 
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to investigate any potential directional dependence of the stiffness, a particle 
embedded within a clot was manipulated in 2D as the clot formed and then after 
clotting was complete the variation in JF was also investigated (see Figure 4-8). 
Note the polymerisation is measured from a single particle as the software is not 
capable of tracking multiple particles. Also, the final stiffness is measured from 
multiple particles distributed throughout a clot.  
 
 
 
Figure 4-8: Clot stiffness and network inhomogeneity. (A) x and y displacement response of a 
single particle manipulated in 4 directions. The x displacement trace has been offset for clarity. 
(B) J
-1
 versus time measured in 4 directions over the first 2 hours of clotting for a single particle. 
(C) Histograms of JF for the 4 different directions. Measurements were taken after 2 hours from 
multiple particles distributed throughout a clot; each particle is moved in 4 directions as in (A). (D) 
Histogram of JF for all 4 directions. Histograms are fitted with a normal distribution as a guide for 
the eye. 
 
ERL fibrinogen at a concentration of 0.5 mg/ml was incubated with 2.5 mM CaCl2 
and magnetic particles. Thrombin was then added at a concentration of 0.5 U/ml. 
After this, force pulses were applied every 10 s for 5 s in four different directions 
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(see Figure 4-8(A)). Forces applied in the up and down directions produced a 
displacement in the y axis. Similarly, forces applied left and right only produced 
movement in the x axis. As described in section 4.4 clot stiffness is determined 
from this response and used to monitor clot stiffness over the first 2 hours of 
clotting (see Figure 4-8(B)). From the four traces, it is evident that a difference in 
stiffness is associated with each direction. Data from Figure 4-8(B) is presented 
in Table 4-2. There is a range of 0.15 Pa in the initial stiffness and this rises to 
0.47 Pa in the final stiffness. The rate of change of stiffness varies by 0.012 Pa.s-
1 indicating polymerisation is also altered in different directions. 
 
After 2 hours, the variation in the final stiffness was investigated by applying 
forces in four directions to multiple particles distributed throughout the clot. The 
results are presented in histogram form (see Figure 4-8(C)). Again, it is evident 
that a variation in stiffness is associated with the direction of the force. This could 
be an artefact due to some effect from the experimental setup. However, the 
trend seen in Figure 4-8(B) where right is stiffest followed by left then down and 
finally up being the weakest is not repeated. Similar trends between stiffness and 
direction were not observed in repeat experiments.  This indicates the variation in 
stiffness arises due to differences which occur from repeated measurements of a 
physical system. 
 
Table 4-2: Stiffness polymerisation data  
Polymerisation 
Parameter 
Up Down Left Right Average 
JI (Pa) 0.36 0.51 0.49 0.46 0.46  0.03 
JF (Pa) 0.64 0.77 0.85 1.07 0.83  0.09 
dJ
-1
/dt (Pa.s
-1
) 0.020 0.022 0.014 0.026 0.021  0.003 
 
Inspection of confocal and SEM micrographs (Figure 4-2 and Figure 4-3) 
revealed that particles are embedded within an inhomogeneous fibrous network. 
Closer inspection of a single particle and the immediate surrounding fibre 
structure shows that the density of fibres varies around the particle. For example, 
in Figure 4-2, the particle located on the far left is surrounded by many fibres 
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except to its right where there are fewer fibres. If a force were applied in the right 
direction then the particle moves into the region of lower fibre density and could 
result in the particle displacing further, hence a lower stiffness would be 
measured. Alternatively, if the particle is anchored to the fibres to the left then the 
particle may be pulling on more fibres and it subsequently displaces less; hence 
greater clot stiffness is measured. 
 
Typically, a particle was chosen and then forces were applied in one direction 
only. A clot was repeated at least 3 times depending upon the variation within the 
data. Now, each particle is moved in 4 different directions, this allows a greater 
proportion of the clot to be probed which subsequently results in greater data 
capture and better reproducibly of data. Figure 4-8(D) and Table 4-2 show the 
results of combining the data from multiple directions. For the final stiffness from 
multiple particles, a normal distribution was observed with a peak stiffness of 0.81 
 0.02 Pa. The average final stiffness obtained from a single particle was 0.83  
0.09 Pa which agrees well.  
 
The variation in mechanical properties may also be used as an indirect probe of 
clot structure. The mechanical properties of a clot are known to be highly 
dependent upon clot structure (33). For example, in a very homogeneous clot the 
variation in stiffness from particle to particle will be small with each particle 
measuring something close to that of the bulk stiffness. Contrary to this, a highly 
inhomogeneous clot where particles are located in regions of either high or low 
fibre density will result in a greater variation in stiffness being observed. In 
addition, it has been observed that fibres are much stiffer when stretching 
compared to bending (122). If a particle is attached or near a large fibre such that 
one direction may bend the fibre and another may stretch it then the observed 
stiffness could be substantially different. Hence, by comparing the variation in 
stiffness from particle to particle it may be possible to measure the degree of 
inhomogeneity within a clot. 
 
For example, the fibrinogen variant A/  is known to produce clots of an 
inhomogeneous structure compared with the highly uniform arrangement of fibres 
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within A/ A clots. Thus, these clots provide a good test for the method outlined 
here. Clots were formed by the procedure detailed in section 4.4. In detail, clots 
were formed from 0.5 mg/ml fibrinogen, 2.5 mM CaCl2, 1 mM FXIII inhibitor and 
1.0 U/ml thrombin. After the required period of clotting, a particle was selected 
and then tested. In brief, a constant force pulse is applied to the particle for a time 
such that the particle stops displacing. Next, for every time point during the 
application of the force the compliance is calculated and then plotted as a 
function of time. The magnitude of the plateau compliance represents the 
mechanical properties of the clot on long times and therefore relates to the large-
scale motion of the clot. In particular, this will be dependent upon the 
number/arrangement of fibres and branch points within the area surrounding the 
particle. In order to quantify the variation from particle-to-particle in the plateau 
compliance, the variance was computed. The variance indicates how spread out 
data is from one another. 
 
There did not appear to be any differences in the variation between A/ A and 
A/  clots. Additionally, data from microrheology experiments of purified fibrin 
clots where fibrinogen, thrombin and CaCl2 concentrations were varied, which are 
known to modulate clot structure, was also analysed in this way. Again, no 
statistically significant difference in the variance was observed which would 
correlate with clot inhomogeneity. Itis suspected that the insensitivity of the 
microrheometer to these differences may be due to the size of the particle in 
relation to the characteristic network length scale. Inspection of Figure 4-2 and 
Figure 4-3 reveals that particles are within regions containing multiple fibres. As 
such when a particle strains the network it pulls on many fibres surrounding it 
which in turn pulls on more fibres which are attached to these fibres. Thus, the 
stiffness measured is close to that of the bulk stiffness of the clot. The difference 
in stiffness between particles distributed throughout a clot and the differences 
from manipulating them in multiple directions appears to be due to the fact that 
measurements of most physical systems result in measurements distributing 
normally around a mean central value. 
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4.6 Strain-hardening  
 
As already seen there are different approaches to applying forces to investigate 
the mechanical properties of a clot. One can apply force pulses of increasing 
magnitude in order to test the Hookean response of a network e.g. F = -kx, where 
F is the magnitude of the force pulse, x is the particle displacement and k is the 
effective spring constant of the clot. Clots were prepared as described in section 
2.2.4 with a final fibrinogen concentration of 0.1 mg/ml, CaCl2 of 5 mM and 
thrombin concentration of 0.5 U/ml. Clots were allowed to form for 2 hours to 
ensure complete development of the mechanical properties. After this time, the 
clot was transferred to the magnetic microrheometer where 2 s force pulses were 
applied in 5 pN steps from 0 up to 80 pN. The subsequent stiffness was 
calculated and plotted as a function of displacement (see Figure 4-9). 
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Figure 4-9: J
-1
 versus displacement of a clot displaying strain-hardening behaviour. The 
data is representative of 3 repeat measurements with error bars representing the standard error in 
the mean. 
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At least 5 particles distributed throughout each clot were selected and tested. It 
was observed that the stiffness remained constant up to bead displacements of 
around 2 μm, after which the stiffness began to increase as the force increased. 
From around 2 to 3 μm, the stiffness increased from ~0.45 Pa up to ~0.65 Pa 
representing an increase in stiffness of 1.4-times. It is evident from the data that 
fibrin clots display a non-linear elastic response and are undergoing strain-
hardening. 
 
The data presented in Figure 4-9 can be explained by several models proposed 
within the literature. Storm et al. (80) propose that reversible strain-hardening 
arises from the entropic response of the individual fibres. Under strain, fibres are 
removed from their thermodynamically stable state and the macroscopic non-
linear behaviour of the clot is due to the collective response of all the fibres. The 
theory of Onck et al. (123) propose that strain-hardening arises from the 
stretching of fibres once they have become aligned under strain. Weigandt et al. 
(67) suggest that these models are not mutually exclusive and that both effects 
could be contributing to the strain-hardening response. However, Brown et al. 
report that in order to model strain-hardening, protein unfolding is required in 
order to fit the various models to the experimental data (81). In the framework of 
this model, up to displacements of ~2 μm the fibres bend and align along the 
direction of strain, protofibrils then untwist and then molecular domains begin to 
unfold. Once they have completely unfolded, the rapid rise in clot stiffness arises 
from the stretching of the unfolded protein chains.  
 
The mechanism of irreversible deformation in fibrin clots is also currently 
unknown. Two theories have been proposed, firstly one in which the knob-hole 
bonds that hold fibrin molecules together break and then reform in a different 
location (90, 124, 125). And secondly, one where protofibrils can slip past one 
another and then reform bonds at different locations (13). The model proposed by 
Brown et al. (81) could explain irreversible deformation if refolding of the uncoiled 
domains was negligible.  
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Whatever the molecular mechanism of strain-hardening and irreversible 
deformation may be, it highlights the importance of working within the linear 
regime when studying fibrin clot mechanics. If for instance, a particular fibrin 
variant begins strain-hardening at lower strains compared to another then this 
would introduce complications when comparing the mechanical properties. 
Irreversibly deforming a clot may also alter its mechanical properties. As such, 
the mechanical properties of clots studied in this work have been performed 
within the linear strain regime. Also, as previously mentioned, when studying how 
clot stiffness varies over time the resulting displacement response is maintained 
as elastic as possible to ensure minimal sample deformation.  
 
In addition, it was found that studying the behaviour of strain-hardening using the 
current experimental setup was not suitable. Due to the particularly low forces 
available with the magnetic microrheometer, the maximum displacements 
achievable are low; of the order of the bead radius. In the example above, very 
low fibrinogen levels were used, in order to produce a particularly weak network, 
which could be sufficiently strained. Despite this, the maximum displacement 
achieved was only around 3 μm. 
 
4.7 Measuring the Frequency-Dependent Viscoelastic 
Moduli of Fibrin Clots 
 
As mentioned in section 2.2.7, in order to measure the frequency-dependent 
viscoelastic moduli of materials, rheological measurements must be performed 
over a range of frequencies. In the case of single particle microrheology 
experiments, measurements must also be averaged from many different 
particles. This is extremely time consuming to perform and magnetic 
microrheometers can be limited to lower frequencies due to hysteresis effects of 
the magnets. Evans et al. provide a direct and straightforward mathematical 
procedure for obtaining the frequency-dependent storage and loss moduli from 
time-dependent experimental measurements (126).  
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In a creep-response measurement, as introduced in section 2.2.7, the time-
dependent bead displacement is related to the time-dependent compliance 
through Equation 2-8. The relaxation modulus )(tG  is connected to the 
compliance )(tJ  by a convolution (58): 
 
 t
dtJG
0
1)()(  4-1 
 
where t is the time and  is the lag time. The numerical inversion of this 
convolution is not a trivial task and typically involves working with the Laplace 
transform of Equation 4-1 (70):  
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where )(
~
tG  and )(
~
tJ  are the Laplace transforms of )(tG  and )(tJ  and s is the 
Laplace frequency. From Equation 4-2, if one function is given analytically then 
the other can be calculated via inverse Laplace transformation (126). The 
procedure of Evans et al. (127) bypasses this approach by working directly with 
the Fourier transform of the compliance. Since the complex modulus )(*G  is 
related to the relaxation modulus )(tG  via: 
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where F[…] denotes the Fourier transform, Equation 4-2 can be written as: 
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where )(
~0 sG  is the Laplace transform of the time derivative of the relaxation 
modulus )(tG . Once )(
~
sJ  is known, the passage from )(
~0 sG  to )(*G  is 
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obtained by substituting the complex variable s with i , where  is the 
frequency: 
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The determination of the quantity )(
~
iJ  in this equation is the final step in 
obtaining the complex modulus and it represents the Fourier transform of the 
time-dependent compliance )(tJ : 
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Due to the condition that 0)(tJ  for 0t  i.e. there is no response from the 
system before a stress is applied, then Equation 4-6 can be written as: 
 
 
0
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Due to the nature of )(tJ , this integral diverges and therefore is not simple to 
solve. The procedure of Evans et al. (127) provides an analytical procedure 
which allows the calculation of Equation 4-7 once an analytical form of )(tJ  is 
provided. This method requires only two conditions for )(tJ . Firstly, that 0)(tJ  
for 0t , as mentioned, and secondly that in the ttJ
t
)(lim  (the long-time limit) 
the compliance asymptotes to a straight line with a gradient equal to the 
reciprocal of the steady-state viscosity, 1 . In addition, there is no restriction 
upon the form of )(tJ . Finally, the real and imaginary parts of Equation 4-5 
represent the elastic and loss moduli respectively: 
 
 )()()(* GiGG  4-8 
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Figure 4-10 shows the data from a typical creep-compliance experiment 
performed using the magnetic microrheometer. The sample under investigation is 
a purified fibrin clot (discussed in detail in section 4.8). The method described 
here is applied to all clot types, e.g. plasma clots, studied throughout this work.  
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Figure 4-10: Creep-compliance versus time for a purified fibrin clot. Final clot concentrations 
were 0.6 mg/ml fibrinogen, 2.5 mM CaCl2, 0.5 U/ml thrombin and 1 mM FXIII inhibitor. The red 
line is the best fit to the data using Equation 4-9. Insert: The same data but plotted on log-log 
axes. 
 
The best fit to the experimental data in Figure 4-10 was performed by fitting the 
following equation: 
 
 n
t
n
neAJtJ
1
)/(
0)(  4-9 
 
with n = 2 in this instance, n is varied to achieve the best fit to the data. 0J , nA  
and n  represent the fitting parameters. The resulting analytical function )(tJ  was 
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then used to solve Equations 4-7 and 4-5. Now the complex viscoelastic moduli 
can be extracted from equation 4-8. The result of this procedure is presented in 
Figure 4-11. 
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Figure 4-11: Storage (G ) and loss (G ) moduli versus frequency ( ) calculated from the 
data in Figure 4-10. 
 
Using the procedure of Evans et al. (127), it is possible to measure the 
viscoelastic response of a material over a wide range of frequencies; the data in 
Figure 4-11 span a frequency window of 5 orders of magnitude. The lowest 
accessible frequency, min  
1
maxt  is determined by the duration of an experiment, 
maxt . This frequency can be expanded to lower frequencies once the terminal 
region, i.e. ttJ )( , has been reached. For oscillatory measurements, obtaining 
data at the same frequency would require several complete oscillations of 
multiple particles which would take considerably longer to perform. The highest 
accessible frequency, max  
1
mint is determined by the capture rate of the camera 
(25 Hz for all measurements presented here). For magnetic rheology, this is 
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particularly advantageous as hysteresis effects can hinder measurements at high 
frequencies. Another advantage of this approach is that any phase shift between 
bead displacement and the applied force does not play a role as the applied force 
is constant. The suitability of the procedure developed by Evans et al. (127) to 
study viscoelastic behaviour has been demonstrated by the successful 
application to a wide range of different systems from viscous liquids, such as 
glycerol, through to actin networks (128-132). 
 
4.8 Stress Relaxation in Fibrin Clots 
 
The procedure of Evans et al. (127) was applied to fibrin networks in order to 
extract the frequency dependent viscoelastic moduli. Clots were prepared as 
described in section 2.2.4 with a final fibrinogen concentration of 0.6 mg/ml, 
CaCl2 of 2.5 mM and thrombin concentration of 0.5 U/ml. A synthetic inhibitor of 
FXIII (detailed in section 2.1) was included at a final concentration of 1 mM in 
order to inhibit cross-linking. Clots were allowed to form for 1 hour to ensure 
complete development of the mechanical properties. After this time the clot was 
transferred to the magnetic microrheometer. A constant force of 40 pN was 
applied for 300s and the displacement was measured. This data was used to 
calculate the compliance via Equation 2-8 for every time point throughout the 
experiment (see Figure 4-10). The steady-state viscosity is determined from the 
reciprocal of the gradient of the asymptote to )(tJ  at long-times. From Figure 
4-10 it is evident the steady-state viscosity approaches zero, and this is the case 
for all fibrin clots studied throughout this work. The initial value of the compliance, 
)0(J  is taken as the first measurable experimental point after the application of 
the force. This data in conjunction with the procedure of Evans et al. (127) was 
then used to compute the frequency dependent storage and loss moduli as 
described above. The result of this analysis is present in Figure 4-11.  
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Figure 4-12: G  vs.  semi-log plot of a fibrin clot. Data taken from Figure 4-11. The roman 
numerals indicate three plateaus which represent stress relaxation mechanisms. Plateau I is 
orientation-dominated, plateau II is curvature-dominated and plateau III is tension-dominated, as 
predicted by the model of Morse (71).  
 
The storage and loss moduli were measured over a frequency range of 0.0008 to 
25 Hz. The storage modulus is approximately an order of magnitude higher than 
the loss modulus over the entire frequency range. This indicates the clot behaves 
predominately elastic on all times scales observed. A cross-over in the moduli i.e. 
G  > G , would indicate the clot is behaving like a liquid and readily deforming. 
For all fibrin clots studied in this work no such cross-over behaviour was 
detected. The observation that on all timescales and for all fibrin types studied 
here the storage modulus is consistently higher than the loss modulus has 
interesting implications for in vivo clot behaviour. Within the circulatory system 
the rate of application of stress varies from <300 s-1 up to 2600 s-1 (60, 61). The 
observation that G  > G  over a wide range of timescales ensures a clot 
maintains its integrity no matter what the rate of application of stress. 
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Unfortunately, it is not possible to test whether this behaviour continues up to 
physiologically relevant timescales as measurements at these frequencies were 
not possible with the current experimental setup. In addition, as time increases (  
< 0.01 s-1) G  begins to plateau and G  diverges to smaller and smaller values. 
This indicates clots are highly stable on long timescales. Again, this behaviour is 
important physiologically as a clot must remain at the site of injury for a prolonged 
period until any damaged tissue is repaired. 
 
The majority of studies conducted into the viscoelastic behaviour of fibrin clots 
report very little or no dependence of G  upon frequency, see (67) for a recent 
example. In Figure 4-12 is a semi-log plot of the dependence of G  upon 
frequency. It is evident that G  varies with frequency and displays structure. Three 
plateaus at different frequencies can be identified: (I)  < 0.01, (II) 0.1 <  < 1 
and (III)  > 10. Each plateau corresponds to a different shear relaxation mode 
allowed on that timescale, as predicted by the model of Morse (71).  
 
We can explain the stress relaxation processes occurring in fibrin within the 
framework of Morse‘s model. On long timescales (t > 100 s) plateau I 
corresponds to large scale motions of the fibres and branches, i.e. an 
orientational contribution arising from forces that resist movement of the entire 
fibre. We see a plateau in G  and a divergence in G  as predicted by Morse for a 
network of branched fibres (71). Therefore, this plateau arises due to the fact that 
fibrin fibres form permanent branches with one another. Hudson et al. report on 
the stretching of 2D fibrin networks and find that on timescales up to 25 s, 
individual fibres and branch points can move distances of several micrometres 
(133). They also report that fibre strain-hardening acts to distribute strain equally 
throughout the network. The branch point therefore acts as a junction to distribute 
strain to other fibres. In addition, Carlisle et al. (34) report that fully cross-linked 
clots mainly fail by fibre rupture rather than branch point rupture. If one considers 
a branch junction of 3 fibres then if the branch point fails, all 3 fibres fail. 
However, if as observed, one of the fibres fails then 2 fibres are still connected 
which could maintain structural integrity. This demonstrates the important role 
branch points play in clot integrity. The data presented here also reveal the role 
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of branch points in the long-time elastic behaviour of fibrin networks and that they 
help clots maintain their integrity for prolonged periods of time.   
 
Next, on intermediate timescales (1 s < t < 10 s), corresponding to plateau II, 
fibres are moving on length scales of the order of the fibre length i.e. distances 
between branch points. This is a curvature contribution which arises from forces 
that are opposing transverse deformation or rotation of the fibre. Here fibres are 
bending and twisting in response to an applied stress. This plateau will be 
dominated by the properties of the single fibres themselves and the density of 
branches.  
 
Finally, on the shortest timescales (t < 0.1 s) corresponding to plateau III, fibres 
are compressing and stretching. This is a tension contribution which arises from 
tangential forces that resist stretching or compression of the fibre. Boal suggests 
this plateau will be dominated by molecular mechanisms. This could be either the 
unfolding of the coiled coil domains (81, 92, 134), the globular  domain (135) or 
the C connector region (136). It was not possible to measure the entire high 
frequency plateau, or any other higher frequency relaxation modes, as the 
acquisition rate of the optics limits higher frequency measurements. This plateau 
is predicted to scale with fibrinogen concentration as G c2.5 by Mackintosh et al. 
(68), and this is tested in Chapter 5.  
 
Liu et al. report on the mechanical properties of single fibrin fibres finding fibres 
show fast (2 - 4 s) and slow (49 - 57 s) stress relaxation times (137). They 
suggest these rates are due to molecular relaxation processes such as unfolding 
events; however they provide no further discussion. This appears at odds with 
the observations of Hudson et al. (82) and the model of Boal (69) whereby it is 
observed that individual fibres can move on these times and only molecular 
mechanisms can occur on very short times. The very short times observed by Liu 
et al. (86) could correspond to the high frequency plateau observed here with the 
longer times corresponding to the intermediate plateau. Differences in times 
could be related to the differing experimental conditions and technique used. The 
observation of relaxation behaviour on very long times i.e. t > 100 s, may not be 
102 
 
observed in the experiments of Liu et al. (86) as the fibre is fixed to a substrate 
and therefore the branches, which would normally be present, cannot move. 
However, it is clear from this work, and that presented within the literature, that 
fibrin displays multiple relaxation mechanisms on distinctly different timescales. 
 
The various calculations by Morse of loosely- and tightly entangled and coil-like 
and rod-like solutions predict that each stress relaxation mode forms a hierarchy 
in which Gtens > Gcurve > Gorient and that each should occur on different timescales 
in which tens < curve < orient. Both conditions are satisfied by the data presented 
in Figure 4-12, and in addition all other measurements throughout this work also 
agree with this prediction.   
 
The apparent discrepancy between the behaviour of G  presented here and those 
presented throughout the literature appear somewhat surprising. As mentioned 
several authors (41, 44, 45, 67, 77) have reported measurements of G  and 
G by conventional rheometry, spanning a frequency range of  = 10-4 – 104 
Hz. However, all these studies report a single plateau in G and not allobserve the 
long-time elastic behaviour predicted by Morse‘s model for branched networks 
i.e. G  >> G  as t  . Similar discrepancies between the results of conventional 
rheometry and microrheometry have been reported for studies of actin networks. 
Although in this instance it appears that differences arise due to microrheological 
techniques having the ability to access much higher frequencies. Disagreement 
between our results and those from the literature could be due to the differing 
experimental conditions used. In most studies the fibrinogen concentration is 
much higher than that used here; 0.6 vs. >2 mg/ml. Measurements presented in 
Chapter 5 reveal that at higher fibrinogen levels plateau I extends over a much 
broader frequency range. If this trend continued we predict that at fibrinogen 
levels above 2 mg/ml we would observe similar behaviour to that reported by 
other authors. Also, it may well be that differences arise due to the nature of the 
microrheological technique used.    
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4.9 The Effects of FXIII on Fibrin Clot Viscoelasticity 
 
In order to assess the validity of the current experimental setup and technique the 
effect of FXIII on clot mechanical properties, which has been widely reported 
upon in the literature (29, 62, 66, 75, 79, 124, 138-143), was tested. Clots were 
prepared as described in section 2.2.4 with a final ERL fibrinogen concentration 
of 0.6 mg/ml and CaCl2 of 2.5 mM. For complete cross-linking, clots were formed 
with a final FXIII concentration of 3.7 μg/ml. Again, the synthetic inhibitor of FXIII 
was included at a final concentration of 1 mM in order to inhibit cross-linking. This 
inhibitor has been used in other studies (33, 122) to successfully inhibit cross-
linking. Thrombin was then added at a final concentration of 0.5 U/ml, after which 
force pulses were applied every 10 s for 2 s until a plateau in J-1 was observed. 
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Figure 4-13: J
-1
 vs. time of clots formed with and without FXIII. Insert: J
-1
 vs. time over the 1
st
 
hour of clotting. Errors represent the standard error in the mean from 3 repeat measurements. 
Errors have been omitted from the main plot for clarity. 
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The results are displayed in Figure 4-13 and analysis is presented in Table 4-3. A 
plateau in J-1 was observed after ~20 mins in clots without cross-linking while 
cross-linked clots continued to increase in stiffness up to 6 hours. Cross-linking 
was studied using SDS-PAGE analysis in clots formed from A/ A and A/  
fibrinogen (Chapter 6) under very similar clotting conditions (0.5 mg/ml fibrinogen, 
2.5 mM CaCl2, 3.7 μg/ml FXIII and 1.0 U/ml thrombin). Disappearance of the  
and  chain monomers, indicating the cross-linking of these chains, in conjunction 
with the appearance of cross-linking products was observed at times up to 6 
hours. This correlates extremely well with the observation that cross-linked clots 
continue to increase in stiffness on long times after the initiation of clotting. In 
addition, very little difference in polymerisation and clot stiffness is observed at 
the earliest times (see Figure 4-13 and Table 4-3). At times <5 minutes very little 
disappearance of the  chain monomers has occurred and virtually no  chain 
monomer has disappeared due to cross-linking. Subsequent increases in clot 
stiffness occur due to the formation of cross-links. Once the plateau in J-1 was 
reached, the final compliance of both clots was measured and found to be 2.3-
times higher in cross-linked clots, indicating a mechanically stiffer clot.  
 
Table 4-3: Stiffness polymerisation data of clots formed with and without FXIII  
Polymerisation Parameter FXIII- FXIII+ 
dJ
-1
/dt (Pa.s
-1
) 0.4  0.1 0.57  0.08 
JI (Pa) 2.5  0.4 2.2  0.3 
JF (Pa) 4.8  0.8 11  1 
Plateau time (mins) 12  2 197  18 
 
Next, the frequency dependent viscoelastic moduli were measured by the 
procedure detailed in section 4.7. The results are displayed in Figure 4-14. The 
effect of FXIII was to increase the storage and loss modulus on all timescales 
observed. The storage and loss moduli were extracted at frequency values of 8 x 
10-4, 0.5 and 20 Hz (Table 4-4). The 1st frequency was chosen in order to extract 
the plateau modulus, G 0 which is defined as G 0 = G ( ) at a frequency for which 
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tan( ) = G ( ) / G ( ) is a minimum (70). The 2nd and 3rd frequencies were 
chosen in order to determine the effect of FXIII on the intermediate and high 
frequency plateaus.   
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Figure 4-14: G  and G  vs.  of clots formed with and without FXIII. 
 
An increase in the storage modulus, ranging between 2.7- and 3.1-times, at all 3 
frequencies was observed in the presence of FXIII. The loss modulus increased 
between 1.6- and 2.6-times in the presence of FXIII. The increase in the storage 
over the loss modulus resulted in an increase in the loss tangent, in the absence 
of FXIII, by 1.2- to 1.7-times. This indicates that cross-linking increases clot 
stiffness and reduces viscous creep, rendering a clot more mechanically stable. 
Studies into the effect of FXIII on clot rheology using bulk techniques reveal 
cross-linking is associated with a 2- to 3.5-times increase in G  (33, 75, 143). This 
demonstrates the suitability of the current experimental technique in order to 
study the viscoelastic behaviour of fibrin clots. 
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In addition, the presence of cross-linking did not significantly alter the stress 
relaxation behaviour of fibrin. The timescales for which the plateaus in G  occur 
were not significantly altered. Similar observations were also reported by Liu et 
al. (86). These observations suggest that cross-linking does not alter the 
dynamics of fibrin clot behaviour. The effect of cross-linking is only to make a clot 
stiffer and less extensible. The effect of FXIII on clot structure has been 
investigated by Ryan et al. (84) who report an increase in fibre length and a 
decrease in fibre diameter, while fibre and branch point density remain 
unaffected. As the overall clot architecture remains essentially unchanged this 
most likely explains the insensitivity of the fibre dynamics to FXIII cross-linking. 
 
Table 4-4: Viscoelastic data of clots formed with and without FXIII  
Viscoelastic 
Parameter 
FXIII- FXIII+ 
Frequency 
(Hz) 
8 x 10
-4 
0.5 20 8 x 10
-4 
0.5 20 
G  (Pa) 2.5  0.3 4.3  0.3 5.0  0.3 7.6  0.1 12.4  0.6 13.4  0.8 
G  (Pa) 0.032  0.003 0.33  0.05 0.21  0.05 0.08  0.03 0.7  0.1 0.33  0.04 
tan  0.013  0.002 0.08  0.01 0.04  0.01 0.011  0.004 0.05  0.01 0.025  0.004 
 
Finally, the frequency behaviour of the loss tangent was also calculated and the 
results are displayed in Figure 4-15. In the presence and absence of cross-linking 
there is a dramatic peak in the loss tangent at ~0.04 Hz. A much smaller, 2nd 
peak occurs at ~2 Hz. In the absence of cross-linking there is a rapid increase in 
the loss tangent from 0.013 up to ~0.28. This represents a 22-times increase in 
the loss modulus. In the presence of cross-linking the loss tangent increases from 
0.011 up to ~0.25; increasing 23-times. The loss tangent in clots without cross-
linking is still higher by 1.1-times. The 2nd peak however is more dramatically 
affected by the presence of FXIII. In the absence of FXIII this peak is ~0.09 and 
in the presence of FXIII this falls to ~0.05; a decrease of around 1.8-times.  
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Figure 4-15: tan  vs.  semi-log plot of clots formed with and without FXIII. 
 
These peaks coincide with the transitions between different stress relaxation 
modes. It appears that if clots are stressed on these timescales then the amount 
of deformation a clot undergoes is rapidly increased. These results suggest that 
when clots are stressed on these timescales they are unable to dissipate the 
stress and therefore readily deform. This highlights a weakness in fibrin clots 
ability to dissipate stress and could be a potential mechanism for embolism.  
 
In addition, this highlights the important of performing viscoelastic measurements 
over a range of frequencies. Typically, most studies within the literature take 
measurements at one specific frequency. From the data, it could be inferred that 
fibrin clots are highly resilient to mechanical deformation as evidenced by their 
extremely small loss tangents. For instance, in an elastic solid tan  << 0, 
therefore measurements taken on long times would indicate fibrin clots are 
behaving essentially elastic and do not display a large degree of viscous 
deformation. However, when considering measurements taken at frequencies of 
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~0.04 Hz this picture rapidly changes. The loss tangent begins to approach a 
significant fraction of unity, i.e. tan  = 1, at which point clots are storing and 
dissipating similar amounts of energy and as such undergoing significant degrees 
of deformation. These observations highlight the importance of performing multi 
frequency measurements. 
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Chapter 5 
5 Fibrin Clot Microrheology 
 
5.1 Introduction 
 
The aim of the work presented in this chapter was to investigate the effects of 
fibrinogen, thrombin and CaCl2 concentrations on the viscoelastic properties of 
fibrin clots.  
 
5.2 Fibrinogen Concentration 
 
The effects of fibrinogen concentration on clot viscoelasticity were investigated 
using the magnetic microrheometer. The following concentrations were tested: 
0, 0.2, 0.4, 0.6, 0.8 and 1 mg/ml. Clots were formed as described in section 
2.2.4 with a final thrombin concentration of 0.5 U/ml, CaCl2 concentration of 2.5 
mM and FXIII inhibitor concentration of 1 mM. These clotting conditions, and 
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those subsequently used for thrombin and CaCl2 experiments, were dictated by 
the effective working limits of the magnetic microrheometer. For instance, 
fibrinogen concentration is limited to ~1 mg/ml, above this concentration the clot 
becomes extremely stiff and as such the device is operating at maximum force 
in order to produce particle displacements with sufficient signal-to-noise.  
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Figure 5-1: J
-1
 versus time for clots formed from different fibrinogen concentrations. 
Measurements were performed over the 1
st
 hour of clotting. Fibrinogen concentration is 
displayed in the legend. Errors represent the standard error in the mean from 3 repeat 
measurements. 
 
After the addition of thrombin, clots were transferred to the magnetic 
microrheometer and force pulses were applied. Pulses of 2 seconds in duration 
were applied every 10 seconds over the first hour of clotting. The magnitude of 
the force pulse is dictated by the stiffness of the network and the need to 
maintain a balance between sufficient signal-to-noise and minimising sample 
deformation. The results of these experiments are presented in Figure 5-1 and 
analysis is provided in Figure 5-2. 
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Figure 5-2: JF, dJ
-1
/dt and plateau time versus fibrinogen concentration. Data extracted 
from Figure 5-1. The JF and dJ
-1
/dt data have been fitted with a power law equation of the form y 
 c
p
, where y is the measured experimental quantity, c is the fibrinogen concentration and p is 
the power. The plateau time data has been fit with a linear equation of the form y = mc + k, 
where m is the gradient and k is the intercept. dJ
-1
/dt was calculated over the 1
st
 minute of 
clotting.  Errors represent the standard error in the mean from 3 repeat measurements.  
 
A clotting period of 1 hour was more than sufficient to ensure complete 
mechanical development of all fibrinogen concentrations under investigation. In 
fact, by around 20 minutes a plateau in J-1 was observed for all fibrinogen 
concentrations (Figure 5-2). As expected no clot formation was detected at 0 
mg/ml fibrinogen concentration. As the fibrinogen levels increased the final 
compliance increased rapidly; the data are fit by a power law relationship with JF 
 c2.9  0.1. For a 5-times increase in fibrinogen concentration this resulted in a 
100-times increase in the final compliance. In addition, the rate of change of 
compliance also increased with increasing fibrinogen levels. Again, the data 
were well fit by a power law relationship with dJ-1/dt  c2.8  0.4. Similarly, for a 5-
times increase in fibrinogen concentration this resulted in a 129-times increase 
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in the rate of change of compliance. The increased rate of mechanical 
development at higher fibrinogen levels is also reflected in the plateau time 
which decreased as fibrinogen concentration increased. The plateau time falls 
by ~10 minutes over the entire fibrinogen concentration range. The data 
presented here reveal clot polymerisation and mechanical properties are 
dramatically affected by small variations in fibrinogen concentration. 
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Figure 5-3 a - e: Storage and loss moduli versus frequency for clots formed at different 
fibrinogen concentrations. Data represent the average from 3 repeat experiments. 
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After a clotting period of 1 hour, the frequency dependent viscoelastic moduli 
were measured as described in section 4.6. The results of this analysis are 
displayed in Figure 5-3. The storage and loss moduli were measured over a 
frequency range of 0.0008 to 25 Hz. At all fibrinogen concentrations the storage 
modulus varied with frequency displaying three plateaus; as previously 
discussed in section 4.7. Again, the storage modulus was consistently higher 
than the loss modulus for all frequencies, indicating predominately elastic 
behaviour. On long-times the loss modulus diverged becoming smaller and 
smaller while the storage modulus reached a plateau. In order to identify the 
effect of fibrinogen on the different stress contributions to G ( ) the storage and 
loss moduli were extracted at 3 specific frequency values of 8 x 10-4, 0.5 and 20 
Hz corresponding to the low (hereafter I), intermediate (II) and high (III) 
frequency plateaus respectively. The results of this analysis are displayed in 
Figure 5-4. 
 
As fibrinogen concentration increased the storage modulus increased rapidly at 
all frequencies. For a 5-times increase in fibrinogen concentration this resulted 
in a 95- to 110-times increase in the storage modulus. The dependence of the 
storage modulus on fibrinogen concentration was fit by a power law relationship 
with G I  c
2.2  0.2, G II  c
2.  8  0.2 and G III  c
2.7  0.2. Plateau III was predicted by 
Mackintosh et al. (68) to scale with concentration as G   c2.5 for branched 
networks of semi-flexible fibres. The value obtained in this work is slightly higher 
than this but still in agreement, within experimental errors, for the expected 
dependence. Figure 5-5 displays a plot of the data to the expected dependence 
and reveals good agreement between the data and the prediction. The inserts 
in Figure 5-4 are log-log plots and reveal good agreement between the 
experimental data the power law fits. There is some discrepancy between the 
storage modulus data and the fit at a fibrinogen concentration of 0.2 mg/ml for 
plateau I. This concentration was repeated but didn‘t result in any improvement 
to the fit. However, overall the data agrees extremely well with a power law 
relationship predicted by MacKintosh et al. (68).  
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Figure 5-4: Storage modulus, loss modulus and loss tangent versus fibrinogen 
concentration. Data were extracted from Figure 5-3 at 3 specific frequency values; I 8 x10
-4 
(orient), II 0.5 (curvature) and III 20 (tension) Hz. Inserts depict log-log plots of the data. For G  
and G  the data has been fitted with the same power law relationship as in Figure 5-2. In the 
plot of tan  vs. concentration the data points are joined by a linear extrapolation which is 
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included as a guide for the eye. Errors represent the standard error in the mean from 3 repeat 
experiments.  
 
At all frequencies, the loss modulus was consistently lower than the storage 
modulus ranging between 10- to 130-times. The loss modulus also displayed 
similar behaviour to the storage modulus; increasing as fibrinogen concentration 
increased. For a 5-times increase in fibrinogen concentration this resulted in an 
8- to 190-times increase in the loss modulus. Again, the data were fit by power 
law relationships with G I  c
1.32  0.07, G II  c
2.7  0.3 and G III  c
2.6  0.2. 
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Figure 5-5: Storage modulus versus fibrinogen concentration. The storage modulus data is 
that in Figure 5-4 extracted at a frequency value of 20 Hz (III). The red line is the scale 
prediction of Mackintosh et al. (68) of G  ~ c
2.5
. Note essentially good agreement between the 
data and this prediction. Errors represent the standard error in the mean from 3 repeat 
experiments. 
 
For plateau I, the loss tangent decreased as fibrinogen concentration increased. 
At 0.2 mg/ml fibrinogen concentration the loss tangent was ~0.1 and then falls 
rapidly by a factor of 10, after which it remained constant, within experimental 
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errors, as fibrinogen concentration increased. This initial dramatic fall could be 
due to the lower value observed for the storage modulus, thus the loss tangent 
at 0.2 mg/ml is higher. In addition, the loss tangent for plateau III also remained 
essentially constant, within experimental errors, over the entire fibrinogen 
concentration range. For plateau II however the loss tangent increased up to a 
fibrinogen concentration of 0.8 mg/ml, after which it reduced. Overall however, 
the loss modulus remained essentially constant within experimental errors. It is 
expected that the loss tangent would begin to decrease due to the higher power 
dependence of the storage modulus over the loss modulus (I: 2.2 vs. 1.32).  
Note the loss tangent could not be calculated for clots containing no fibrinogen. 
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Figure 5-6: tan  versus  for clots formed at different fibrinogen concentrations. Insert: 
maximum tan  vs. fibrinogen concentration. A linear extrapolation is included as a guide for the 
eye. Errors represent the standard error in the mean from 3 repeat experiments. 
 
The dependence of the loss tangent on frequency as fibrinogen concentration is 
varied is displayed in Figure 5-6. Again, peaks in the behaviour of the loss 
tangent were observed. The maximum loss tangent was approximately a factor 
of 10 higher than the loss tangents displayed in Figure 5-4 and displayed very 
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similar behaviour as fibrinogen concentration increased. There was initially a 
dramatic fall in the loss tangent, as for plateau I, after which it remained 
constant. At 1 mg/ml fibrinogen concentration the loss tangent was 1.7-times 
smaller than at 0.2 mg/ml concentration. In addition, it was observed that the 
peak in the loss tangent was shifted to higher frequencies as fibrinogen levels 
increased. For example, the maximum loss tangent in clots formed at 0.2 mg/ml 
fibrinogen occurs at ~6 mHz while clots formed at 1.0 mg/ml the peak is shifted 
up to a frequency of ~70 mHz. Thus, the maximum loss tangent occurs on very 
different timescales; the order of minutes in clots formed at low fibrinogen levels 
compared to seconds for those formed at higher levels. 
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Figure 5-7: G  and G  versus frequency. Clots were formed at 0.2 mg/ml fibrinogen, 0.5 U/ml 
thrombin, 2.5 mM CaCl2 and 1 mM FXIII inhibitor. Note the plot is a linear-log plot in order to 
emphasize changes in the behaviour of the storage modulus. The blue arrows indicate the 
association between changes in the storage and loss moduli. I is the time of the 1
st
 turning 
point in G and corresponds to the low-to-intermediate plateau transition in G . II is the time of 
the 2
nd
 turning point in G  and corresponds to the intermediate plateau in G . III is the time of 
the 3
rd
 turning point in G  and corresponds to the intermediate-to-high plateau transition in G
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Analysis of the plots in Figure 5-3 reveals that fibrinogen modulates the 
viscoelastic dynamics of fibrin clots. Figure 5-7 reveals the association between 
the behaviour of the storage and loss moduli. A change in the storage modulus 
is accompanied by a change in the loss modulus. For example, the change 
between the low frequency plateau and the intermediate plateau in the storage 
modulus is associated with a turning point in the loss modulus and occurs within 
the middle of this transition. Two further turning points are associated with the 
intermediate plateau and the transition up to the higher frequency plateau. Due 
to the frequency limit of the magnetic microrheometer, as previously discussed, 
it is not possible to completely resolve this plateau however the transition up to 
this plateau can be seen. The temporal position of these turning points, 
designated I, II and III, will be calculated ( n = 1 / n) and used to quantify 
changes in the stress relaxation behaviour of fibrin clots as fibrinogen levels are 
varied (Figure 5-8). 
 
The position of the low-to-intermediate plateau transition, given by I, decreased 
as fibrinogen concentration increased. Initially, there was a dramatic fall of ~80 
seconds as fibrinogen concentration increased from 0.2 to 0.4 mg/ml. After this 
I continued to fall as fibrinogen levels increased, albeit less rapidly, decreasing 
a further 10 seconds as fibrinogen concentration reach 1.0 mg/ml. Overall, I 
decreased ~10-times over the entire fibrinogen concentration range. As the low-
to-intermediate plateau transition moves to shorter times, i.e. higher 
frequencies, the low frequency plateau extends over a longer time range. This 
results in the low frequency plateau occurring on shorter time-scales. Clots 
formed at 0.2 mg/ml fibrinogen plateau at ~1 mHz, as fibrinogen concentration 
increased up to 1.0 mg/ml this plateau begins at ~4 mHz; a time difference of 
~10 minutes. Thus, as fibrinogen concentration increases clots begin to display 
predominately elastic behaviour on much  shorter time-scales. 
Next the position of the intermediate plateau, given by II, was measured and 
found to decrease as fibrinogen concentration increased. Overall there was 
around a 3 second drop, corresponding to a 6.5-times decrease, over the entire 
fibrinogen concentration range. Thus, the intermediate plateau occurs at shorter 
times, i.e. higher frequencies, as fibrinogen concentration increases. Inspection 
of the curves in Figure 5-3 reveals that as the low frequency plateau grows and 
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the transition to the intermediate plateau moves to higher frequencies this 
subsequently shortens the intermediate plateau. 
 
Finally, the position of the intermediate-to-high plateau transition, given by III, 
was measured and found to show no variation, within experimental 
uncertainties, as fibrinogen concentration increased. It is difficult to speculate on 
the effect of fibrinogen on the high frequency plateau as it was not possible to 
measure the entire plateau. As previously mentioned, high frequency 
measurements are limited by the acquisition rate of the optics.  
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Figure 5-8: I, II and III versus fibrinogen concentration. The data include a linear fit, of the 
form y = mx + c, as a guide for the eye. Insert: I vs. fibrinogen concentration from 0.4 to 1.0 
mg/ml. Errors represent the standard error in the mean from 3 repeat measurements. 
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5.3 Thrombin Concentration  
 
The effects of thrombin concentration on clot viscoelasticity were investigated 
using the magnetic microrheometer. The following concentrations were tested: 
0, 0.25, 0.5, 1 and 5 U/ml. Clots were formed as described in section 2.2.4 with 
a final fibrinogen concentration of 0.6 mg/ml, CaCl2 concentration of 2.5 mM 
and FXIII inhibitor concentration of 1 mM. The lower limit of thrombin 
concentration was 0.25 U/ml; below this polymerisation proceeds so slowly that 
the magnetic particles sink out of the clot before they become trapped by the 
network. 
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Figure 5-9: J
-1
 versus time for clots formed from different thrombin concentrations. 
Clotting was measured for 60 minutes and found to be sufficient for a plateau in J
-1
 to be 
reached for all concentrations studied. Thrombin concentration (U/ml) is displayed in the legend. 
Note clots formed from 0 and 0.1 U/ml thrombin concentration could not be measured. Errors 
represent the standard error in the mean from 3 repeat measurements. 
 
After the addition of thrombin, clots were transferred to the magnetic 
microrheometer and force pulses were applied. The results of these 
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experiments are presented in Figure 5-9 and Figure 5-10. A clotting period of 1 
hour was sufficient to ensure complete mechanical development of all thrombin 
concentrations investigated. As expected no clot formation was detected at 0 
U/ml. In addition, it was not possible to measure clots formed at 0.1 U/ml as 
polymerisation preceded so slowly the magnetic particles sank out of the clot. 
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Figure 5-10: JF, dJ
-1
/dt and plateau time versus thrombin concentration. Data extracted 
from Figure 5-9. The data points are joined by linear extrapolation which is included as a guide 
for the eye. Note clots formed at 0 and 0.1 U/ml thrombin concentration could not be measured. 
The rate of change of compliance was calculated over the 1
st
 minute of clotting. Errors 
represent the standard error in the mean from 3 repeat measurements. 
 
The final compliance initially increased rapidly to a maximum and then 
decreased as thrombin levels increased. From 0.5 to 1 U/ml there was no 
change in the final compliance, falling after this as concentrations were 
increased to 5 U/ml. There was around a 2-times increase in the final 
compliance as thrombin levels were lowered to 0.25 U/ml.  
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The rate of change of compliance increased as thrombin concentration 
increased, increasing 2.8-times as thrombin increased from 0.25 to 1.0 U/ml. 
However, at high thrombin levels (5 U/ml) compliance rates fell to below that of 
the lowest thrombin levels investigated. This may be surprising as one may 
expect an increased rate of development at higher enzyme levels. Inspection of 
the data in Figure 5-9 reveal clots formed at 5 U/ml have almost reached a 
plateau in their compliance once measurements have commenced. The 
reduced compliance rate appears to be artificial and most likely arises because 
of the extremely rapid increase in compliance. At times below 2 minutes it was 
not possible to capture data with the current experimental setup hence the 
stiffness had nearly reached a plateau by the time the experiment commences.  
 
The plateau time however did indicate an increased rate of mechanical 
development as thrombin levels increased. Between 0.25 and 1.0 U/ml there is 
a fall of 5.5 minutes and then a further fall of 4 minutes as thrombin 
concentration reaches 5 U/ml. This indicates that the plateau time is a better 
measure of the mechanical development in this instance. The data reveal clot 
polymerisation is modulated by thrombin levels, as expected, but in addition 
there exists an optimum level of thrombin which leads to increased mechanical 
strengths.  
 
After a clotting period of 1 hour the viscoelastic moduli were measured. The 
results of this analysis are displayed in Figure 5-11. Similar features in the 
behaviour of the storage and loss modulus and their relation to one another 
were observed. The viscoelastic moduli were extracted at the same frequencies 
as that used for fibrinogen experiments in order to investigate the effect of 
thrombin concentration on the viscoelastic moduli (Figure 5-12). 
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Figure 5-11 a - d: Storage and loss moduli versus frequency for clots formed at different 
thrombin concentrations. Data represents the average from 3 repeat experiments.  
 
At all frequencies, the storage modulus increased sharply between 0 and 0.25 
U/ml and reached a maximum. As thrombin increased to 0.5 U/ml the storage 
modulus decreased and stayed essentially constant up to a concentration of 1 
U/ml. Further increases in thrombin concentration resulted in a decrease in the 
storage modulus. The storage modulus was around 2-times higher at low 
thrombin levels compared with maximum levels. Again, the storage modulus 
was consistently higher than the loss modulus; 9- to 79-times higher over the 
entire concentration range for all frequencies. 
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Figure 5-12: Storage modulus, loss modulus and loss tangent versus thrombin 
concentration. Measurements were extracted from Figure 5-11 at a at 3 specific frequency 
values; 8 x10
-4 
(I), 0.5 (II) and 20 (III) Hz. The data points are joined by a linear extrapolation 
which is included as a guide for the eye. Errors represent the standard error in the mean from 3 
repeat experiments. 
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Again, at all frequencies the loss modulus rose sharply as thrombin 
concentration was raised to 0.25 U/ml. A further increase led to a fall in the loss 
modulus which then remained constant up to 1.0 U/ml. Except for plateau II 
where a dip in the loss modulus at 0.5 U/ml was observed before increasing 
again as levels reached 1.0 U/ml. The loss modulus again decreased as 
thrombin concentration reached 5 U/ml. At low thrombin levels the loss modulus 
was 1.8- to 4.6-times higher than at 5 U/ml.  
 
Finally, no difference in the loss tangent for plateau I was observed as thrombin 
levels changed, except when comparing clots formed at 0.5 and 5 U/ml. Clots 
formed at the higher thrombin levels displayed increased loss tangents of 
around 1.4-times. For plateau II, the loss tangent dropped sharply between 0.25 
and 0.5 U/ml and then decreased further beginning to plateau as thrombin 
levels reached 5 U/ml. Over the entire thrombin concentration range the loss 
modulus decreased 2.2-times. For plateau III, no difference in the loss tangent 
was observed, within experimental errors.  
 
The dependence of the loss tangent on frequency as thrombin concentration 
varied is displayed in Figure 5-13. Once again, peaks in the behaviour of the 
loss tangent were observed. Thrombin had a limited effect on the height and 
relative frequency position of these peaks. The insert in Figure 5-13 shows the 
maximum loss tangent as a function of thrombin concentration. Between 0.25 
and 0.5 U/ml there was a fall in the maximum loss tangent, however further 
increases in thrombin concentration did not significantly alter the loss tangent. 
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Figure 5-13: tan  versus  for clots formed from different thrombin concentrations. 
Insert: maximum tan  vs. thrombin concentration. A linear extrapolation is included as a guide 
for the eye. Errors represent the standard error in the mean from 3 repeat experiments. 
 
The insensitivity of the frequency position of the peaks in the loss tangent to 
thrombin levels indicates thrombin does not significantly alter the viscoelastic 
dynamics. In order to investigate this further, the data in Figure 5-11 was 
analysed, as above for fibrinogen experiments, and I, II and III were extracted. 
No correlation between any of the relaxation times and thrombin concentration 
was detected.  
 
5.4 CaCl2 Concentration 
 
The effects of CaCl2 concentration on clot viscoelasticity were investigated 
using the magnetic microrheometer. The following concentrations were tested: 
0, 1.5, 2.5, 5 and 10 mM. Clots were formed as described in section 2.2.4 with a 
final fibrinogen concentration of 0.6 mg/ml, thrombin concentration of 0.5 U/ml 
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and FXIII inhibitor concentration of 1 mM. It was possible to analyse clots 
formed at all CaCl2 concentrations. 
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Figure 5-14: J
-1
 versus time for clots formed from different CaCl2 concentrations. Clotting 
was measured for 60 minutes and found to be sufficient for a plateau in J
-1
 to be reached for all 
concentrations studied. CaCl2 concentration (mM) is displayed in the legend. Errors represent 
the standard error in the mean from 3 repeat experiments. 
 
After the addition of thrombin, clots were transferred to the magnetic 
microrheometer and force pulses were applied. The results of these 
experiments are presented in Figure 5-14 and Figure 5-15. Once again, a 
clotting period of 1 hour was sufficient to ensure complete mechanical 
development of all concentrations of CaCl2 under investigation. Also, it was 
possible to analyse clots formed in the absence of CaCl2.  
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Figure 5-15: JF, dJ
-1
/dt and plateau time versus CaCl2 concentration. Data extracted from 
Figure 5-14. The data points are joined by a linear extrapolation which is included as a guide for 
the eye. The rate of change of compliance was calculated over the 1
st
 minute of clotting. Errors 
represent the standard error in the mean from 3 repeat experiments.  
 
As CaCl2 concentration increased from 0 mM, the final compliance increased 
reaching a maximum at 2.5 mM. As CaCl2 levels increased further the final 
compliance began to fall; by 10 mM the final compliance was very similar to that 
of clots formed at 0 mM. There is around a 2-times increase in final compliance 
at 2.5 mM as compared with minimum and maximum CaCl2 concentrations. It is 
interesting to note that the compliance peaks at 2.5 mM CaCl2 as this is the 
concentration of CaCl2 in plasma. The rate of change of compliance displayed 
remarkable similar behaviour to that of the final compliance. Initially there is an 
increase, which peaks between 1.5 and 2.5 mM, after which it decreases as 
CaCl2 levels are increased. However, again the analysis of the time to plateau 
suggested that this drop in the rate of compliance change at high calcium 
chloride concentration may be an artefact from the data analysis. As CaCl2 
concentration increased, the time to plateau time gradually decreased. Over the 
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entire CaCl2 concentration range the time to plateau decreased by 7 minutes 
indicating increased rates of mechanical development at high CaCl2 levels. 
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Figure 5-16 a - e: Storage and loss moduli versus frequency for clots formed at different 
CaCl2 concentrations. Data represents the average from 3 repeat experiments. 
 
After a clotting period of 1 hour the viscoelastic moduli were measured. The 
results of this analysis are displayed in Figure 5-16. Similar features in the 
behaviour of the storage and loss modulus and their relation to one another 
were observed. The viscoelastic moduli were extracted at the same frequencies 
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as that used for fibrinogen and thrombin experiments in order to investigate the 
effect of CaCl2 concentration on the viscoelastic moduli (Figure 5-17).  
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Figure 5-17: Storage modulus, loss modulus and loss tangent versus CaCl2 
concentration. Measurements were extracted from Figure 5-16 at 3 specific frequency values; 
8 x10
-4 
(I), 0.5 (II) and 20 (III) Hz. The insert is a plot of GI  vs. c plotted on a different scale for 
clarity. The data points are joined by a linear extrapolation which is included as a guide for the 
eye. Errors represent the standard error in the mean from 3 repeat experiments. 
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The storage modulus increased sharply between 0 and 1.5 mM at all 
frequencies. For plateau I, the storage modulus further increased when CaCl2 
reached 2.5 mM and then stayed approximately constant up to 5 mM, after 
which it began to decrease as CaCl2 levels reached 10 mM. The storage 
modulus was 4.3-times higher once it had reached a plateau (2.5 – 5 mM) 
compared with clots formed in the absence of CaCl2. For plateaus II and III, the 
storage modulus peaked at 1.5 mM and then decreased as CaCl2 
concentrations increased further. The storage modulus was 2.4- and 2.7-times 
higher at 1.5 mM CaCl2 concentration for plateaus II and III respectively 
compared with clots formed in the absence of CaCl2. The storage modulus was 
consistently higher than the loss modulus; around 12- to 550-times over the 
entire concentration range. 
 
For plateau I, the loss modulus decreased as CaCl2 concentration increased. 
The loss modulus remained approximately constant, within experimental errors, 
up to 2.5 mM after which it decreased as CaCl2 levels increased to 10 mM. The 
loss modulus was ~10-times lower at 10 mM CaCl2 levels compared with lower 
levels (0 – 2.5 mM). For plateaus II and III, the loss modulus peaked at 1.5 mM 
then decreased as CaCl2 levels reached 5 mM, before increasing again slightly 
as CaCl2 levels reached 10 mM.   
 
For plateau I, the loss tangent initially decreased by 3.9-times as CaCl2 levels 
increased to 1.5 mM. As CaCl2 concentration increased further, the loss tangent 
continued to fall, decreasing a further 10-times as CaCl2 levels reached 10 mM. 
The loss tangent decreased 39-times over the entire CaCl2 concentration range. 
Again, for plateaus II and III, the loss tangent peaked at 1.5 mM then 
decreased at 5 mM before increasing again as CaCl2 concentration increased to 
10 mM.    
 
The dependence of the loss tangent on frequency as CaCl2 concentration 
varied is displayed in Figure 5-18. Once again, peaks in the behaviour of the 
loss tangent were observed. It appears that CaCl2 levels are modulating both 
the height and relative frequency position of these peaks. As CaCl2 
concentration increased, the maximum loss tangent decreased and moved to a 
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higher frequency position. The insert in Figure 5-18 shows the behaviour of the 
maximum loss tangent as a function of CaCl2 concentration. In agreement with 
the loss tangent data for plateau I, presented in Figure 5-17, a reduction in the 
loss tangent was observed at high CaCl2 concentrations. A decrease of 4.4-
times over the entire CaCl2 concentration range was observed. These data 
indicate CaCl2 significantly modulates the viscoelastic dynamics of fibrin clot 
behaviour.  
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Figure 5-18: tan  versus  for clots formed from different CaCl2 concentrations. Insert: 
maximum tan  vs. CaCl2 concentration. A linear extrapolation is included as a guide for the eye. 
Errors represent the standard error in the mean from 3 repeat experiments. 
 
Closer inspection of the plots in Figure 5-16 reveals that CaCl2 concentration 
does indeed modulate the viscoelastic dynamics of fibrin clots. In order to 
investigate this further I, II and III were extracted from the data in Figure 5-16. 
The results of this analysis are displayed in Figure 5-19. 
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Figure 5-19: I, II and III versus CaCl2 concentration. The data include a linear fit, of the 
form y = mx + c, as a guide for the eye. Note III for the 0 mM clot couldn‘t be measured. Errors 
represent the standard error in the mean from 3 repeat measurements.  
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The low-to-intermediate plateau transition, given by I, decreased as CaCl2 
concentration increased. Overall, I decreased by ~20 seconds corresponding 
to a decrease of 4.3-times over the entire CaCl2 concentration range. As the 
low-to-intermediate plateau transition moved to shorter times, this again 
resulted in the low frequency plateau occurring on a much earlier time-scale, as 
for fibrinogen experiments. Clots formed at 0 mM CaCl2 plateau at ~5 mHz, as 
CaCl2 concentration increased up to 10 mM this plateau began at ~20 mHz; a 
time difference of ~2-3 minutes. Thus, as CaCl2 concentration increased, clots 
begin to display predominately elastic behaviour on much earlier times. 
 
Next the position of the intermediate plateau, given by II, was measured. 
Overall there appeared to be little or no effect on II  as CaCl2 levels increased. 
Initially there was a slight increase after which II remained at ~0.5 seconds. The 
only exception was at 2.5 mM where II increased up to 1.8 seconds before 
decreasing again as CaCl2 concentration increased further. In contrast to 
fibrinogen experiments it appears that as the low frequency plateau increases to 
higher frequencies this has no effect upon the intermediate plateau.      
 
Finally, the position of the intermediate-to-high plateau transition, given by III, 
was measured. Again, as for II, overall there was a limited effect on III as 
CaCl2 concentration increased. The temporal position remained at ~0.1 
seconds as CaCl2 increased. Except again at 2.5 mM where III increased 
slightly up to 0.5 seconds before decreasing again. Note III could not be 
measured for clots formed at 0 mM. Surprisingly, clots formed in the absence of 
CaCl2 displayed only 2 plateaus in G , a low frequency and intermediate 
frequency plateau. 
 
5.5 Discussion and Conclusions 
 
The effects of fibrinogen, thrombin and CaCl2 on fibrin clot polymerisation and 
viscoelasticity have been studied using a magnetic microrheometer over a 
broad range of frequencies. It is well known that fibrin polymerisation kinetics 
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modulate clot structure (144-149), and furthermore it has been shown by Ryan 
et al. that clot rheology is highly sensitive to structural changes (84). In the 
present study, the frequency dependent viscoelastic moduli of clots formed 
under a range of differing concentrations have been measured. The 
experimental conditions selected were chosen to closely match that of the study 
of Ryan et al. (84) in order to compare our findings and also correlate changes 
in viscoelasticity with changes in network architecture. The data presented here 
are the first to study the frequency behaviour of fibrin clot viscoelasticity in 
combination with the effects of fibrinogen, thrombin and CaCl2 on the stress 
relaxation behaviour of fibrin clots. 
 
The effect of fibrinogen on clot polymerisation was studied and found to have a 
profound effect on the polymerisation kinetics of fibrin. As fibrinogen levels 
increased, the rate of change of mechanical development increased rapidly. As 
a result, clots formed at a higher fibrinogen concentration reached a plateau in 
their stiffness at earlier times. Contrary to this, measurements by Ryan et al. 
reported increased clotting times as fibrinogen concentration is raised (84). 
Clotting time in their study refers to the gel-point time; the time at which a clot 
turns from liquid to solid (100), which was detected visually. Their data however 
revealed no difference in clotting times, within errors, for clots formed between 
0.5 and 4.5 mg/ml. Only at the highest fibrinogen levels of 6 mg/ml did they 
observe an increase. Inspection of their stiffness polymerisation data reveals an 
increased rate of mechanical development as fibrinogen levels increase, in 
agreement with our observations. Increased rates of mechanical development 
could be explained by the increased rate of monomer formation due to higher 
substrate levels.  
 
Increased rates of mechanical development does not necessarily contradict a 
longer clotting time as suggested by Ryan et al. (84) as both are essentially 
separate process in the polymerisation reaction. Currently very little is known 
about fibrin gelation; recent experimental work by the Weisel group (121, 150) 
showed the types of structure and dynamic changes in their proportions prior to 
the gel point. However, they provide no model for the process of branching 
which is key in the gelation process. Based on the data in this thesis, it is 
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proposed that as fibrinogen concentration increases, protofibril formation 
increases while branching occurs at a slower rate, hence the prolonged clotting 
times. The process of lateral aggregation and radial fibre growth could then be 
increased due to the greater number of protofibrils available. This highlights the 
need for a better understanding of fibrin polymerisation prior to the gel-point.  
 
Increased clot stiffness, indicated by G , was associated with increased 
fibrinogen concentration. Similar findings have been reported by several other 
authors (48, 65, 67, 84, 151). An increased incidence of myocardial infarction 
has been associated with high levels of plasma fibrinogen and attributed to 
elevated clot rigidities (37). In addition, it has been found that fibrinogen 
concentration of in vivo thrombi is much higher (20 – 70 mg/ml) than normal 
fibrinogen plasma levels (2 – 4 mg/ml) (152). Ryan et al. (84) suggested that 
increased clot stiffness at higher fibrinogen levels is due to increased fibre 
density. However, increases in fibre and branch point density are only observed 
at the highest concentrations of fibrinogen studied (6 mg/ml). Between 0.5 and 
3 mg/ml they observed no changes in clot architecture. A more recent study by 
Weigant et al. (67) used neutron scattering to probe the internal structure and 
radial dimensions of fibrin fibres over a fibrinogen concentration of 1 – 40 
mg/ml. They reported that the internal volume fraction of protein in fibres 
increases while fibre diameter decreased slightly up to fibrinogen 
concentrations of 20 mg/ml. They proposed two different models (Figure 20): at 
higher fibrinogen levels individual proteins pack closer together leading to a 
contraction in fibre diameter or alternatively, the increased amount of protein 
available can correct potential defects, such as vacancies, in the internal fibre 
structure. Estimates for the internal volume fraction of fibrin in a fibre has been 
placed between 10 – 20% by Weigant et al. (67) and 20 – 30% by Guthold et al. 
(26). Hence, fibrin fibres are very porous structures and could potentially 
accommodate more protein without a change in diameter. Currently there are 
conflicting reports on the effects of fibrinogen on fibre diameter with some 
authors reporting a decrease (67, 84), some an increase (147) and others no 
difference (153). 
 
138 
 
 
 
Figure 20: Schematic of two possible theories to account for the increase in internal 
protein fraction of fibrin fibres (adapted from (67)). (A) Low fibrinogen concentration and (B) 
high fibrinogen concentration. Left: increased fibrinogen levels results in fewer internal fibre 
defects and/or an increased internal protein density. Right: contraction of the proteins within the 
fibre results in a thinner fibre with an increased volume fraction. 
 
In this study, fibre diameter is expected to change very little due to the very 
small change in fibrinogen level over the concentration ranged probed (0.2 – 1 
mg/ml). Ryan et al. (84) suggested a decrease of 26 nm as fibrinogen 
concentration increases. However there appeared to be no statistically 
significant difference, within errors, in fibre diameter between the lowest (0.5 
mg/ml) and highest (6 mg/ml) fibrinogen concentrations investigated. In 
addition, Weigant et al. (67) reported only a slight decrease in fibre diameter, 
which appeared to be <10 nm, over a much greater concentration range (2 – 20 
mg/ml). Data on increased clot stiffness at higher fibrinogen concentration 
presented in this thesis could perhaps be attributed to an increased density of 
protein within each fibre. The increased amount of fibrin could potentially correct 
any internal fibre defects or may just result in an increased internal protein 
density. The net effect would be stiffer fibres resulting in a stiffer clot. As 
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fibrinogen concentration increased an increase in both Gtens and Gcurve was 
observed, indicating that fibres become stiffer for both stretching and bending. 
In addition, Gtens was consistently higher than Gcurve. That is, fibres are much 
stiffer for stretching than for bending, as expected from their length to diameter 
ratio, something which has also been confirmed by other authors (83, 154).  
 
As previously mentioned the majority of studies reported a concentration 
dependence of G  ranging between 1.5 and 2.3 Pa (48, 65, 67, 84, 151), below 
that predicted by Mackintosh et al. for a network of branched fibres (G   c2.5) 
(68). In this thesis, a concentration dependence of G  is shown which is in 
agreement with this prediction. This indicates that fibrin fibres are semi-flexible 
i.e. ℓc ~ ℓp, suggesting that fibres are very straight between branches; which has 
indeed been observed in confocal micrographs (Figure 1-4). In addition, Storm 
et al. reported a persistence length of 0.5 μm for fibrin fibres measured from 
TEM micrographs (80). This is similar to fibre lengths previously reported from 
SEM micrographs which range between 0.3 - 5 μm (84). Mackintosh‘s theory 
proposes that elasticity in networks of semi-flexible fibres is entropic in origin. 
However, this does not rule out an enthalpic contribution to the elastic 
response. The theory of Storm et al. (80) proposes that at low strain entropic 
elasticity dominates but at higher strain an enthalpic contribution is required to 
fit the theory to the experimental data. This enthalpic contribution arises by 
assuming fibres can stretch longitudinally.  
 
The measurements presented in this thesis of G  vs. c show better agreement 
with the theory than those previously reported due to the ability of my 
measurements to identify the plateau modulus Gtens to which the theory of 
Mackintosh et al. applies (68). The majority of studies reported a value of G  at 
one particular frequency. For example, Ryan et al. (84) performed 
measurements at 0.1 Hz and reported a concentration dependence of G   c1.67 
which is much lower than that predicted. Similarly, Weigant et al. (67) reported a 
dependence of G   c2.22 measured at a frequency of 1 Hz. Measurements 
reported here reveal a lower power dependence for values of G  measured at 
lower frequencies e.g. G I  c
2.2  0.2 vs. G III  c
2.7  0.2. In addition, the 
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measurements could possibly be improved using higher frequencies 
measurements which would enable Gtens to be completely measured. 
 
Increased viscous deformation, as indicated by G , was also associated with 
increased fibrinogen concentration and closely matched the behaviour of G . 
Ryan and Shan et al. both reported an increased storage modulus associated 
with an increased loss modulus (77, 84). At the lowest frequencies studied, I 
observed a loss modulus which displays a lower power dependence upon 
concentration when compared with the storage modulus (G I  c
1.32  0.07 vs. G I 
 c2.2  0.2). At higher frequencies the dependence of the storage modulus was 
still slightly higher; however this difference was not statistically significant. As a 
result very little difference in the behaviour of the loss tangent with fibrinogen 
concentration was observed at the higher frequencies studied. The maximum 
loss tangent agreed well with measurements performed at the lowest frequency 
revealing initially a sharp decline in the loss tangent after which it remained 
relatively constant.   
 
Ryan et al. (84) also reported very little difference in the loss tangent with 
increasing fibrinogen concentration. This agrees with their findings that the loss 
tangent is most strongly modulated by fibre diameter. They observed smaller 
values for tan  in clots with thinner fibres and suggested that this was due to the 
greater degree of branching in these clots. The relative insensitivity of the loss 
tangent to fibrinogen concentration in the measurements presented in this 
thesis could be due to the limited effect of fibrinogen levels on fibre diameter. 
 
Microrheological measurements performed over a broad frequency range reveal 
that fibrinogen modulates the viscoelastic dynamics of fibrin clots, something 
not previously reported in the literature. As mentioned almost all studies report 
little or no dependence of G  upon frequency. In this thesis, fibrinogen 
concentration has a dramatic effect upon the stress relaxation behaviour of 
fibrin clots. As fibrinogen concentration increased, plateau I, corresponding to 
Gorient, began at a higher frequency, i.e. on a much shorter time-scale. As a 
result of this plateau II, corresponding to Gcurve, was much shorter and also 
occurred at a higher frequency (Figure 21).  
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The following hypothesis can be proposed to explain this behaviour. Consider 
an extremely flexible fibre i.e. one formed at low fibrinogen concentration, under 
the influence of a stress. This fibre will stretch and bend in response to this 
stress and then the entire fibre will move and pull on other connected fibres. As 
fibrinogen concentration increases fibres become stiffer due to an increased 
internal protein density. Therefore fibres formed at high fibrinogen concentration 
under the influence of the same stress will stretch and bend less and as a result 
begin to move and pull on other fibres at much earlier times. 
 
 
Figure 21: Schematic diagram of G  versus frequency. The frequency behaviour is depicted 
for clots formed at high and low fibrinogen concentration. As fibrinogen levels are increased the 
stress relaxation time, I moves to shorter times i.e. higher frequencies. As a result of this the 
Gorient plateau occurs at an earlier time and the Gcurve plateau spans a smaller frequency range 
and also occurs at an earlier time. 
 
Next, the effects of thrombin on clot polymerisation and viscoelasticity were 
investigated. Higher levels of thrombin lead to increased rates of fibrin 
polymerisation. The effects of thrombin on clot polymerisation measured by 
turbidity are well known (149). At high thrombin levels changes in concentration 
have little effect. While at low levels increases result in a decreased lag phase, 
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increased maximum rate and a decreased final absorbance. Thus, at higher 
thrombin levels fibrinopeptide cleavage is accelerated resulting in increased 
monomer formation and subsequently increased clot formation thereafter. The 
results reported in this thesis are consistent with turbidity measurements and 
agree well with those of Ryan et al. (84) who observed similar effects by 
thrombin on the mechanical development of fibrin clots. 
 
Final compliance, indicating clot stiffness, reached a maximum at thrombin 
levels of 0.25 U/ml. This suggests an optimum level of thrombin exists which 
results in maximal clot stiffness. The effects of thrombin on clot structure have 
been studied by several authors who report a reduction in fibre size with 
increasing thrombin concentration (84, 147, 149, 153, 155-157). Reduced 
thrombin levels result in reduced monomer formation and subsequently 
protofibrils grow longer and aggregate laterally to produce networks of long, 
thick fibres with a low degree of branching (3, 84, 149). High thrombin levels 
result in rapid monomer formation compared with relatively slow longitudinal 
and lateral protofibril growth. As a result, clots formed at higher thrombin levels 
consist of thin, short and highly branched fibres (3, 84, 149). Ryan et al. (84) 
suggested that an intermediate thrombin concentration exists at which clot 
structure displays a balance between large fibre size and maximal branching, 
which occurs at 0.25 U/ml. We observed increased clot stiffness, as indicated 
by G , did indeed occur at thrombin concentrations of 0.25 U/ml, in agreement 
with the findings of Ryan et al. and several other authors (158-160).  
 
Viscous deformation, as indicated by G , closely matched the behaviour of G . 
Subsequently the loss tangent displayed little variation as thrombin levels 
changed except at intermediate frequencies. Here the behaviour of tan  closely 
matched that observed by other authors (84, 158) where tan  decreased as 
thrombin levels were raised. This indicates clots formed at high thrombin levels 
will incur less permanent deformation. As clots formed at high thrombin 
concentration consist of short, thin fibres which are highly branched, this again 
points towards the importance of branching in maintaining clot integrity.  
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In addition, these measurements also raise the important point that clot stability 
is not only dependent upon stiffness. Clots formed at low thrombin levels 
display the greatest stiffness, however they possess the greatest loss tangents 
and as a result will incur more permanent deformation. These clots may 
therefore exhibit a greater propensity to rupture, i.e. embolise. Similarly, clots 
unable to deform and dissipate energy may also be more likely to rupture. 
Guthold et al. observed that the rupture force of single fibres increases with 
diameter (26). One would expect clots formed at low thrombin levels, which 
posses thick fibres, to be more mechanically stable, even though they exhibit 
increased deformation. Very little is currently known about the relationship 
between clot rupture and the viscoelastic moduli and better understanding may 
help to interpret in vitro measurements with clot embolism in vivo.   
 
The effects of thrombin on the viscoelastic dynamics of fibrin clots was limited, 
with little or no difference in any of the stress relaxation times being observed. 
Changes in clot structure due to variations in thrombin are more complex than 
those brought about by variations in fibrinogen concentration. Changes in fibre 
structure are also accompanied by changes in macroscopic clot structure due to 
varying thrombin levels (3, 84). It could be that these changes negate one 
another and result in relatively little change in the stress relaxation behaviour. In 
addition, changes in the viscoelastic moduli were much more pronounced due 
to changes in fibrinogen compared with thrombin. The storage modulus 
increased ~100-times for fibrinogen and only 2-times for thrombin between the 
weakest and stiffest clots. Furthermore, in Chapter 4 measurements of clots 
formed in the presence and absence of FXIII revealed no change in the stress 
relaxation behaviour. In this instance, FXIII cross-linking resulted in an increase 
in stiffness of around 3-times. It could be that changes in the stress relaxation 
behaviour are only associated with large changes in clot stiffness. This may 
account for the fact that no differences in the stress relaxation behaviour were 
observed due to changes in thrombin concentration.  
 
Finally, the effects of CaCl2 concentration on clot polymerisation and 
viscoelasticity were investigated. It was observed that increasing CaCl2 
concentration increased the rate of fibrin polymerisation. The accelerating effect 
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of CaCl2 on fibrin polymerisation has been demonstrated (161, 162) and 
attributed to the enhancement of polymerisation mechanisms after 
fibrinopeptide removal (24, 163-167). In particular, it has been suggested that 
lateral aggregation may be enhanced through either decreases in charge from 
calcium binding (168) and/or through the enhancement of FpB removal (169). 
The effect in either case, or a combination, would be an increase in fibre 
diameter at increased CaCl2 concentrations; consistent with both turbidity (155, 
170, 171) and SEM measurements (84). The presence of CaCl2 has also been 
reported to enhance longitudinal protofibril growth (144, 172, 173), again 
consistent with SEM measurements (84). In addition, Ryan et al. (84) observed 
a decrease in fibre and branch point density at elevated CaCl2, in agreement 
with observations for thrombin experiments that large fibre lengths and 
diameters are associated with a low degree of branching. Similarly, clots formed 
at low CaCl2 concentrations consist of short, thin fibres with a high degree of 
branching. Again, indicating the existence of an optimal CaCl2 concentration 
where clots exhibit a balance between thick fibres and maximal branching, 
occurring at 1.5 mM. 
 
Peak stiffness, indicated by G , occurred between 1.5 to 2.5 mM CaCl2 
concentration, consistent with the findings of several other authors (47, 48, 84, 
160, 171). Ryan et al. (84) attribute increased clot stiffness at these CaCl2 
levels to the balance between large fibre diameters and maximal branching, as 
they do for thrombin experiments. The maximum clot stiffness observed in both 
CaCl2 and thrombin experiments are in striking agreement with that observed by 
Ryan et al. (84) and it is therefore concluded that this is due to these clots 
displaying a balance between high branching density and large fibre diameters.  
 
Viscous deformation, as indicated by G , did not match the behaviour of G  at 
all frequencies, as was the case for fibrinogen and thrombin experiments. At 
intermediate and high frequencies, the behaviour was essentially the same, with 
a peak in G  occurring at 1.5 mM. The effect on the loss tangent was an overall 
increase as CaCl2 concentration increased, consistent with previous reports 
(84). At elevated CaCl2 levels, branching decreases, as previously discussed, 
and this could account for the increased values in the loss tangent, supporting 
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the idea that branching prevents structural rearrangements within clots. At low 
frequencies, G  consistently decreased as CaCl2 concentration increased, 
which was also the case for the loss tangent and the maximum loss tangent. At 
low frequencies this corresponds to Gorient, the large scale motion of fibres. At 
maximum CaCl2 concentration, fibres display some of their largest lengths and 
diameters which could account for the reduced loss tangent on these 
timescales. It has been suggested that branching reduces clot deformation, as 
indicated by an association with lower values of the loss tangent, however these 
measurements also indicate fibre thickness may play a role in maintaining clot 
integrity. 
 
The effect of CaCl2 on the stress relaxation behaviour of fibrin was similar to 
that of fibrinogen, albeit to a lesser degree. As CaCl2 concentration increased 
plateau I occurred at a higher frequency, i.e. a shorter time, as indicated by the 
reduction in I. Plateaus II and III remained unaffected by changes in CaCl2 
concentration. Again, we propose that changes in the stress relaxation 
behaviour arise due to changes in fibre structure. As CaCl2 concentration 
increases fibre size increases (84) and their rupture force also increases (26). In 
addition, increased fibre diameters have been associated with increased clot 
stiffness (84). For fibrinogen experiments, it was proposed that fibres became 
stiffer through increased internal protein density and this resulted in the 
changes in the stress relaxation behaviour observed. For CaCl2 experiments, it 
is proposed that a similar effect occurs except that fibres become stiffer due to 
increased radial diameter. 
 
In addition, we observed an association between the loss tangent and the 
stress relaxation behaviour. For fibrinogen experiments a rapid decrease in 
tan I between 0.2 and 0.4 mg/ml fibrinogen concentration was observed and 
this coincided with a dramatic change in I. Similarly, for CaCl2 experiments I 
fell consistently as concentration increased and this was associated with a 
similar decrease in tan I. Thus, clots consisting of fibres which display less 
permanent deformation exhibit predominately elastic behaviour at much earlier 
times. Which is to be expected as a material with tan  << 1 is essentially an 
elastic solid. 
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In this thesis, I have not only attempted to determine the effect of fibrinogen, 
thrombin and CaCl2 on the viscoelastic moduli, but also to determine the effect 
on different timescales and ascertain the role, if any, that these reactants play in 
modulating the stress relaxation behaviour of fibrin clots. The data presented 
demonstrate new and important insights into the behaviour of fibrin clot 
viscoelasticity.  
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Chapter 6 
6 Gamma Prime 
 
6.1 Introduction 
 
A variant of the common A chain arises due to alternative processing of the 
mRNA chain and is called  (174). This alternative form has the carboxy-
terminus end 4 amino acids replaced by a new 20 amino acid sequence (175). 
Due to the overall negative charge of the  chain, plasma fibrinogen is 
separable by anion-exchange chromatography into 2 major peaks (176). Peak 1 
fibrinogen contains 2 A chains and is homodimeric with respect to the A chain 
( A/ A), whereas peak 2 fibrinogen contains both a A and a  chain (Figure 
6-1) and is heterodimeric with respect to the  chain ( A/ ) (177). Plasma 
fibrinogen contains approximately 8% to 15% A/  fibrinogen, whereas 
homodimeric /  fibrinogen accounts for less than 0.5% of the total fibrinogen 
population (178). 
 
148 
 
 
 
Figure 6-1: Polypeptide structure of A/  fibrinogen, adapted from (12). The individual 
chains, A , B ,  and  are blue, green, red and yellow respectively. The amino acid extension 
of the  chain extends from the c-terminus of the  chain which is located within the D region of 
fibrinogen. Fibrin polymerises through D-E-D interactions placing the  extension at the D-D 
interface. The extra 16 amino acids of the  chain could extend 30 to 40 Å or more depending 
on folding, however the structure of the  chain is unknown (178). 
 
Several studies have highlighted that plasma levels of fibrinogen  may 
modulate thrombotic disease. Elevated levels have been associated with 
coronary artery disease (179), myocardial infarction (180) and stroke (181). In 
contrast, reduced levels have been associated with deep vein thrombosis (182) 
and thrombotic microangiopathy syndrome (183). Additionally, numerous 
functional studies have shown that clots formed from fibrinogen A/  behave 
differently than clots formed from fibrinogen A/ A, with differences in 
polymerization rates and maximum turbidity, network structure and fibre 
thickness, the extent of cross-linking and resistance to fibrinolysis (96, 184-189) 
although there is quite some disagreement in these findings. 
 
It has been demonstrated that the fibrinogen  chain binds to thrombin with high 
affinity (190-192) Thrombin binds  through exosite II (191) and it is thought 
that negatively charged residues of , in particular residues 414-427 and two 
sulfated Tyr residues in this sequence, play a crucial role in this interaction 
(192). Binding of thrombin to the  chain has been reported to inhibit thrombin 
activity and it has been suggested that this may influence clot structure (184). It 
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has also been reported that the  chain may bind directly to FXIII (188, 193, 
194) however another study could not confirm this interaction (195). 
 
Most recently, Gersh et al. studied the polymerization and structure of fibrin 
clots formed from recombinant A/ A, A/  and /  fibrinogens; the first study to 
include recombinant A/  fibrinogen (185). They reported that A/  clots 
polymerised slower than A/ A clots but fibrinopeptide release was unaltered. In 
contrast to this, both Cooper et al. and Siebenlist et al. found differences in 
fibrinopeptide release associated with purified plasma A/  fibrinogen (96, 184).  
 
Differences in structure have also been reported by most studies (Figure 6-2): 
Gersh et al. (196) found A/  clots had similar fibre diameters to A/ A clots but 
were more inhomogeneous in structure while both Cooper et al. (96) and 
Siebenlist et al. (184) found A/  clots were composed of thinner more 
branched fibres which were arranged more uniformly. The study by Collet et al. 
which used recombinant A/ A and /  fibrinogen found no differences in 
structure (186). The discrepancy in results between each study may be 
attributed to differing experimental conditions, the sources of  fibrinogen and 
contaminating amounts of FXIII which may be present in plasma purified 
fibrinogen samples. 
 
The work of Collet et al. (96) also showed the effect  fibrinogen has on the 
mechanical properties of fibrin clots, the first study to attempt this. In particular, 
the stiffness G  was measured using a torsion pendulum (197). They reported 
that in the absence of cross-linking /  clots have a similar stiffness to A/ A 
clots, while in the presence of cross-linking /  clots are 3-times stiffer.  They 
suggest this dramatic increase in stiffness is brought about by an increased 
amount of cross-linking. The extent of cross-linking in fibrin clots formed from 
A/  fibrinogen has been the subject of debate with two studies finding 
conflicting results.  Farrell et al. found that A/  clots were more highly cross-
linked, with more extensive  and  chain cross-linking (187, 189). They also 
reported that A/  fibrinogen accelerated FXIII activation. On the contrary 
Siebenlist et al. (184) reported no measurable difference in the rate or extent of 
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 chain cross-linking and the overall rate and onset of  cross-linking was 
slower for A/  fibrinogen. Siebenlist et al. (184) argue that differences in 
results are due to Farrell et al. (187, 189) having unaccounted for FXIII in their 
A/  fibrinogen. 
 
 
Figure 6-2: Scanning electron micrographs of fibrinogen -chain variants (178). A: clots 
made from purified A/  fibrinogen. B: clots made from purified A/ A fibrinogen. Images from 
Cooper et al. (96) C: clots made from purified A/  fibrinogen. D: clots made from purified A/ A 
fibrinogen. Images from Siebenlist et al. (184) E: clots made from recombinant /  fibrinogen. 
F: clots made from recombinant A/ A fibrinogen. Images from Collet et al. (198) G: clots made 
from recombinant /  fibrinogen. H: clots made from recombinant A/  fibrinogen. I: clots made 
from recombinant A/ A fibrinogen. Images from Gersh et al. (196). 
 
The aim of the work presented here was to investigate the mechanisms 
underpinning the effects of fibrinogen  on fibrin structure and function. We 
studied the effects of  on protofibril formation and clot structure, and 
investigated the roles of thrombin and FXIII. In addition, we determined the 
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viscoelastic properties of A/  clots. We provide qualitative and quantitative 
evidence that the  chain directly inhibits protofibril growth and produces a 
mechanically weaker clot composed of thinner fibres. Our findings provide novel 
insight into the early stages of protofibril formation and could help in 
understanding the role of the fibrinogen  chain in modulating thrombotic 
disease. 
 
6.2 Preparation of A/ A and A/  Fibrinogen 
 
A/ A and A/  fibrinogen were purified from ERL fibrinogen as previously 
described (96) by Dr Shirley Uitte de Willige. In brief, the variants were 
separated by anion-exchange chromatography on a DE-52 column using a 
BioCad Sprint chromatography system (Perseptive Biosystems, Framingham, 
MA). Before chromatography, fibrinogen was dialyzed against equilibration 
buffer (0.039 M Tris, 0.005 M H3PO4, 0.5 mM phenylmethylsulfonyl fluoride, 1 
mM benzamidine, and 5 mM aminocaproic acid, pH 8.6). Elution of the variants 
was established by a concave gradient from equilibration buffer to elution buffer 
(0.5 M Tris, 0.5 M H3PO4, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM 
benzamidine, and 5 mM aminocaproic acid, pH 4.2) (193).  
 
SDS-PAGE analysis (Figure 6-3 (A)) revealed a single band at the location of 
the  chain for A/ A fibrinogen, indicating this preparation contained only A 
fibrinogen (lane 2). In contrast, the A/  fibrinogen contained two bands of 
approximately equal intensity but different molecular weight indicating the 
presence of both the A and  chains (lane 11).  In all experiments (unless 
stated otherwise) the final concentrations were: 0.5 mg/ml fibrinogen, 1.0 U/ml 
thrombin (or 5 BU/ml reptilase), 2.5 mM CaCl2 and either 1 mM FXIII inhibitor or 
3.7 g/ml FXIII.  
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6.3 Cross-linking by FXIIIa 
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Figure 6-3: (A) Cross-linking of A/ A and A/  fibrinogen by FXIIIa. Lane 1: molecular 
marker (kDa). Lanes 2-10: A/ A fibrinogen. Lanes 11-19: A/  fibrinogen. In lanes 11-19 two  
chain bands exist corresponding to the A and  chains respectively, as compared to the single 
 chain band in lanes 2-10 corresponding to the A chain. X1-X6 denote - and -
multimers/polymers. (B) Cross-linking analysis of clots formed from A/ A and A/  
fibrinogen. The percentage intensity of the A  and  chains, normalized to the B  chain, were 
measured for both A/ A and A/  fibrinogen from the SDS-PAGE gel and plotted as a function 
of time. The inset shows the first 30 minutes of cross-linking. 
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The effect of the  chain on cross-linking by FXIIIa was investigated using SDS-
PAGE analysis. Clots were prepared as described in section 2.2.1. Clotting was 
allowed to proceed for 0, 1, 2, 5, 15, 30, 60, 120 and 360 minutes at room 
temperature after which SDS-PAGE analysis was performed as described in 
section 2.2.1.  
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Figure 6-4: Cross-linking analysis of the A and  chains in A/  clots. The percentage 
intensity of the A and  chains, normalized to the B  chain, were measured for A/  fibrinogen 
from the SDS-PAGE gel in Figure 6-3(A) and plotted as a function of time. Inset: First 30 
minutes of cross-linking. It is clear, within errors, there was no difference in the rate of cross-
linking for either the A or  chains. 
 
The decrease in intensity of the A  and  chain monomer bands was measured 
relative to that of the  chain (which is not a FXIIIa substrate and therefore does 
not undergo cross-linking) as a function of time to determine the relative amount 
of cross-linking (Figure 6-3). In both variants similar species of higher molecular 
weight cross-linking products were observed (X1, X2, X3, X4, X5 and X6). In 
A/  clots, 3 species of  cross-link were detected corresponding to A- A, A-  
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and -  as opposed to the single A- A cross-linking band in A/ A clots. The 
cross-linking rate and overall reduction in intensity of the  chain monomer was 
similar when comparing A/  fibrin with A/ A fibrin, indicating a similar amount 
of  chain cross-linking (Figure 6-3 (B)). In addition, within A/  clots, the 
reduction rate of the individual -chain monomer species ( A vs. ) were similar 
(Figure 6-4). Together, these data demonstrate that FXIIIa is equally effective in 
cross-linking the A- and -chains.  
 
A significant difference in cross-linking was detected between A/ A and A/  
clots in the amount of -chain cross-linking (Figure 6-3 (B)). The reduction in -
chain monomer band was less in A/  clots, with a final intensity of 42% 
compared with 27% for A/ A fibrin. These findings indicate -chain cross-
linking is reduced in A/  fibrin clots. 
 
6.4 Fibrin Polymerisation  
 
Polymerization of A/ A and A/  fibrin was studied by turbidity analysis. Clots 
were prepared in triplicate as described in section 2.2.2. Thrombin or Reptilase 
was added to initiate clotting after which absorbance was measured every 12 
seconds over the first 60 minutes of clotting (Figure 6-5). 
 
The analysis of the turbidity data in Figure 6-5 is provided in Table 6-1. Turbidity 
initiated by thrombin showed a significant difference between polymerization of 
A/ A and A/  fibrin. The maximum polymerization rate of A/ A fibrin was 3.8-
times higher than that of A/  and the time to plateau was shorter by 6 minutes 
(Table 6-1). Final absorbance of A/ A fibrin was 4.1-times higher than that of 
A/ . At equal fibrinogen concentrations, the maximum absorbance is directly 
related to the fibre diameter and/or the arrangement of fibres. This suggests 
A/  clots are either composed of thinner fibres, have an altered structure or 
posses thin fibres arranged non-uniformly.  
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Figure 6-5: Turbidity analysis of polymerizing clots produced with A/ A and A/  
fibrinogen. Each curve is representative of 3 repeat measurements with error bars representing 
the standard error in the mean. 
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Table 6-1: Polymerisation data of clots formed from A/ A and A/   
 Thrombin Reptilase 
Polymerisation Parameter A/ A A/  A/ A A/  
Maximum rate (units min
-1
) 0.030  0.004 0.008  0.001 0.026  0.002 0.010  0.003 
Final Absorbance 0.123  0.002 0.030  0.001 0.156  0.004 0.062  0.003 
Plateau time (minutes) 16  1 22  1 15  2 18  1 
 
Polymerization of A/ A and A/  fibrin was further investigated using reptilase, 
a snake venom enzyme which cleaves fibrinopeptide A only (unlike thrombin) 
and does not bind to the -chain. Similar differences in polymerization were 
observed as with thrombin (Figure 6-5 and Table 6-1). Maximum polymerization 
rate of A/ A fibrin was 2.6-times higher, and the time to plateau was shorter by 
3 minutes. Final absorbance of A/ A fibrin was 2.5-times higher than A/ . 
These data demonstrate that the effects of  on fibrin formation are 
independent of  binding to thrombin and are likely due to a direct interference 
of the negatively charged peptide with fibrin formation. 
 
The effect of FXIII inhibitor, FXIII and inhibitor-FXIII combination on 
polymerisation of A/ A and A/  clots was also investigated using turbidity 
analysis. The results of this analysis are presented in Table 6-2. No differences 
were observed in any of the polymerisation parameters, within experimental 
errors, for A/ A and A/  clots. It is therefore concluded that both the inhibitor 
and FXIII do not play a significant role in the polymerisation or final structure of 
either A/ A or A/  clots. 
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Table 6-2: Polymerisation data of clots formed from A/ A and A/   
Polymerisation 
Parameter 
Maximum Rate (units 
min
-1
) 
Final 
Absorbance 
Plateau Time 
(minutes) 
A/ A + In 0.127  0.001 0.041  0.004 14  2 
A/ A + FXIII 0.133  0.004 0.042  0.003  14  1  
A/ A + In + FXIII 0.136  0.006 0.037  0.005  15  5  
A/  + In 0.034  0.002  0.009  0.001  24  2  
A/  + FXIII 0.029  0.004 0.010  0.001  26  4  
A/  + In + FXIII 0.031  0.008 0.013  0.003  18  4  
 
6.5 Fibrin Structure 
 
As suggested by turbidity analysis, A/  demonstrated a different structure than 
A/ A fibrin. In order to investigate this further, LSCM (Figure 6-6) and SEM 
imaging (Figure 6-7) were performed as described in sections 2.2.4 and 2.2.5 
respectively.  
 
Both imaging techniques revealed a clear difference between the structure of 
A/  and A/ A fibrin. The spatial distribution of fibres within A/  clots was less 
uniform than that of A/ A clots. A/  fibres were arranged into tight 
interconnecting bundles producing large open pores. Imaging multiple optical 
slices which were then combined into one projection (200 x 200 x 50 μm) 
revealed that these pores were not localized structural inhomogeneities, but 
extended through the 50 μm z-stack (Figure 6-6 (C)). 
 
158 
 
 
Figure 6-6: Confocal micrographs of clots formed from A/ A (A) and A/  (B) fibrinogen. 
The first and second rows show micrographs, 200 x 200 μm and 100 x 100 μm respectively, of 
clots formed from thrombin. The third row shows three dimensionally reconstructed micrographs 
200 x 200 x 50 μm. Brightness and contrast have been altered in both micrographs by the same 
amount. Scale bars indicate 20 μm and arrows indicate fibre bundles and pores. Final 
concentrations within a clot were 0.5 mg/ml fibrinogen, 5% fluorescently labelled fibrinogen 1.0 
U/ml thrombin, 2.5 mM CaCl2 and 1 mM FXIII inhibitor.  
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SEM imaging further revealed, in agreement with lower maximum absorbance 
in turbidity, that A/  clots were composed of thinner fibres compared with A/ A 
(Table 6-3). Fibre diameters were decreased by ~33% in A/  clots. LSCM 
showed lower fibre density in A/  clots, by ~22%. This decreased fibre density 
may be attributed to an underestimate of the fibre count in A/  clots. Many 
fibres were arranged into tight bundles and as such may not be resolved by 
confocal microscopy. However, SEM also revealed a decreased fibre density for 
A/  clots, although a smaller decrease of ~11% was observed. 
 
 
Figure 6-7: Scanning electron micrographs of clots formed from A/ A (upper panels) and 
A/  (lower panels) fibrinogen. Images are (A) 5 000, (B) 20 000 and (C) 100 000 x 
magnification. Arrows indicate fibre bundles, pores and free fibre ends in A/  clots. Final 
concentrations within a clot were 0.5 mg/ml fibrinogen, 1.0 U/ml thrombin, 2.5 mM CaCl2 and 1 
mM FXIII inhibitor. Scale bars represent (A) 10 μm, (B) 2 μm and (C) 500 nm.  
 
Fibre density was much greater in SEM imaging; 49- and 43-times higher in 
A/  and A/ A clots respectively compared with corresponding confocal 
images (Table 6-3). This discrepancy is attributed to differences in the sample 
preparation and imaging. SEM provides significant depth detail and will 
therefore show inherently more fibres in this case than the confocal microscopy 
images which were based on a single optical slice. In addition, clots prepared 
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for SEM will undergo significant shrinking as a clot consists of ~98% water (121) 
and must be dehydrated prior to imaging. Similar discrepancies comparing 
structural data from SEM and confocal imaging have been reported previously 
(186). 
 
Table 6-3: Structural data of clots formed from A/ A and A/   
Structural Parameter A/ A A/  
Fibre diameter* (μm) 43  2 29  3 
Fibre density* (fibres μm
-1
) 9.9  0.3 8.8  0.3 
Fibre density
†
 (fibres μm
-1
) 0.23  0.01 0.18  0.01 
*SEM 
†
Confocal 
 
 
Figure 6-8: Confocal micrographs of clots formed from A/ A (A) and A/  (B) fibrinogen 
by the snake venom reptilase. Micrographs are 100 x 100 μm and the scale bars indicate 20 
μm. Final concentrations within a clot were 0.5 mg/ml fibrinogen, 5% fluorescently labelled 
fibrinogen, 5.0 BU/ml reptilase and 2.5 mM CaCl2.  
 
We next investigated whether the differences in structure between A/ A and 
A/  fibrin observed by LSCM were dependent on thrombin. When reptilase 
was used instead of thrombin, fibrin fibres were arranged non-uniformally 
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producing a more porous structure in A/ clots (Figure 6-8), comparable to the 
structures observed with thrombin (Figure 6-6). Again, fibre density was lower in 
A/  clots compared with A/ A clots ( A/  = (0.12  0.01) fibres μm
-1 vs. A/ A = 
(0.20  0.02) fibres μm-1). These data are in agreement with turbidity data 
(Figure 6-5) and show that the effects of on fibrin structure are independent of 
interaction with thrombin. 
 
 
Figure 6-9: Confocal micrographs of clots formed from A/ A (A) and A/  (B) fibrinogen 
in the Presence of FXIIIa. Micrographs are 100 x 100 μm and the scale bars indicate 20 μm. 
Final concentrations within a clot were 0.5 mg/ml fibrinogen, 5% fluorescently labelled 
fibrinogen, 1.0 U/ml thrombin 2.5 mM CaCl2 and 3.7 μg/ml FXIIIa. Fibre density was lower in 
A/  clots compared with A/ A clots.  
 
Finally, the structure of clots formed in the presence of FXIIIa was also 
investigated (Figure 6-9). Once again similar differences in structure and fibre 
density ( A/  = (0.18  0.01) fibres μm
-1 vs. A/ A = (0.22  0.01) fibres μm
-1) 
between A/  and A/ A clots were observed. These data show that the effect 
of  chain on fibrin structure is independent of cross-linking by FXIIIa as well. 
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6.6 Viscoelastic Properties 
 
The mechanical and viscoelastic properties of A/ A and A/  fibrin were 
measured using the magnetic microrheometer described in chapter 3. Samples 
were prepared as described in section 2.2.4. In the absence and presence of 
FXIIIa cross-linking there are clear differences in the mechanical properties of 
A/ A and A/  clots. From the data in Figure 6-10 the following parameters 
were extracted: the rate of change of the compliance (dJ-1/dt) during the initial 5 
minutes of data capture, the initial (JI) and final (JF) compliances along with the 
plateau time which gives a measure of the kinetics of the mechanical 
development. 
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Figure 6-10: J
-1
 vs. time of clots formed from A/ A and A/  fibrinogen in the absence 
and presence of FXIIIa. Each data plot is representative of 3 repeat measurements where 
errors are the standard error in the mean. Each data set is fitted with an exponential curve as a 
guide for the eye. 
 
164 
 
In the absence of cross-linking the initial compliance of A/ A clots increased 7-
times faster than A/  clots. This increased rate of compliance development is 
also reflected in the shorter plateau time for A/ A clots, which is nearly half that 
of A/  clots, indicating an earlier plateau in the mechanical properties for A/ A 
clots. This is consistent with turbidity measurements where an increased rate of 
development was observed for A/ A clots. In the presence of cross-linking the 
rate of change of compliance increased for both A/ A and A/  clots; 
increasing by 1.6- and 1.7-times respectively. However, the rate of change of 
compliance was still higher for A/ A clots by 6.6-times. Again, A/ A clots 
exhibited a shorter plateau time, however for both clot types these were much 
longer when compared to clots without cross-linking. This increased time to 
plateau is attributed to cross-linking which is still occurring on these timescales 
(Figure 6-3 (A)). 
 
Table 6-4: Mechanical data of clots formed from A/ A and A/   
  Cross-linked 
Mechanical Parameter A/ A A/  A/ A A/  
dJ
-1
/dt (Pa s
-1
) 0.16  0.04 0.023  0.002 0.25  0.02 0.038  0.005 
JI (Pa) 2.1  0.2 0.54  0.04 2.2  0.2 0.56  0.05 
JF (Pa) 2.87  0.03 0.76  0.01 6.3  0.6 1.2  0.1 
Plateau time (minutes) 10  1 20  3 175  18 200  12 
 
The initial compliance of A/ A clots was ~3.9-times higher than A/  clots both 
in the presence and absence of cross-linking. This indicates that the nascent 
network of the clot is mechanically stiffer prior to further fibre growth, branch 
point formation and cross-linking. The final compliance of A/ A clots was 3.8-
times higher than A/  clots in the absence of cross-linking, this difference 
increased to 5.3-times in the presence of cross-linking. Since there is little 
change in the initial compliance for both clots with and without cross-linking this 
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suggests the increased final compliance in A/ A clots over A/  clots is due to 
increased amounts of -chain cross-linking as observed in SDS-PAGE analysis.  
 
There was also a significant difference in the viscoelastic properties of A/ A 
and A/  clots (Table 6-5). In the absence of cross-linking, A/ A clots were 2.7-
times stiffer than A/  clots, as shown by the difference in the storage modulus 
G . In the presence of cross-linking this difference increased, with A/ A clots 
becoming 4.6-times stiffer than A/  clots. Therefore, A/ A clots became 3.9-
times stiffer and A/  clots 2.3-times stiffer due to cross-linking. These data 
show that cross-linking by FXIIIa induces a greater increase in stiffness in A/ A 
than in A/  clots. As mentioned above this is attributed to the increased 
amounts of -chain cross-linking observed. 
 
Table 6-5: Viscoelastic data of clots formed from A/ A and A/   
  Cross-linked 
Viscoelastic Parameter A/ A A/  A/ A A/  
G  (Pa) 1.5  0.2 0.56  0.06 5.8  0.2 1.27  0.09 
G  (mPa) 8  2 40  10 1.2  0.4 7  2 
tan  (10
-3
) 5  3 71  43 0.2  0.1 5  3 
 
The energy dissipated by deformation processes as indicated by the loss 
modulus G  was around 5-times higher in A/  clots than in A/ A clots, both 
with and without cross-linking. This suggests that A/  clots are more likely to 
deform compared with A/ A clots. In addition, the loss tangent of A/  clots 
was 14- and 25-times greater than that of A/ A clots in the absence and 
presence of cross-linking respectively. Altogether these data indicate that the 
decreased stiffness and increased viscosity render A/  clots less resistant to 
deformation than A/ A clots. 
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6.7 Protofibril Arrangements 
 
The AFM was used to visualise protofibril formation during the very early stages 
(< 1min) of fibrin polymerization and investigate the molecular mechanisms 
underpinning the role of  in fibrin structure. Samples were prepared and 
imaged as described in section 2.2.6. Prior to imaging fibrin polymerisation, the 
binding of A/ A and A/  fibrinogen to the mica substrate was measured in 
order to investigate any potential differences. 
 
 
Figure 6-11: AFM image of A A fibrinogen on a mica substrate. Multiple 2 x 2 μm images 
were obtained and the surface density of molecules was measured.  The scale bar represents 
500 nm. 
 
A/ A and A/  fibrinogen were diluted in TBS buffer to ~1 μg/ml, placed onto 
the NiCl2 treated mica surface and allowed to incubated for 2 minutes. Multiple 
images of fibrinogen molecules distributed across the surface were obtained 
and the surface density of molecules was measured (Figure 6-11). No 
difference between the surface binding of A/ A and A/  fibrinogen was 
observed ( A/  = (121  6) molecules μm
-2 vs. A/ A = (108  8) molecules μm
-2; 
n = 5, p = 0.19). 
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Figure 6-12: AFM imaging of A/ A and A/  polymerization. Each image is 5 x 5 μm and the scale bar indicates 1 μm. It wasn‘t possible to image up to 50 
seconds for the A/  clot as the clot had gelled by this time. 
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Next, the AFM was used to visualize protofibril formation during the initial 
stages of polymerization after the addition of thrombin (Figure 6-12). After 10 
seconds of polymerization there was already a notable difference; fibrin 
monomers arranged themselves into loose associations on the surface in A/ A 
clots, these could be seen as regions of higher density fibrin. However, in A/  
clots, large agglomerations of fibrin monomers were observed. By 20 seconds 
oligomer formation appeared more extensive in A/  clots. At 30 seconds 
oligomer formation and growth was observed in both A/ A and A/  clots. At 40 
seconds A/ A fibrinogen oligomers were 96 nm longer than A/  fibrinogen 
oligomers (L A/ A = (327  11) nm (n = 229) vs. L A/  = (231  12) nm (n = 218); p 
< 0.0001). At 50 seconds, A/ A oligomers continued to grow longer, reaching 
526  6 nm in length, and appeared to be forming protofibrils and fibres. It was 
not possible to image A/  clots at 50 seconds as the network had gelled by this 
time. These data show that the -chain directly interferes with oligomer 
formation and protofibril growth. 
 
6.8 Gel time 
 
The gel point was analyzed both manually and with a coagulometer as 
described in section 2.2.3. Manual inspection showed that A/  clots gelled 
between 40 and 45 and A/ A clots between 50 and 55 seconds. Using the 
coagulometer, we found that A/  clots gelled ~10 seconds quicker than A/ A 
clots (t A/  = 32.9  0.9 vs. t A/ A = 43.4  0.3 seconds; p < 0.001). We attribute 
the overall quicker gelling time observed with the coagulometer to the 
experiment being performed at 37°C as opposed to room temperature for the 
manual test. The instrument has no temperature control hence it wasn‘t 
possible to perform both experiments under the same conditions. Nevertheless, 
both measurements agreed that A/  fibrin gels earlier by ~10 seconds. 
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6.9 Fibrinolysis 
 
Fibrinolysis of A/ A and A/  fibrin was studied by turbidity analysis. Clots were 
prepared in triplicate as described in section 2.2.2. Plasminogen (final 
concentration of 0.3 M) was incubated with fibrinogen and then a mixture of 
thrombin and tPA (final concentration of 1 nM) was added to initiate coagulation 
and fibrinolysis simultaneously. Changes in absorbance were measured every 
12 seconds over the first 80 minutes of clotting (Figure 6-13). 
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Figure 6-13: Turbidity analysis of fibrinolysis in clots formed from A/ A and A/  
fibrinogen. Each curve is representative of 3 repeat measurements with error bars representing 
the standard error in the mean. 
 
The analysis of the turbidity data in Figure 6-13 is provided in Table 6-6. In 
agreement with turbidity measurements we observed both an increased 
maximum rate and higher absorbance for A/ A clots. The maximum 
polymerization rate of A/ A fibrin was 4.2-times higher than that of A/ . The 
maximum absorbance of A/ A fibrin was 3.2-times higher than that of A/ . 
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Again, there was no observable lag phase for either fibrinogen variant. The lysis 
time, defined as the time taken to reach half the peak absorbance, was longer 
in A/  clots by 5 minutes. 
 
Table 6-6: Fibrinolysis data of clots formed from A/ A and A/   
Fibrinolysis Parameter A/ A A/  
Maximum Rate (units min
-1
) 0.022  0.002 0.0052  0.0004 
Maximum Absorbance 0.059  0.001 0.0187  0.0003 
Lysis time* 14  1 19  2 
*Lysis time is defined as the time taken to reach half the peak absorbance 
 
6.10 Discussion and Conclusions 
 
Our study shows major differences in the viscoelastic properties of clots 
produced with a naturally occurring fibrinogen  chain splice variant ( ), with 
reduced stiffness and increased deformation for  fibrin. These differences in 
stiffness and deformation occurred both with and without cross-linking by FXIIIa. 
In addition, we present qualitative and quantitative evidence that the  chain 
inhibits protofibril growth directly. We show dramatic differences in fibrin 
polymerization and structure, and show that these are independent of thrombin 
binding to the  chain and of its interactions with FXIII. This direct interference 
of the  chain with protofibril growth provides a potential mechanism that 
explains the altered structure and mechanical properties of A/  fibrin. 
 
We found a reduced maximal rate of polymerisation and final absorbance 
associated with the  chain in turbidity measurements, in agreement with 
previous observations (96, 185). Our data suggest that clot formation is slowed 
through a decrease in lateral aggregation, resulting in a clot consisting of 
thinner fibres.  This interpretation is consistent with the observation from 
scanning electron microscopy, where we observed A/  clots consist of thinner 
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fibres. In addition, magnetic microrheometer measurements also reveal the rate 
of mechanical stiffness development is reduced in A/  clots. Again, consistent 
with the idea of reduced radial fibre growth.    
 
Two possible models have previously been suggested to explain the role of the 
 chain in clot polymerization. Firstly, one in which the binding of the  chain to 
thrombin inhibits its activity (190). And secondly, one whereby the  chain 
disrupts protofibril and fibre formation through charge-charge interactions (185). 
A study by Siebenlist et al. suggested that thrombin binding to the  chain 
results in delayed release of fibrinopeptide A and that this may be responsible 
for the observed structural alterations between A/   and A/ A clots (184). In 
order to elucidate the mechanism responsible for altered polymerization we 
formed clots with either thrombin or reptilase; a snake venom which cleaves 
fibrinopeptide A but does not bind to the  chain. Turbidity data clearly showed 
that a decreased maximum rate and final absorbance remained associated with 
the  chain when clots were formed with reptilase, demonstrating that the effect 
of the  chain on fibrin structure is independent of its interactions with thrombin. 
There were some minor differences in polymerization when comparing thrombin 
to reptilase, which may be explained by differences in enzyme concentrations or 
fibrinopeptide release rates, however the difference between A/  and A/ A 
fibrin remained clear. Confocal microscopy imaging also showed minor overall 
differences in clot structure between clotting with thrombin or reptilase, but 
again a striking difference between A/  and A/ A fibrin was apparent. It has 
been observed that thrombin remains active while bound to the  chain (191). 
In addition, previous studies from our laboratory and others reported normal 
fibrinopeptide A release from recombinant A/  fibrinogen by thrombin (96, 
185). Our current data provide new evidence that the differences in 
polymerization arise from direct disruption of clot formation by the  chain 
through physical interaction and not through inhibition of thrombin.     
 
In the present study we find that A/  fibrinogen formed clots composed of 
thinner fibres and found that they are arranged non-uniformly. Several reports in 
the literature show changes in clot structure for  fibrin, however, the reports 
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have not been entirely consistent. Part of these differences may be due to the 
different source materials used (recombinant versus plasma purified) and the 
experimental conditions. Previous studies from our laboratory and from 
Siebenlist et al. found an association between  and thinner fibres (96, 184). 
Gersh et al. find no difference in fibre diameter between recombinant A/ A and 
A/  clots, however they did observe thinner fibres in /  clots (185). Both 
Siebenlist et al. and our previous study found that  was associated with a more 
branched network (96, 184). Gersh et al. reported that clots formed from A/  
fibrinogen were non-uniform with fibres that bundled together and produced 
large open pores (185). The latter authors also reported the presence of free 
fibre ends, which they suggested arise when multiple  ends come together and 
terminate the polymerization process due to the concentration of negative 
charge. In agreement with this, the SEM and confocal imaging carried out in our 
current study show the presence of structures that were non-uniform. The 
heterogeneity of the  fibrin structure was particularly evident at lower SEM 
magnification (5000x), which may explain why this aspect was not observed in 
our previous study in which fibrin was imaged at higher magnification (185). 
Overall, most studies appear to confirm an effect of the  chain on fibrin 
structure and most studies agree with a decrease in fibre diameter for  fibrin.   
 
Magnetic microrheometer measurements reveal that A/  clots are inherently 
weaker, independently of cross-linking by FXIIIa, and that these mechanical 
properties are attributable to differences in their fibrin structure. Larger fibres 
are associated with maximum rigidities in clots (33). Thus, the thinner and 
shorter fibres in A/  clots, combined with a non-uniform distribution of the 
fibres, may lead to the reduced stiffness observed. Collet et al. previously 
reported on the role of the fibrinogen  chain in modulating fibrin viscoelasticity 
(186). However, their study refers to homodimers of /  fibrin (produced by 
recombinant expression), which occur at a maximum concentration of 0.5% in 
human plasma, while the heterodimer A/  presented in our current study 
circulates at a concentration of 8-15% of total fibrinogen. They observed no 
difference in stiffness between clots made with recombinant /  clots and A/ A 
clots in the absence of cross-linking. Instead an increase in stiffness of around 
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3-times was observed in recombinant /  clots over A/ A clots in the presence 
of cross-linking. Other studies have suggested that  fibrin undergoes more 
cross-linking by FXIIIa (187, 189). We suggest that the discrepancy between 
our findings and those of Collet et al. (198) may be due in part to differences in 
source material (recombinant /  compared with plasma purified A/ ). 
 
The extent of cross-linking in clots produced with A/  fibrinogen has been 
subject of debate. Farrell et al. found that A/  clots were more highly cross-
linked, with more extensive - and -chain cross-linking (187, 189). They also 
reported that A/  fibrinogen accelerated FXIII activation. On the contrary, 
Siebenlist et al. found no measurable differences in the rate or extent of -chain 
cross-linking, whereas the overall rate and onset of -cross-linking was slower 
for A/  fibrinogen (184). In agreement with the latter study, our data show that 
A/  fibrin is associated with reduced -chain cross-linking. In the presence of 
FXIIIa cross-linking, we observed a smaller increase in stiffness in A/  clots 
when compared with A/ A clots. The combination of thinner, less uniform fibres 
with less extensive -chain cross-linking is likely responsible for the reduced 
stiffness observed in A/  clots.  
 
To elucidate the mechanism by which the  chain alters clot polymerization we 
performed AFM imaging during the early stages of polymerization. Fibrin 
polymerization studies are typically performed by analyzing the lag phase via 
turbidity. However, turbidity only increases during the phase of lateral 
aggregation of fibrin protofibrils (30) and therefore does not provide information 
on protofibril formation. Recently, Chernysh et al (199). visualized and 
characterized structures formed during the early stages of fibrin polymerization 
using transmission electron microscopy. Here, we used the AFM to directly 
visualize and measure protofibril formation. We report that the presence of the 
 chain inhibits protofibril growth. One hypothesis may be that normal protofibril 
growth occurs through either A- A or A-  chain combinations at the D-D 
interface, but when two  chains come together at this interface, they disrupt 
the growth of the protofibril. Turbidity data indicating that the  chain disrupts 
polymerization and the existence of free fibre ends in SEM micrographs as 
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observed by Gersh et al. (196) gives further support to this hypothesis. 
However, in absence of structural information on the  C-terminal extension, 
the orientation of with respect to the D-D interface remains unknown.  
 
 
Figure 6-14: Schematic diagram of network formation in A/ A and A/  clots. (A) diagram 
representing the ―knob-hole‖ interaction of 3 fibrinogen molecules (adapted from Medved et 
al.(11)). The C-domains are shown only in the upper molecule for clarity. Protofibril growth 
occurs through highly specific A:a interactions,(16) as indicated in the dashed box which 
highlights the exposed binding sites at the ends of the protofibril. (B) Schematic representation 
of A/ A and A/  clots prior to the gel-point. The same amount of material is present within 
both clots but distributed differently. A/  clots are composed of a greater number of smaller 
protofibrils, the result is many more biochemically ―sticky‖ ends (dashed box) are present within 
the same volume of clot as compared with A/ A clots. (C) A/ A and A/  clots after the gel-
point. At this stage the protofibrils have branched and produced an interconnected path of fibrils 
which spans the clot structure. As seen by the experimentally determined gel-point time this 
process occurs ~10 seconds quicker in A/  clots.  
 
175 
 
In addition to differences in protofibril growth, A/  protofibrils gelled earlier than 
A/ A. It has been reported that 70% of fibres have reached their maximum 
length at the gel-point (121). Weisel and Nagaswami developed a model to 
predict fibrin formation based on fibrinopeptide A release, protofibril formation 
and lateral aggregation of the protofibrils to form fibres (149). This model 
predicts that longer protofibrils lead to increased lateral aggregation, in 
agreement with our findings of increased fibre diameter for A/ A fibrin which 
showed longer protofibrils by AFM. However, this model cannot predict our 
findings with regards to the earlier gel-point in A/  fibrin, which produced 
shorter protofibrils and thinner fibres. We therefore propose a working model 
hypothesis of gel formation to explain the relationship between inhibition of 
protofibril growth in A/  fibrin, reduced gel formation time and differences in 
fibrin structure (Figure 6-14). In this model hypothesis, inhibiting protofibril 
growth would lead to a greater number of smaller protofibrils in a given area. 
Assuming that only the ends of a fibrin protofibril are biochemically active (with 
at least half of the binding sites on the E-region and all those of one D-region 
still exposed), these can therefore attach to another fibril or to another fibrin 
monomer. In A/  clots, which contain a larger number of protofibril ends per 
given area, there may therefore be a greater likelihood of protofibril interaction 
and branching, resulting in a higher chance for the occurrence of an 
interconnected path of fibrils which spans a length scale long enough to turn a 
clot from liquid to gel (defined as the gel point (100)). This model could explain 
why A/  clots gel while protofibrils are still in this premature stage. The model 
could also agree with the formation of a non-uniform structure due to early 
gelling of highly branched, short protofibrils. However, a note of caution needs 
to be added that this model represents a simplified working hypothesis, and that 
it is therefore likely incomplete and speculative, until further experimental data is 
obtained to support it.  
 
Finally, we observed longer lysis times in A/  clots. Delayed clot lysis rates 
have been associated with altered fibre and clot architecture (200-202). Thinner 
fibres support a slower rate of tPA-mediated plasmin generation (203) reducing 
the fibrinolytic activity of the clot. It has also been observed that clots consisting 
of thinner fibres are more resistant to fibrinolysis. This is attributed to the fact 
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that clots consisting of thinner fibres form a tighter and less porous network (33, 
200-204). Our observations of slowed lysis in A/  clots are consistent with 
these findings. The thinner fibres of A/  clots will result in reduced plasmin 
generation. This coupled with the non-linear structure where fibres form dense 
knots will further reduce the fibrinolytic activity of A/  clots. In addition, our 
findings are consistent with other studies in the literature reporting an 
association between the  chain and reduced fibrinolysis (184, 186, 187). 
 
In conclusion, we provide evidence that the  chain alters fibrin polymerization 
and that this is independent of the  chain binding to thrombin or FXIIIa. Direct 
imaging of protofibril formation reveals that the  chain is associated with 
inhibition of protofibril growth. Our data are consistent with a model hypothesis 
whereby shorter, more numerous protofibrils could lead to earlier gelling of A/  
clots. Subsequently, this results in a clot which is altered both structurally and 
mechanically. A/  clots are composed of thinner, shorter fibres arranged non-
uniformly producing large open pores which extend throughout the clot 
structure.  The production of a mechanically weaker, non-uniform fibrin clot 
which results in delayed lysis may help to explain the differential association of 
fibrinogen  with thrombosis in the venous and arterial vascular beds.  
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Chapter 7 
7 Plasma Clots 
 
7.1 Introduction 
 
The aim of the work presented within this chapter was to investigate the effect 
of different plasma proteins on clot polymerisation and structure and determine 
the subsequent effect on clot mechanical properties and viscoelasticity. Four 
different plasma proteins, factor VIIa, IXa, XIIa and XIII, were chosen and each 
displayed a range of different effects on clot behaviour.  
 
7.2 Sample Preparation 
 
Clots were formed using FVII-, FIX-, FXII- and FXIII-deficient plasmas with and 
without reconstitution with purified human proteins. The plasma was diluted 1/6 
in the final reaction mixture, so the final fibrinogen concentration was assumed 
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to be around 0.5 mg/ml, which represents a 6-times dilution from normal in vivo 
plasma concentration. Final thrombin concentration was 0.5 U/ml with a final 
CaCl2 concentration of 7.5 mM. The final concentration of plasma protein was 
as follows,  
 
 FVIIa: 83 ng/ml  
 FIXa: 0.83 μg/ml 
 FXIIa: 5 μg/ml 
 FXIII: 3.7 μg/ml 
 
All of which represent 1/6 in vivo zymogen plasma concentration. For FXIIa 
clots an intermediate concentration of 1.25 μg/ml, representing 25% of the 
corresponding plasma level, was also tested. For details of all plasmas and their 
respective proteins please see section 2.1.  
 
7.3 FVIIa 
 
The effect of FVIIa on clot polymerization was studied by turbidity analysis. 
Clots were prepared as described in section 2.2.2 with 5 repeats being made for 
each clot type. Thrombin was added to initiate clotting after which absorbance 
was measured every 12 seconds over the first 60 minutes of clotting (Figure 
7-1). This procedure was used to investigate the overall effects of the selected 
plasma proteins on clot polymerisation. 
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Figure 7-1: Absorbance vs. time for clots formed from FVII-deficient plasma in the 
absence and presence of FVIIa. Each curve is representative of 3 repeat measurements. The 
dashed lines represent the standard error in the mean from 3 repeat measurements. 
 
The analysis of the turbidity data in Figure 7-1 is provided in Table 7-1. It is 
clear from this analysis that FVIIa had no major effect on the polymerisation of 
fibrin. No significant changes in lag phase, maximum rate, final absorbance or 
plateau time were detected within the experimental uncertainties. It is therefore 
concluded that FVIIa had little or no direct effect upon clot structure.  
 
Table 7-1: Polymerisation data of clots formed from FVII-deficient plasma in the absence 
and presence of FVIIa 
 FVIIa - FVIIa + 
Lag time (minutes) 3.7  0.5 3.6  0.6 
Maximum rate (units min
-1
) 0.015  0.003 0.018  0.005 
Final absorbance  0.13  0.03 0.13  0.03 
Plateau time (minutes) 23  2 25  2 
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In order to investigate clot structure further, clots were investigated by SEM 
analysis. Samples were prepared (with above concentrations of thrombin, CaCl2 
and fibrinogen), and further processed, imaged and analysed as described in 
section 2.2.5. All clots studied in this chapter were allowed to form for 6 hours in 
a humidity chamber at room temperature. The results of this analysis are 
presented in Figure 7-2 and Table 7-2. As expected no difference in structure 
was detected between clots formed in the presence or absence of FVIIa. Both 
clots displayed a homogeneous arrangement of fibres. Analysis of SEM 
micrographs revealed fibre diameter and density were unchanged in the 
presence of FVIIa.  
 
 
Figure 7-2: Scanning electron micrographs of clots formed from FVII-deficient plasma in 
the absence (left) and presence (right) of FVIIa. Images are 5 000 x magnification. 
 
Table 7-2: Structural data of clots formed from FVII-deficient plasma in the absence and 
presence of FVIIa 
 FVIIa - FVIIa + 
Fibre diameter (nm) 84  3 85  3 
Fibre density (#fibres m
-1
) 3.3  0.2 3.0  0.1 
 
Next, the mechanical properties were measured using the magnetic 
microrheometer described in chapter 3. Samples were prepared as described in 
section 2.2.4. The mechanical data during clot polymerisation is presented in 
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Figure 7-3 and the analysis is provided in Table 4-2. Minimal differences in the 
mechanical development of clots formed with or without FVIIa were observed. 
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Figure 7-3: J
-1
 vs. time for clots formed from FVII-deficient plasma in the absence and 
presence of FVIIa. 
 
Table 7-3: Stiffness polymerisation data of clots formed from FVII-deficient plasma in the 
absence and presence of FVIIa 
 FVIIa - FVIIa + 
dJ
-1
/dt (Pa.s
-1
) 0.11  0.02 0.17  0.03 
JI (Pa) 1.0  0.2 1.1  0.1 
JF (Pa) 2.6  0.4 3.0  0.3 
Plateau time (minutes) 68  3 74  4  
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Figure 7-4: G  and G  vs. frequency for clots formed from FVII-deficient plasma in the 
absence and presence of FVIIa. 
 
Table 7-4: Viscoelastic data of clots formed from FVII-deficient plasma in the absence 
and presence of FVIIa 
 FVIIa - FVIIa + 
G  (Pa) 2.4  0.3 2.4  0.1 
G  (x10
-3
 Pa) 1.3  0.3 0.9  0.1 
tan  (x10
-3
) 0.5  0.1 0.38  0.04 
  
Finally, the viscoelastic properties were also measured using the magnetic 
microrheometer. The viscoelastic data are presented in Figure 7-4 and the 
analysis is provided in Table 7-4. No significant differences in the viscoelastic 
behaviour were observed over the entire frequency probed. There appeared to 
be some differences at very low frequencies, however the data provided in 
Table 7-4 indicate that these differences were not statistically significant. Similar 
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comparisons were made at multiply frequencies with no differences detected. 
As such there was no difference in the loss tangent either. 
 
7.4 FIXa 
 
The effect of FIXa on clot polymerization was studied by turbidity analysis. The 
data are presented in Figure 7-5 and the analysis is provided in Table 7-5.  
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Figure 7-5: Absorbance vs. time for clots formed from FIX-deficient plasma in the 
absence and presence of FIXa. Each curve is repeated at least 5 times. The dashed lines 
represent the standard error in the mean of each curve. 
 
It is evident that the presence of FIXa has a strong effect on clot polymerisation. 
In the presence of FIXa the lag phase was shorter by 2.9 minutes, the 
maximum rate was 6-times higher and the final absorbance at 60 minutes was 
1.5-times higher. However, at 60 minutes the absorbance of clots without FIXa 
was still continuing to increase and ~30 minutes later (at 90 minutes) there was 
no difference in absorbance within experimental errors.  
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The shortening of the lag phase and the increased maximum rate indicate that 
protofibril formation and lateral aggregation are both enhanced in the presence 
of FIXa. These effects are in keeping with the central role that FIXa plays in 
enhancing intrinsic thrombin generation during the consolidation phase of 
coagulation. However, it appears that these differences may have little or no 
effect upon clot structure as eventually the final absorbance remains 
unchanged, indicating similar fibre diameter and/or fibre distribution.  
 
Table 7-5: Polymerisation data of clots formed from FIX-deficient plasma in the absence 
and presence of FIXa 
 FIXa - FIXa + 
Lag time (minutes) 4  1 1.1  0.4 
Maximum rate (units min
-1
) 0.006  0.001 0.036  0.002 
Final absorbance (at 90 minutes)  0.06  0.02 0.09  0.02 
Plateau time (minutes) 91  5 15  2 
 
Clot structure was investigated by SEM analysis. The results of this analysis are 
presented in Figure 7-6 and Table 7-6. Fibre arrangement appeared less 
homogeneous than FVIIa clots with regions of higher fibre density forming. 
However, the difference in structure between clots formed with and without FIXa 
appeared minimal. Analysis of SEM micrographs revealed fibre diameter 
remained unchanged while fibre density was 1.2-times higher in clots formed 
with FIXa. 
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Figure 7-6: Scanning electron micrographs of clots formed from FIX-deficient plasma in 
the absence (left) and presence (right) of FIXa. Images are 5 000 x magnification. 
 
Table 7-6: Structural data of clots formed from FIX-deficient plasma in the absence and 
presence of FIXa 
 FIXa - FIXa + 
Fibre diameter (nm) 88  2 92  2 
Fibre density (#fibres m
-1
) 2.9  0.1 3.4  0.1 
 
Next, the mechanical properties during polymerisation were measured. The 
data are presented in Figure 7-7 and the analysis is provided in Table 7-7. The 
initial compliance and the rate of change of compliance remained unchanged 
within the experimental uncertainties. However, in the presence of FIXa the final 
compliance was found to be 1.4-times higher and the time to plateau was 
shorter by 31 minutes. Thus, the mechanical properties of the clot develop at an 
increased rate, indicating fibre and/or branch point formation is altered in the 
presence of FIXa. The resulting final clot was therefore mechanically stiffer due 
to the presence of FIXa. 
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Figure 7-7: J
-1
 vs. time for clots formed from FIX-deficient plasma in the absence and 
presence of FIXa. 
 
Table 7-7: Stiffness polymerisation data of clots formed from FIX-deficient plasma in the 
absence and presence of FIXa  
 FIXa - FIXa + 
dJ
-1
/dt (Pa.s
-1
) 0.098  0.004 0.11  0.06 
JI (Pa) 1.3  0.4 1.7  0.2 
JF (Pa) 3.3  0.4 4.6  0.8 
Plateau time (mins) 145  3 114  5 
  
Finally, the viscoelastic properties were also measured using the magnetic 
microrheometer. The viscoelastic data are presented in Figure 7-8 and the 
analysis is provided in Table 7-8. Differences in the viscoelasticity due to the 
presence of FIXa were apparent. The storage modulus was 1.4-times higher in 
the presence of FIXa. Also, the storage modulus was consistently higher over 
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the entire frequency range. In addition, no major differences in the viscoelastic 
dynamics were observed. 
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Figure 7-8: G  and G  vs. frequency for clots formed from FIX-deficient plasma in the 
absence and presence of FIXa. 
 
Table 7-8: Viscoelastic data of clots formed from FIX-deficient plasma in the absence and 
presence of FIXa.  
 FIXa - FIXa + 
G  (Pa) 2.35  0.07 3.2  0.1 
G  (x10
-3
 Pa) 1.6  0.1 1.1  0.1 
tan  (x10
-3
) 0.68  0.04 0.34  0.01 
  
The loss modulus was found to be 1.5-times higher in the absence of FIXa. The 
loss tangent was therefore 2-times higher in clots without FIXa. The increased 
storage modulus and reduced loss modulus of clots formed in the presence of 
FIXa render them stiffer and more resistant to deformation. 
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7.5 FXIIa 
 
The effect of FXIIa on clot polymerization was studied by turbidity analysis. The 
data are presented in Figure 7-9 and the analysis is provided in Table 7-9. 
There is a clear difference in polymerisation due to the presence of FXIIa. The 
lag phase was shorter by 2.1 minutes and the maximum rate was 2.7-times 
higher in the presence of FXIIa. The effect of this increased polymerisation was 
that FXIIa clots reached a plateau in their absorbance around 30 minutes 
earlier. However, the final absorbance of clots formed without FXIIa was 1.8-
times higher. 
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Figure 7-9: Absorbance vs. time for clots formed from FXII-deficient plasma in the 
absence and presence of FXIIa. Each curve is repeated at least 5 times. The dashed lines 
represent the standard error in the mean of each curve. 
 
Again, as with FIXa clots, the shorter lag phase coupled with the increased 
maximum rate indicate that protofibril formation and lateral aggregation are 
enhanced by the presence of FXIIa. This resulted in a much shorter plateau 
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time as the network formed quicker. However, the final absorbance was much 
lower indicating that clots formed in the presence of FXIIa were comprised of 
thinner fibres and/or an altered fibre arrangement. 
 
Table 7-9: Polymerisation data of clots formed from FXII-deficient plasma in the absence 
and presence of FXIIa 
 FXIIa - FXIIa + 
Lag time (mins) 3.1  0.9 1.0  0.7 
Maximum rate (units min
-1
) 0.015  0.001 0.041  0.006 
Final Absorbance 0.18  0.03 0.10  0.01 
Plateau time (mins) 39  4 8  1 
 
Clot structure was investigated by SEM analysis. The results of this analysis are 
presented in Figure 7-10 and Table 7-10. Both clots displayed a homogeneous 
arrangement of fibres. Analysis of SEM micrographs revealed that fibre density 
was increased 1.1-times in FXIIa clots while fibre diameters were significantly 
thinner (by 29 nm on average) in FXIIa clots. 
 
 
Figure 7-10: Scanning electron micrographs of clots formed from FXII-deficient plasma in 
the absence (left) and presence (right) of FXIIa. Images are 5 000 x magnification. 
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Table 7-10: Structural data of clots formed from FXII-deficient plasma in the absence and 
presence of FXIIa 
 FXIIa - FXIIa + 
Fibre diameter (nm) 104  4  75  2 
Fibre density (#fibres m
-1
) 3.4  0.1 3.71  0.07 
 
Next, the mechanical properties during polymerisation were measured. The 
data are presented in Figure 7-11 and the analysis is provided in Table 7-11. 
The initial compliance was 1.8-times higher in the presence of FXIIa. In 
addition, the final compliance was higher, albeit slightly less so, for FXIIa clots 
by 1.2-times. Inspection of both curves revealed little difference between their 
time-development and this was reflected in the plateau time which remained 
unchanged. It appears that the effect of FXIIa was to increase the mechanical 
stiffness of the network prior to further fibre growth and branch point formation.  
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Figure 7-11: J
-1
 vs. time for clots formed from FXII-deficient plasma in the absence and 
presence of FXIIa. 
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Table 7-11: Stiffness polymerisation data of clots formed from FXII-deficient plasma in 
the absence and presence of FXIIa  
 FXIIa - FXIIa + 
dJ
-1
/dt (Pa.s
-1
) 0.18  0.02 0.15  0.03 
JI (Pa) 1.2  0.3 2.1  0.4 
JF (Pa) 3.9  0.3 4.6  0.4 
Plateau time (mins) 170  22  162  15 
  
Finally the viscoelastic properties were measured. The viscoelastic data are 
presented in Figure 7-12 and the analysis is provided in Table 7-12. An 
additional intermediate concentration, representing 25% of in vivo levels, was 
also tested. Differences in the viscoelasticity due to the presence of FXIIa were 
apparent. The presence of FXIIa resulted in an increase in the storage modulus 
over all frequencies. Similarly, the loss modulus was higher in the presence of 
FXIIa, except at high frequencies for 100% FXIIa. No differences in the 
viscoelastic dynamics were observed due to the presence of FXIIa.   
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Figure 7-12: G  and G  vs. frequency for clots formed from FXII-deficient plasma in the 
absence and presence of FXIIa. 
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Table 7-12: Viscoelastic data of clots formed from FXII-deficient plasma in the absence 
and presence of FXIIa 
% FXIIa 0 25 100 
G  (Pa) 2.89  0.05 4.9  0.2 3.47  0.05 
G  (x10
-3
 Pa) 0.8  0.1 1.1  0.2 1.2  0.1 
tan  (x10
-3
) 0.28  0.02 0.22  0.04 0.36  0.02 
 
A non-linear increase in the storage modulus is associated with the presence of 
FXIIa. The storage modulus increased 1.7-times with 25% FXIIa and 1.2-times 
with 100% FXIIa. The loss modulus remained unchanged with 25% FXIIa but 
increased 1.5-times with 100% FXIIa. No difference in loss tangent was 
observed at 25% FXIIa while at 100% FXIIa there was an increase of 1.3-times.  
 
The increased storage modulus and unchanged loss modulus of clots formed 
with 25% FXIIa indicates these clots are stiffer and more resistant to 
deformation compared with clots formed from 0 and 100% FXIIa. In addition, 
increased FXIIa levels of 100% lower the storage modulus and increase the 
loss modulus. This results in an elevated loss tangent compared with 0 and 
25% FXIIa clots. Thus, clots formed with 100% FXIIa will deform more and as 
such are mechanically weaker. The increase in clot stiffness at intermediate 
FXIIa concentrations generally agrees with the U-shaped curve of other 
functions of FXIIa and is typical of contact-mediated reactions. Recent studies 
suggest that FXIIa binds strongly to fibrin, so the fibrin clot itself could provide a 
surface that mediates the effects of FXIIa on clot structure and stiffness (205). 
 
7.6 FXIII 
 
The effect of FXIII on clot polymerization was studied by turbidity analysis. The 
data are presented in Figure 7-13 and the analysis is provided in Table 7-13. In 
this experimental set-up, the presence of FXIII had no effect upon clot 
polymerisation. No change in lag phase, maximum rate, final absorbance or 
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plateau time was detected within the experimental uncertainties. It is therefore 
assumed that FXIII had little or no effect upon clot structure.  
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Figure 7-13: Absorbance vs. time for clots formed from FXIII-deficient plasma in the 
absence and presence of FXIII. Each curve is repeated at least 5 times. The dashed lines 
represent the standard error in the mean of each curve. 
 
Table 7-13: Polymerisation data of clots formed from FXIII-deficient plasma in the 
absence and presence of FXIII 
 FXIII - FXIII + 
Lag time (mins) 4.1  0.8 2.8  0.7 
Maximum rate (units min
-1
) 0.026  0.002 0.026  0.001 
Final Absorbance 0.13  0.02 0.13  0.02 
Plateau time (mins) 16  3 15  4 
 
Clot structure was investigated by SEM analysis. The results of this analysis are 
presented in Figure 7-14 and Table 7-14. There was very little difference in clot 
structure associated with FXIII. Analysis of SEM micrographs revealed a fall in 
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fibre density of 1.1-times was associated with FXIII. No difference in fibre 
diameter was detected. 
 
 
Figure 7-14: Scanning electron micrographs of clots formed from FXIII-deficient plasma 
in the absence (left) and presence (right) of FXIII. Images are 5 000 x magnification. 
 
Table 7-14: Structural data of clots formed from FXIII-deficient plasma in the absence and 
presence of FXIII 
 FXIII - FXIII + 
Fibre diameter (nm) 92  4 87  12 
Fibre density (#fibres m
-1
) 3.4  0.1 3.1  0.1 
 
Next, the mechanical properties during polymerisation were measured. The 
data are presented in Figure 7-15 and the analysis is provided in Table 7-15. 
The initial compliance and rate of change of compliance remained unchanged. 
However, the final compliance was 2.1-times higher in the presence of FXIII. 
There was also a striking difference between the rates at which each clot 
developed over time as indicated by the difference in plateau time. Clots formed 
in the presence of FXIII took an additional 147 minutes to reach a plateau in 
their compliance. As discussed in chapter 4 clots formed in the presence of 
FXIII continue to stiffen for much longer periods due to the formation of cross-
links.   
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Figure 7-15: J
-1
 vs. time for clots formed from FXIII-deficient plasma in the absence and 
presence of FXIII. 
 
Table 7-15: Stiffness polymerisation data of clots formed from FXIII-deficient plasma in 
the absence and presence of FXIII  
 FXIII - FXIII + 
dJ
-1
/dt (Pa.s
-1
) 0.05  0.01 0.07  0.01 
JI (Pa) 0.76  0.05 0.84  0.4 
JF (Pa) 1.1  0.2 2.3  0.2 
Plateau time (mins) 15  2  162  12 
  
Finally the viscoelastic properties were measured. The viscoelastic data are 
presented in Figure 7-16 and the analysis is provided in Table 7-16. Differences 
in the viscoelasticity due to the presence of FXIII were apparent. The presence 
of FXIII resulted in an increased storage and loss modulus over all frequencies. 
No differences in the viscoelastic dynamics were observed due to the presence 
of FXIII.   
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Figure 7-16: G  and G  vs. frequency for clots formed from FXIII-deficient plasma in the 
absence and presence of FXIII. 
 
Table 7-16: Viscoelastic data of clots formed from FXIII-deficient plasma in the absence 
and presence of FXIII  
 FXIII - FXIII + 
G  (Pa) 0.84  0.08 2.8  0.7 
G  (x10
-3
 Pa) 2.7  0.8 4.0  0.5 
tan  (x10
-3
) 3.2  0.5 1.4  0.3 
  
The storage modulus was 3.3-times higher and loss modulus was 1.5-times 
higher in the presence of FXIII. It has been reported that cross-linking is 
associated with a 2- to 3.5-times increase in G  (33, 75, 143). However, the loss 
tangent was 2.3-times higher in clots without FXIII. This indicates that clots 
formed in the presence of FXIII are stiffer and will deform less when stressed. 
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7.7 Discussions and Conclusions 
 
The effects of four different plasma proteins, factors VIIa, IXa, XIIa and XIII, on 
clot polymerisation, structure, and mechanical and viscoelastic properties were 
studied. The data presented here reveal that combinations of different effects 
on clot behaviour are associated with each individual plasma protein. 
 
Firstly, FVIIa was studied and found to have no effect on clot behaviour. 
Polymerisation was unaltered in the presence of FVIIa. In agreement, SEM 
imaging revealed no differences in clot structure i.e. the presence of fibre 
bundling or pores, due to FVIIa. No difference in fibre diameter or density were 
detected either. A study by He et al. report a minimal effect on clot permeability, 
a direct measure of pore size, by the addition of recombinant FVIIa in normal 
plasma suggesting clot structure remains unaltered (206). In addition, we 
measured no differences in the mechanical or viscoelastic properties. This 
agrees with the work of Carr et al. who found recombinant FVIIa has a minimal 
effect on clot stiffness in normal blood clotted with thrombin (207). The 
insensitivity of the mechanical properties to the presence of FVIIa most likely 
arises due to the negligible effect FVIIa has on clot structure, which is known to 
modulate clot viscoelasticity (33). These data reveals that FVIIa does not play a 
significant role in clot formation in a plasma system where clotting is initiated by 
the addition of thrombin. In vivo FVIIa is involved in the initiation and generation 
of thrombin (202) through activation of FIX and FX by the TF-VIIa complex 
(208). However, in the system used here a large amount of thrombin is added, 
which will immediately convert fibrinogen to fibrin triggering immediate fibrin 
polymerisation. Any additional, thrombin generated through the addition of FVIIa 
could well be negligible in comparison to this and/or play a limited role as the 
nascent network may already have formed.  
 
Secondly, the effects of FIXa were studied and found to modulate clot 
polymerisation. In the presence of FIXa, clots polymerised at a quicker rate as 
indicated by a shorter lag time and increased maximum rate. In addition, the 
absorbance reached a plateau at a shorter time. However, in the absence of 
FIXa clots still reached a very similar final absorbance, albeit at a much later 
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time. Similar values for the final absorbance suggest FIXa does not play a 
significant role in modulating clot structure. No significant differences in the 
macroscopic structure of clots formed with or without FIXa were detected in 
SEM micrographs. In addition, analysis of these micrographs revealed fibre 
diameter remained unchanged. This most likely explains the insensitivity of the 
final absorbance to the presence of FIXa. However, FIXa was associated with a 
slight increase in fibre density.    
 
Measurements of the mechanical properties during polymerisation revealed that 
in the presence of FIXa initially clot stiffness was the same and developed at a 
similar rate. However, FIXa clots eventually became stiffer at an earlier time. 
This agrees with turbidity measurements which show quicker clot formation in 
the presence of FIXa. In addition, viscoelastic measurements revealed that clots 
were stiffer in the presence of FIXa and were less susceptible to permanent 
deformation. The study of Carr et al. report that FIX deficient patients form clots 
with a reduced stiffness as compared to controls (207). We attribute the 
increased mechanical stability of FIXa clots to the increased fibre density, and 
therefore branch point density, as observed in SEM micrographs, which is 
known to elevate clot stiffness (84). 
 
The effect of FIXa on clot polymerisation and structure is interesting. Typically, 
increased polymerisation rates, due to higher levels of thrombin, are associated 
with denser clots composed of thinner fibres. We observe increased 
polymerisation where a denser structure forms but fibre diameter remains 
unaltered. It appears that protofibril formation is enhanced but lateral 
aggregation remains unaffected. One potential mechanism could be that FIXa 
enhances FpA but not FpB cleavage. Thus, more protofibrils form resulting in a 
denser structure but lateral aggregation proceeds at the same rate leading to 
similar fibre diameters. However, it is not clear what the potential mechanism 
could be by which FIXa modulates fibrinopeptide release.      
 
Next, the effects of FXIIa were studied; differences in polymerisation, structure 
and mechanical and viscoelastic properties were all observed. In the presence 
of FXIIa the lag time was shorter and the maximum rate was higher resulting in 
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a lower final absorbance occurring. The study of Konings et al. reported very 
similar observations and suggested increased polymerisation in plasma is due 
to increased thrombin generation via FXI activation (205). In agreement with 
turbidity measurements, SEM imaging revealed FXIIa resulted in a denser clot 
composed of thinner fibres. A denser clot would typically increase the final 
absorbance; the decrease was attributed to the more dramatic change in fibre 
diameter. Similar observations have also been reported from confocal 
microscopy, SEM and permeation experiments (205). As FXIIa concentration 
increased from 0% to 25% and then up to 100% fibre density increased but fibre 
diameter decreased (Figure 7-17) (205). 
 
 
Figure 7-17: Scanning electron micrographs of plasma clots formed in the presence of 0, 
25 and 100% FXIIa (taken from konings et al. (205)). Fibre density increased from left to right 
while fibre diameter increased from right to left. At 25% FVIIa clots displayed a balance between 
maximal fibre diameter and density. Scale bar represents 1 μm.  
  
Measurements of the mechanical properties during polymerisation revealed that 
FXIIa had a limited effect on the mechanical development. Clots formed in the 
presence of 100% FXIIa are initially stiffer and then develop at a very similar 
rate with no further increases in stiffness observed. Additionally, viscoelastic 
measurements revealed an increase in stiffness associated with FXIIa. 
However this was accompanied by an increase in the viscous component. The 
result is that clots formed from 100% FXIIa are mechanically weaker and will 
undergo permanent deformation more easily than clots formed from 0% FXIIa.  
 
At 25% FXIIa levels, however, clot stiffness reached a maximum and the 
viscous component remained unchanged. This resulted in a stiffer clot which 
will undergo less permanent deformation than clots formed at either high or low 
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FXIIa levels. Thus, at intermediate FXIIa levels clots displayed an optimal 
viscoelastic balance; possessing maximal stiffness and displaying minimum 
deformation. This correlates particularly well with structural data from SEM 
imaging which revealed that an optimal balance between fibre branching and 
diameter are achieved at 25% FXIIa levels. Maximal clot stability has been 
correlated with a balance between large fibre diameters and increased 
branching (33). Konings et al. (205) proposed that, in addition to increased 
thrombin generation in plasma which influences clot structure, FXIIa also 
modulates fibrin clot structure independently of thrombin generation through 
direct binding of the N-terminus of FXIIa to fibrinogen and fibrin.  
 
Finally, the effects of FXIII were studied. Clot polymerisation was found to be 
unaffected by the presence of FXIII in this experimental set-up. In addition, clot 
structure was only minimally affected, with a slight decrease in fibre density due 
to FXIII. Previous studies (33, 75, 154, 209) observed minimal effects of FXIII 
on clot structure, although some authors reported slight decreases in fibre 
diameter and increases in fibre density.  In contrast, the mechanical properties 
during polymerisation showed a much more dramatic influence due to the 
presence of FXIII. The initial stiffness and rate of development remained 
unchanged. However, after around 10 minutes clotting displayed a marked 
difference. In the absence of FXIII, stiffness reached a plateau very early while 
in the presence of FXIII clots continued to stiffen for a sustained period. Similar 
effects have been observed in a purified system where cross-linking was 
controlled with a synthetic inhibitor (84). As previously discussed in chapter 4, 
clots formed in the presence of FXIII continued to stiffen due to the formation of 
cross-links. In addition, the viscoelastic properties revealed that an increase in 
stiffness was also accompanied by an increase in the viscous component. 
However, a greater increase in the stiffness rendered the loss tangent lower in 
the presence of FXIII. Thus, FXIII clots were stiffer and more resistant to 
deformation. Previous studies reporting on the mechanical properties of single 
fibres found that in the presence of FXIII, fibres were stiffer and less extensible 
(83, 86). We therefore infer that the increased stiffness of cross-linked clots is 
due to the stiffening of the individual fibres as opposed to structural alterations. 
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The data presented here demonstrate that the effect of FXIII is very similar in 
both purified and plasma systems. 
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Chapter 8 
8 Summary and Conclusions 
 
This project has used multiple complimentary techniques in order to study fibrin 
clot polymerisation, structure and viscoelasticity. The initial stages of this work 
were concerned with adapting and developing a magnetic microrheometry 
device in order to measure the frequency dependent viscoelastic moduli (G ( ) 
and G ( )) of fibrin clots over a broad frequency range. The latter stages of the 
project were then concerned with applying this magnetic microrheometry 
technique to a range of different fibrin samples. Both purified and plasma 
systems were studied along with the fibrinogen variant  as well as the effects 
of the plasma proteins FVII, FIX, FXII and FXIII.  In addition, viscoelastic 
measurements were correlated with fibrin clot structure and polymerisation as 
measured by turbidity, confocal microscopy, SEM and AFM techniques. 
 
The magnetic microrheometer used throughout this work was designed and 
constructed by Dr R. Harrand (210) and was based on the design of Huang et 
al. (211) to perform active particle tracking microrheology measurements. The 
204 
 
device originally consisted of 8 electromagnets and was capable of producing 
forces of ~60 pN in magnitude. Initially, work focused on increasing the force 
range of the device and this was achieved by removing 4 of the electromagnets 
and reconfiguring the device based upon magnetic modelling data. This 
resulted in an increase in the available force up to 120 pN; a 2-fold increase in 
the maximum force. This was achieved by positioning the electromagnet tips in 
the plane of the sample region, and not slightly above and below as was the 
previous configuration. The device was then tested with standard fluids of 
water-glycerol mixtures and found to agree well with bulk measurements 
presented within the literature. This had previously been demonstrated along 
with the ability to correctly measure the viscoelastic properties of 
polyacrylamide solutions (210).  
 
Prior to proceeding onto a comprehensive study of the mechanical and 
viscoelastic behaviour of fibrin clots, the suitability of the device to study clots 
was assessed. The effect of magnetic particles on fibrin polymerisation and 
structure was investigated by turbidity, confocal microscopy and SEM. This was 
important as any alterations would affect the interpretation of results. The 
presence of magnetic particles was found to have no effect upon clot 
polymerisation or structure as indicated by turbidity analysis. In order to directly 
visualise the effect the magnetic particles were having on clot structure, SEM 
and confocal microscopy were employed. Imaging revealed particles had little 
or no effect upon the fibres surrounding them and that they became trapped 
within the clot as the network grew around them.  
 
The effect of the microcell, used to hold clots for microrheology experiments, 
has on clot structure was also studied by confocal microscopy. The fibre density 
as a function of distance from the microcell wall was measured. This revealed 
fibre density was ~2-times lower within the vicinity of the microcell wall. Moving 
away from the wall, the fibre density increased and reached a plateau where the 
fibre density was constant throughout the centre of the capillary. Next, clot 
stiffness as a function of distance from the microcell wall was measured. This 
revealed clot stiffness increased with distance from the microcell wall and then 
reached a plateau. This correlated well with fibre density measurements and the 
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increased stiffness was attributed to increased fibre density. The reason for the 
decrease in fibre density at the microcell wall was not ascertained but the effect 
on the overall clot structure appeared minimal. These observations reveal that 
forming clots within microcells and embedding magnetic particles within them 
does not significantly alter the structural or mechanical properties. 
 
After validation of the magnetic microrheometer as a suitable device, different 
techniques and approaches were developed to study the mechanical and 
viscoelastic properties of fibrin clots. One such approach was to measure the 
change in stiffness of a clot during polymerisation which allows kinetic 
information on clot formation to be gathered. It was observed that clots undergo 
a rapid increase in stiffness which then reaches a plateau once the clot has 
formed. It was assumed that once this plateau had been reached, a clot was 
fully formed both structurally and mechanically. Further measurements revealed 
that the final stiffness did not change significantly over prolonged periods of 
time giving justification to this claim.  
 
The variation in clot stiffness from particle-to-particle and also the variation due 
to the direction of manipulation of a magnetic particle were also investigated. 
Measurements revealed that there was a difference in stiffness depending upon 
which direction a magnetic particle was moved. However, no one direction was 
consistently associated with either a higher or lower measure of clot stiffness. In 
addition, the variation in stiffness from particle-to-particle also revealed a 
distribution in stiffness. This variation was investigated as an indirect probe of 
clot structure, which is known to modulate clot viscoelasticity. However, 
measurements of clots formed from A/ A and A/ fibrinogen, two clots known 
to have very different structures, revealed no correlation between stiffness 
variation and clot inhomogeneity. It is thought that differences in clot stiffness 
arise from repeated measurements of a physical system where measurements 
distribute normally. 
 
The non-linear behaviour of clot elasticity, termed strain-hardening, was also 
investigated with the magnetic microrheometer. It was possible to resolve some 
relatively weak clots undergoing strain-hardening behaviour. At low strains the 
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stiffness remained essentially constant but as strain increased, clots displayed 
increased stiffness.  This approach was investigated as a potential diagnostic of 
fibrin clot elasticity. However, due to the low forces achievable with the 
magnetic microrheometer it was not possible to strain clots sufficiently to 
observe and compare their non-linear response. As fibrinogen levels increase 
and clots become stiffer their elastic response approaches that of Hooke‘s Law. 
 
Next, a method to measure the frequency dependent viscoelastic moduli was 
developed. The author of (210) had previously developed a technique with the 
current magnetic microrheometer and studied the viscoelasticity of 
polyacrylamide solutions. However, a study of the frequency dependent 
viscoelastic moduli of fibrin clots was not carried out. In order to do so with the 
current magnetic microrheometer and the method of (210) would be extremely 
time consuming to perform and as such it was decided to implement a more 
straightforward approach. Using the procedure of Evans et al. (127) the 
frequency dependent viscoelastic moduli were calculated directly from time 
dependent creep compliance measurements. This approach allowed the 
viscoelastic moduli of clots to be measured over a frequency range spanning 5 
orders of magnitude. 
 
This approach was used to investigate the viscoelastic behaviour of purified 
fibrin clots. It was observed that fibrin clot behaviour was predominantly elastic 
on all timescales. Furthermore, it was observed that fibrin clots were highly 
stable on very long times. This was the case for all fibrin types studied 
throughout this work. This behaviour could account for the stability and integrity 
of clots in vivo which must withstand varying degrees of shear stress and 
maintain their integrity for prolonged periods during wound repair. 
 
To date, very little or almost nothing has been reported upon the frequency 
dependence of the storage modulus. Most studies report a storage modulus 
which remains constant with frequency. Measurements in this work revealed 
that the storage modulus varied with frequency and displayed three distinct 
plateaus. Each plateau corresponds to a different shear relaxation mechanism 
as predicted by the model of Morse (71). On long-times the behaviour is 
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dominated by large scale motions of the fibres and branches, i.e. an 
orientational contribution, Gorient arising from forces that resist movement of the 
entire fibre. In addition, the plateau in G  and the divergence of G  to smaller 
values as predicted by Morse for a network of branched fibres was also 
observed. This reveals the role of branch points in the long-time elastic 
behaviour of fibrin networks in that they help maintain clot integrity on long 
timescales. At intermediate times, fibres are moving on length scales of the 
order of the fibre length, i.e. distances between branch points. This is a 
curvature contribution, Gcurve which arises from forces that are opposing 
transverse deformation or rotation of the fibre. Finally, on very short times fibres 
are compressing and stretching. This is a tension contribution, Gtens which 
arises from tangential forces that resist stretching or compression of the fibre. 
This plateau is predicted to scale with fibrinogen concentration as G c2.5 by 
Mackintosh et al. (68) and measurements in this work were found to agree well 
with this scaling prediction. We believe that discrepancies between our 
observations of relaxation behaviour and that presented within the literature 
may arise due to differing experimental conditions and/or the microrheological 
technique employed. Other micron based measurements of single fibrin fibres 
also report relaxation behaviour on differing timescales (86).  
 
In addition, the effect of FXIII on clot mechanical and viscoelasticity properties, 
which has been widely reported upon in the literature, was tested with the 
magnetic microrheometer. This also serves as a validation for the procedure of 
Evans et al. (127) which previously has not been applied to the study of fibrin 
clots. The polymerisation of clot stiffness displayed a marked difference in the 
presence of FXIII. Initially, at times <5 minutes there was no difference in 
polymerisation. However, after this time clots formed in the presence of FXIII 
displayed an increased stiffness and continued to stiffen for up to 6 hours. This 
was attributed to cross-linking of the - and -chains. Viscoelastic 
measurements revealed clot stiffness increased ~3-times, agreeing well with 
previous measurements presented in the literature (33, 75, 143). Also, cross-
linking reduced viscous creep, thus overall a clot is rendered more mechanically 
stable. In addition, it was observed that cross-linking did not significantly alter 
the stress relaxation behaviour of fibrin. As clot architecture remains essentially 
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unchanged this most likely explains the insensitivity of the fibre dynamics to 
FXIII cross-linking. 
 
Measurements of the frequency behaviour of the loss tangent revealed that 
cross-linking decreased the loss tangent on all times.  In addition, increases in 
the loss tangent were observed at two specific frequencies. These peaks in the 
loss tangent coincide with the transitions between different stress relaxation 
modes. This indicates that when clots are stressed at these specific times they 
incur a greater degree of deformation which could be a potential mechanism for 
embolism. These observations also highlight the importance of performing multi 
frequency measurements as clot viscoelastic behaviour is highly dependent 
upon the timescale on which one observes. 
 
A comprehensive study to investigate the frequency dependent viscoelastic 
behaviour of purified fibrin clots was performed. Specifically, the effects of 
fibrinogen, thrombin and calcium concentration on clot viscoelasticity were 
investigated. The work presented in this thesis is the first to study fibrin in this 
way under such conditions. Increased clot stiffness was associated with 
increased fibrinogen concentration and attributed to an increase in the internal 
protein density of fibres. Good agreement between experimental data and the 
scaling prediction of G  with fibrinogen concentration, as proposed by 
Mackintosh et al. (68), was observed. Indicating fibrin fibres are semi-flexible 
and that fibrin clot elasticity is essentially entropic in origin. However, other 
theories suggest that at high strain an enthalpic contribution may also play a 
role in fibrin elasticity. It was observed that fibrinogen concentration also had an 
effect upon the stress relaxation behaviour of fibrin clots; at higher fibrinogen 
levels Gorient and Gtens occurred at earlier times. This indicates that as fibres 
become stiffer they alter the intermediate- and long-timescale behaviour of fibrin 
clot viscoelasticity. Under varying thrombin levels, increased clot stiffness 
occurred at intermediate thrombin levels. Similarly, maximal clot stiffness was 
also observed at intermediate calcium levels. It is concluded that clots formed at 
these intermediate concentrations display a balance between a degree of 
branching and large fibre diameters, both of which are known to increase clot 
stiffness. 
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Next, the molecular mechanisms underpinning the effects of the fibrinogen  
chain on clot polymerisation, structure and viscoelasticity, still currently under 
debate, were investigated. We observed that the presence of the fibrinogen  
chain slows fibrin polymerization and that this is independent of the  chain 
binding to thrombin or FXIII. It was also observed that protofibril formation is 
inhibited by the presence of the  chain, and this is through either electrostatic 
or steric effects. Surprisingly, the  chain was also associated with an earlier 
clotting time. In order to explain these apparently conflicting observations, a 
model hypothesis was developed whereby shorter, more numerous protofibrils 
lead to earlier gelling of A/  clots. Subsequently, this results in a clot 
composed of thinner, shorter fibres arranged non-uniformly producing large 
open pores which extend throughout the clot structure. This non-uniform 
structure is mechanically weaker and results in prolonged lysis times. Such 
observations may help to explain the differential association of fibrinogen  with 
thrombosis in the venous and arterial vascular beds. 
 
Finally, the effects of the plasma proteins FVIIa, FIXa, FXIIa and FXIII on 
plasma clot behaviour were also studied. It was observed that FVIIa had no 
effect on clot behaviour. This is believed to be due to the use of thrombin to 
initiate coagulation which dwarfs any thrombin generated through reactions 
involving FVIIa. The presence of FIXa was found to increase polymerisation and 
alter clot structure with an increase in fibre density observed. Viscoelastic 
measurements revealed clots were stiffer and less susceptible to permanent 
deformation in the presence of FIXa. This increased mechanical strength was 
attributed to increased fibre density.  
 
Differences in polymerisation, structure and viscoelasticity were observed due 
to the presence of FXIIa. Clot polymerisation was quicker and is believed to be 
due to increased thrombin generation via FXI activation. As FXIIa concentration 
increased, fibre density increased while fibre diameter decreased. Viscoelastic 
measurements revealed that clots formed at 100% FXIIa levels are 
mechanically weaker and will undergo permanent deformation more easily than 
clots formed in the absence of FXIIa. At 25% FXIIa levels clots displayed an 
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optimal viscoelastic balance; possessing maximal stiffness and displaying 
minimum deformation. This correlates with structural data indicating that an 
optimal balance between fibre branching and diameter are achieved at these 
levels. Konings et al. (205) proposed that, in addition to increased thrombin 
generation which influences clot structure, FXIIa also modulates clot structure 
through direct binding of the N-terminus of FXIIa to fibrinogen and fibrin. 
 
FXIII had little or no effect on either clot polymerisation or structure but did, as 
expected, alter clot viscoelasticity. In the presence of FXIII, plasma clots 
continued to increase in stiffness for prolonged periods due to the formation of 
cross-links by FXIII. Viscoelastic measurements revealed clots were stiffer and 
more resistant to deformation when formed in the presence of FXIII. In addition, 
the effects of FXIII in purified and plasma systems are very similar.   
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Chapter 9 
9 Future Work 
 
9.1 High Frequency Measurements 
 
A relatively simple and straightforward improvement to the magnetic 
microrheometer would be to replace the current CCD camera with a higher 
capture rate camera. Currently, measurements are limited to frequencies < 
25 Hz and as seen in this work it was not possible to completely measure 
Gtens, the high frequency contribution to G ( ). The ability to access higher 
frequencies may also result in the detection of further stress relaxation 
mechanisms in fibrin and more specifically molecular stress contributions. 
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9.2 AFM Study of Early Stage Fibrin Polymerisation 
 
Currently the accepted model for fibrin polymerisation is that the release of 
FpA results in the formation of fibrin oligomers which grow longitudinally to 
form protofibrils. These protofibrils, upon the release of FpB, aggregate 
laterally to form fibres. Protofibril divergence and interaction result in the 
formation of branch points. Experimental evidence has shed light on this 
process; increased polymerisation rates result in networks with a high degree 
of branching consisting of thin fibres while, decreased polymerisation rates 
result in networks consisting of thick fibres with a low degree of branching. 
However, a definitive model of branch point formation has yet to be agreed 
upon and the role of FpB is still poorly understood. Using the AFM, as in this 
work, it is possible to directly image the time development of this process 
and gather quantitative information. Through the use of snake venoms which 
cleave only one set of Fps, e.g. reptilase which cleaves only FpA, or by 
mutating functional sites of fibrinogen, it would be possible to study the roles 
of FpA and FpB in the very early stages of fibrin polymerisation helping to 
develop a more complete model of fibrin polymerisation and branch point 
formation.     
 
9.3  Computational Modelling of Fibrin Clots 
 
To date, a model to predict the viscoelastic behaviour of fibrin networks does 
not exist. Morse (71-73) and Mackintosh et al. (68) have both developed 
models in order to compute the viscoelastic properties of networks of 
concentrated isotropic solutions of semi-flexible filaments for a range of 
concentrations and chain lengths. This model is most applicable to solutions 
of actin filaments. The effect of permanent branches on these networks was 
computed and found to agree with measurements for fibrin presented in this 
work. We propose that a model for fibrin could be developed based on the 
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branched model of Morse (71). Magnetic microrheometer measurements 
could be used to validate and test predictions from such a model. 
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